Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Polysaccharide

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514023000 - Carbohydrate (i.e., saccharide radical containing) DOAI

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514058000 Dextrin or derivative 121
514056000 Heparin or derivative 78
514055000 Chitin or derivative 67
514057000 Cellulose or derivative 47
514061000 Tri- or tetrasaccharide 31
514060000 Starch or derivative 17
514059000 Dextran or derivative 15
Entries
DocumentTitleDate
20130045945Treatment of Arthritis and Other Musculoskeletal Disorders With Crosslinked Hyaluronic Acid - A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.02-21-2013
20130029933Hydrogel for Natural Cosmetic Purposes - The subject matter of the present invention is a hydrogel which includes a combination of at least four polysaccharides. These polysaccharides are those which are in the natural state and which are not produced, altered or modified by chemical reactions. The combination of konjac mannan, xanthan gum, pullulan and carrageenan and optionally sclerotium gum produces, within certain concentration ranges, a stable, slightly sticky, neutral smelling, flexible and transparent hydrogel which can be used as a cosmetic product for skin care.01-31-2013
20130029932COMPOSITION FOR EXTERNAL USE ON SKIN, COSMETIC, AND CLEANING AGENT - A composition for external use on skin that can be spread evenly on the skin, does not produce a liquid residue as a result of temperature change, and can suppress a feeling of sliminess of xanthan gum is provided. There are provided a composition for external use on skin containing 0.1% by mass to 10% by mass of a component (A) (a water-soluble polymer obtained by mixing agar with xanthan gum) and 30% by mass or more of a component (D) (water); the composition for external use on skin containing 0.5% by mass to 40% by mass of a divalent polyol as a component (B); the composition for external use on skin according to any one of the above compositions, which contains moisturizers as a component (C); and the composition for external use on skin according to any one of the above compositions, which contains oil as a component (E).01-31-2013
20130029931PLEUROTUS TUBER-REGIUM POLYSACCHARIDE FUNCTIONALIZED NANO-SELENIUM HYDROSOL WITH ANTI-TUMOR ACTIVITY AND PREPARATION METHOD THEREOF - The preparation of 01-31-2013
20090163441Hyaluronic Acid Binary Mixtures and Therapeutic Use Thereof - The present invention is related to hyaluronic acid compositions consisting in a binary mixtures of hyaluronic acid samples having mainly different weight-average molecular weight and then different rheological properties in aqueous solution. The resulting compositions have demonstrated peculiar rheological behaviour with a balance between viscosity and viscoelasticity. Accordingly, these compositions of hyaluronic acid are useful for treatment of joint diseases by intra-articular administration or extra-articular application in soft tissue disorders.06-25-2009
20100063003Pet food composition - Pet food comprising trisodium L-ascorbic acid-2-monophosphate (STAY-050) or sodium-calcium L-ascorbic acid-2-monophosphate (STAY-C35), or mixtures thereof and, optionally, a polymer (for fixation of the ascorbate on the dental surface) and use 5 thereof as additive to pet food for preventing or treating calculus, plaque, gingivitis and periodontal disease and for enhancing the antioxidative capacity in the whole organism.03-11-2010
20120184507LEAVEN-BASED MIXTURE - A mixture obtainable by a process comprising the following steps: a) adding a culture comprising sprouted rye grains and water to a rye fine or coarse meal and subjecting the mixture to a process of heating to 30-34° C. within 3 to 5 hours, a strong maltose formation being initiated from enzymatic reactions; b) followed by a further addition of rye fine or coarse meal, water and a bacteriological inoculum from the group of heterofermentative lactic-acid bacteria; c) acidifying the mixture until the metabolic activity of the microorganisms ceases, and optionally pasteurizing at 90-95° C.; d) separating the mixture by centrifugation into a solution and a precipitate, after which the solution is optionally filtered at least once.07-19-2012
20120184506USE OF SULFATED OLIGOSACCHARIDES AS SLIMMING COSMETIC INGREDIENTS - This invention relates to the use of a preparation comprising sulfated oligosaccharides which trap spermine or spermidine or both, as an active slimming ingredient in a cosmetic, pharmaceutical and/or nutraceutical composition. One of the objectives of the invention is to supply a cosmetic, pharmaceutical or nutraceutical composition with a slimming effect.07-19-2012
20100056470PLANT COMPOSITIONS ENRICHED IN DEHYDROSOYASAPONIN I (D-I) AND METHODS OF PRODUCING SUCH COMPOSITIONS - There is provided a method of producing a plant composition comprising dehydrosoyasaponin I (D-I), the method comprising the steps of extracting a plant flour with a solvent capable of extracting soyasaponins to produce an extract, and treating the extract with light. Also provided are compositions produced according to the method of the present invention.03-04-2010
20100056472GRAIN COMPOSITIONS CONTAINING PRE-BIOTIC ISOMALTO-OLIGOSACCHARIDES AND METHODS OF MAKING AND USING SAME - Methods for the production of substrate, tuber, and grain compositions containing isomalto-oligosaccharides are described. The methods comprise (a) contacting a substrate, tuber or grain containing ungelatinized starch with a maltogenic enzyme and a starch liquefying enzyme to produce maltose; (b) contacting said maltose with a transglucosidic enzyme, wherein said steps (a) and step (b) occur at a temperature less than or at a starch gelatinization temperature; and (c) obtaining a substrate, grain or tuber composition having an enzymatically produced isomalto-oligosaccharide, wherein the oligosaccharide is derived from the grain. The maltogenic enzyme can be either exogenous or endogenous to the grain. The contacting steps can be sequential or concurrent. The present invention also describes flour, oral rehydrating solutions, beer adjuncts, food, feed, beverage additives incorporating the grain compositions made as described.03-04-2010
20090203641ANTIBIOTIC COMPOSITIONS AND RELATED SCREENING METHODS - Moenomycin inhibits bacterial growth by clocking the transglycosylase activity of class A penicillin-binding proteins (PBPs), which are key enzymes in bacterial cell wall synthesis. The binding affinities of moenomycin A with various truncated PBPs were compared showing that the transmembrane domain is important for moenomycin binding. Full-length class-A PBPs from 16 bacterial species were produced, and their binding activities showed a correlation with the antimicrobial activity of moenomycin against 08-13-2009
20110195927Compositions Comprising Polymers Having Amino Sugar Units and Methods of Making and Using Same - Compositions comprise a polymer having units of an amino sugar, a polyol other than sorbitol, and boric acid, a salt thereof, or a combination thereof. Such compositions remain for an extended period in the eye and can be used for relief, treatment, or control of a condition of dry eye or discomfort resulting therefrom.08-11-2011
20110195926PURIFIED BETA GLUCAN COMPOSITION - The invention provides methods of using beta glucans to treat conditions associated with bone loss or low bone density as well as methods for promoting bone growth in situations where enhanced bone growth is desirable. In the invention methods beta glucans are administered so as to enhance the development of osteoblasts and the inhibition of the development and recruitment of osteoclasts. The inhibition of the recruitment and development of osteoclasts, coupled with the enhancement of osteoblast maturation by beta glucans leads to decreased bone resorption and increased bone formation, making beta glucans ideal agents for the treatment of osteoporosis and other bone resorption diseases.08-11-2011
20100087391TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to compositions (including medicaments and nutritional products) for use in the prevention or treatment of Inflammatory Bowel Disease. Such compositions comprise a therapeutically effective amount of a soluble fibre derivable from fruit of the 04-08-2010
20130085118METHOD AND MIXTURE FOR TREATING AND PREVENTING INFLAMMATORY BOWEL DISEASE - A method and a mixture for treating and preventing the inflammatory bowel disease (IBD) by applying a predetermined therapeutically effective amount of a mixture of hyaluronic acid to individuals is disclosed. The mixture includes at least two different average molecular weight hyaluronic acids (Mw) with different rheology to gain a hyaluronic acid with the proper adhesion property, functions of tissue scaffold and insulation and treatment time, in order to treat and to prevent IBD (inflammatory bowel disease) includes ulcerative colitis, Crohn's disease or wound healing in stomach and intestine, thus to achieve the prompt treatment and to prolong the effect.04-04-2013
20090118229CAROTENOID-CONTAINING COMPOSITIONS AND METHODS - The present invention is directed to carotenoid-containing compositions and methods for improving bone or respiratory health in a subject comprising administering to the subject a combination of lycopene, beta-carotene, and beta-cryptoxanthin.05-07-2009
20100113385COMPLEX COMBINING AN ORGANIC SILICON DERIVATIVE WITH HYALURONIC ACID CALIBRATED FRAGMENTS, FOR PREVENTIVE AND REPAIRING ACTION OF CUTANEOUS DAMAGES - The invention concerns a complex based on an organic silicon derivative. The invention is characterized in that said derivative is combined, by weak bonds, with one or several hyaluronic acid calibrated fragments of molecular weight comprised between 150 and 750 kDa, said derivative being of general formula (I):05-06-2010
20100075921Pr paration of hyaluronic acid with desired low molecular weight as a food supplement - A process for preparing hyaluronic acid primarily as a food supplement which is capable of absorption and assimilation by the human body includes desirable control of both the purity and molecular weight range of the resulting product. Chicken comb tissue is subjected to one of two disclosed processes for extracting, purifying, and controlling the molecular weight range of hyaluronic acid in solution, which is then dried and powdered to a form suitable for human consumption as a food supplement. The resulting hyaluronic acid product can also be used topically in creams or solutions for beneficial treatment of skin conditions, such as dry skin or wrinkling, for example.03-25-2010
20100075920SMALL MOLECULE STIMULATORS OF NEURONAL GROWTH - Provided herein are small molecule stimulators of neuronal growth, their preparation, and their use for treatment of neurological disorders. In one embodiment, provided herein are methods of treatment, prevention, or amelioration of a variety of medical conditions associated with neurological disorders using the compounds and compositions provided herein.03-25-2010
20100075919COMPOSITIONS COMPRISING ALKYLDIMONIUM HYDROXYPROPYL ALKYLGLUCOSIDES - A pharmaceutical formulation for topical, ophthalmic or nasal administration comprising one or more alkyldimonium hydroxypropyl alkylglucosides of general formula I or general formula II and a pharmaceutical active,03-25-2010
20120245121METHODS FOR IMPROVING BONE HEALTH IN INFANTS USING LONG CHAIN POLYUNSATURATED FATTY ACIDS - Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including at least one LCPUFA to a woman during pregnancy and optionally during lactation and breastfeeding of an infant.09-27-2012
20100144668SEMI-FLUID FOOD PRODUCT INCLUDING BETA GLUCANE FIBRES AND GUAR GUM, AND USE THEREOF AS A FUNCTIONAL FOOD PRODUCT - The invention relates to a semi-fluid food product containing from 2.5 to 16 g of guar gum and from 2.8 to 11.3 g of beta-glucane fibres per portion of said food product, said portions ranging from 125 to 250 g, characterised in that the guar gum: beta-glucane fibres mass ratio ranges from 2:1 to 4:1.06-10-2010
20090062231Appetite Suppressant Composition and Method of Appetite Suppression - The present invention provides an appetite suppressant composition including alginate, hydroxycitric acid, and piperine. The present invention also provides an appetite suppressant composition including alginate, hydroxycitric acid, and garcinol. The present invention further provides a method of suppressing appetite utilizing an appetite suppressant composition for creating an immediate and sustained feeling of satiety; reducing total cholesterol, glucose, insulin, and triglyceride levels; and preventing gastric reflux.03-05-2009
20100048507FOOD/BEVERAGE AND PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION FOR IMPROVEMENT IN ACIDIC URINE EACH COMPRISING FUCOIDAN AS ACTIVE INGREDIENT - The present invention provides a food/drink or pharmaceutical composition for oral administration for improving an acidic urine, comprising fucoidan or a fucoidan-containing material as an active ingredient, characterized in that a urinal pH is persistently increased; use of fucoidan or a fucoidan-containing material for production of the food/drink or the pharmaceutical composition for oral administration; and a method for improving an acidic urine by persistently increasing a urinal pH of a patient, which comprises orally administering fucoidan or a fucoidan-containing material to a patient.02-25-2010
20130035308COMPLEX COMBINING AN ORGANIC SILICON DERIVATIVE WITH HYALURONIC AND ACID CALIBRATED FRAGMENTS, FOR PREVENTIVE AND REPAIRING ACTION OF CUTANEOUS DAMAGES - The invention concerns a complex based on an organic silicon derivative. The invention is characterized in that said derivative is combined, by weak bonds, with one or several hyaluronic acid calibrated fragments of molecular weight comprised between 150 and 750 kDa, said derivative being of general formula (I):02-07-2013
20130079299Arthritis Therapeutic Agent - Disclosed is a composition for preventing, treating, or alleviating arthritis, and particularly, a composition effective for preventing, treating, or alleviating arthritis comprising β-1,3-1,6-branched D-glucan. The β-1,3-1,6-branched D-glucan of the composition is characterized in that glucoses are linked via a beta-1,3 linkage between two glucose molecules and a gluclose is branched via a linkage between 1 and 6 positions of two glucose molecules in every 1-20 of the beta-1,3 linked glucoses, and the branched glucose is bound with an organic acid. Further, an arthritis therapeutic agent and a health supplement food including the composition, and a method of preventing, treating, or alleviating arthritis including administering a pharmaceutically effective amount of the composition, are disclosed.03-28-2013
20130210765HYALURONIC ACID CONTAINING PHARMACEUTICAL OR VETERINARY COMPOSITIONS - A pharmaceutical or veterinary composition comprises a hyaluronic acid or a salt thereof or an ester of hyaluronic acid with an alcohol of the aliphatic, heterocyclic or cycloaliphatic series, or a sulphated form of hyaluronic acid, together with at least one eicosanoid or tetraenoic polyunsaturated fatty acid or an ester or a salt thereof, preferably in the form of an extract of fatty acids from the New Zealand Green Lipped Mussel 08-15-2013
20100144666Biomaterials In the Form of Fibres for Use as Medical Devices In the Treatment of Wounds, and Their Production Process - The present invention relates to new biomaterials in the form of fibres, essentially consisting of a mixture of gellan and hyaluronic acid derivatives, for use in surgery, especially in the treatment of wounds and mild burns. The present invention also relates to the process for the preparation of said biomaterials.06-10-2010
20100323984COSMETIC ORAL AND/OR PARENTERAL USE OF GLUCOSAMINE OPTIONALLY IN COMBINATION WITH AT LEAST ONE POLYPHENOL COMPOUND, AND CORRESPONDING COMPOSITION - The present invention relates to the cosmetic oral and/or parenteral use of glucosamine as an active agent for preventing and/or treating the cutaneous signs of ageing, optionally in combination with at least one polyphenol compound.12-23-2010
20100041623Aqueous liquid preparation comprising gatifloxacin - Disclosed is an aqueous liquid preparation comprising (A) gatifloxacin, a pharmacologically acceptable salt thereof or a hydrate gatifloxacin or the salt, (B) hyaluronic acid or a pharmacologically acceptable salt thereof, and (C) a polyhydric alcohol. The aqueous liquid preparation is an ophthalmic aqueous liquid preparation excellent in the retention of gatifloxacin in a tear fluid and the penetration of gatifloxacin into an aqueous humor and a conjunctiva.02-18-2010
20130123210DERMAL FILLER COMPOSITIONS INCLUDING ANTIOXIDANTS - Provided are injectable, hyaluronic acid-based hydrogel compositions including conjugated vitamins.05-16-2013
20130035307METHODS FOR TREATING OR PREVENTING THE SPREAD OF CANCER USING SEMI-SYNTHETIC GLYCOSAMINOGLYCOSAN ETHERS - Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEs”). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.02-07-2013
20090156551NOVEL COMPOSITION - The invention relates to novel compositions comprising magnolol and honokiol wherein the mol ratio of magnolol to honokiol is less than 0.6 as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.06-18-2009
20090156549MUCOSAL TREATMENT - The invention provides a method of treatment of a female human or non-human subject to enhance cervical mucus penetrability by spermatozoa, which method comprises vaginally applying to said subject an effective amount of a spermicide-free, physiologically tolerable oligouronate.06-18-2009
20100105632Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals - The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothionine, one or more avocado/soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.04-29-2010
20090239819PERITONEAL DIALYSIS SOLUTION TEST METHOD - A method of testing a glucose polymer or a glucose polymer derivative includes providing a sample of the glucose polymer or glucose polymer derivative. The sample is filtered at a specified molecular weight cutoff to obtain a retentate portion and a filtrate portion. The retentate portion is added to a first assay. The filtrate portion is added to a second assay. A reagent is added to each of the first assay and the second assay. The reagent produces a proinflammatory response. The proinflammatory response of each of the first assay and the second assay is measured. The proinflammatory response of the first assay is compared to the proinflammatory response of the second assay to determine if the glucose polymer or glucose polymer derivative is suitable for use in a patient.09-24-2009
20100029583PROCESS FOR OBTAINING AN ACTIVE INGREDIENT WITH AN IMMEDIATE TENSOR EFFECT ON THE SKIN, ACTIVE INGREDIENT AND COMPOSITIONS - The invention relates to a method for obtaining an active ingredient having an immediate anti-wrinkle and skin-tensioning effect, characterised in that it comprises extracting and purifying high molecular weight polysaccharides from oat bran and/or fibres and/or grains, and solutioning and stabilising the polysaccharides in water. The invention also relates to the product thus obtained, to uses thereof, and to cosmetic compositions containing this active ingredient.02-04-2010
20100093659POLYVALENT BIOCONJUGATES - The present invention is directed to conjugates for biorecognition comprising (i) an carbohydrate backbone structure (PO) of 5 to 20 monosaccharide units, (ii) oligosaccharide biorecognition groups (Bio) of 1 to 10 monomer units, (iii) a bifunctional spacer groups of the formula -(y)p-(S)q-(z)r-, wherein S is a spacer group, p, q and r are each 0 or 1, whereby at least one of p and r is different from 0, and y and z are chemoselective ligation groups, which covalently link a said Bio group to said backbone structure, and the degree of conjugation, indicating the average number of covalently attached Bio biorecognition groups per monomer unit of the backbone, being from 0.2 to 1. The invention is also directed to processes for their preparation, intermediates for use in the process as well as use of said conjugates, especially for inhibiting pathogenic bacteria.04-15-2010
20090124573IMMUNOMODULATING COMPOUNDS AND RELATED COMPOSITIONS AND METHODS - Provided herein are compounds, compositions and methods for balancing a T-helper cell profile and in particular Th1, Th2, Th17 and Treg cell profiles, and related methods and compositions for treating or preventing an inflammatory condition associated with an imbalance of a T-helper cell profile.05-14-2009
20120165291ACIDIC COMPOSITION FOR EXTERNAL USE AND AGENT FOR ACCELERATING INFILTRATION OF COSMETIC PREPARATION, HAIR-GROWING AGENT, AND PREPARATION FOR EXTERNAL USE EACH CONTAINING THE COMPOSITION INTO SKIN OR THE LIKE - An acidic composition for external use which contains an acidic polysaccharide and water as essential ingredients, and an agent for accelerating the penetration into skin or the like of a cosmetic preparation, hair-growing agent or preparation for external use, each containing the composition. The composition is easy to manufacture, and shows a stronger cosmetic or therapeutic effects than conventional compositions.06-28-2012
20110003769ANTI-AGING COMPOSITION FOR EXTERNAL USE COMPRISING LOW AND HIGH MOLECULAR WEIGHT HYALURONIC ACIDS AND THE POLYSACCHARIDES EXTRACTED FROM ROOT BARK OF ULMUS DAVIDIANA - Disclosed is an anti-aging composition for external use on skin, which includes low-molecular weight hyaluronic acids, high-molecular weight hyaluronic acids and polysaccharides extracted from root bark of 01-06-2011
20090042833PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF OSTEOARTHRITIS CONTAINING CLODRONIC ACID AND HYALURONIC ACID - Disclosed are pharmaceutical compositions containing clodronic acid and hyaluronic acid or their salts as active constituents, mixed with suitable vehicles.02-12-2009
20100267661BETA GLUCANS AND METHODS OF USE THEREOF - The present invention relates to therapeutic uses of beta glucan for treating cancer, cytopenia, and symptoms associated with negative side effects of chemotherapy. As such, the current invention provides methods of using beta glucan for treating cancer, for increasing hematopoiesis, and for improving the quality of life of subjects undergoing chemotherapeutic treatment.10-21-2010
20090306012THERAPEUTIC PROTOCOLS - The present invention relates to the field of chemotherapy of diseases such as cell proliferation disorders including cancer. In particular, the present invention relates to the use of hyaluronan (HA) as a protective agent in the treatment of subjects. HA is administered in conjunction with a chemotherapeutic agent to facilitate the prolonged administration of a dose of the chemotherapeutic agent to be administered to a subject. Owing to the protective effects of the HA, the dose of chemotherapeutic agent may be substantially higher than a generally accepted effective dose, which would otherwise be expected to cause unacceptable side effects in the subject.12-10-2009
20080300218CROSSLINKABLE POLYSACCHARIDE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, CROSSLINKABLE POLYSACCHARIDE COMPOSITION, AND MEDICAL TREATMENT MATERIAL - A process for producing an uncrosslinked, crosslinkable polysaccharide derivative having an active ester group, said process including: dissolving an acid-containing polysaccharide having a carboxy group and/or a carboxyalkyl group which are originally possessed or which have been introduced, in its non-salt form, into an aprotic polar solvent at a temperature of 60° C. to 120° C., and reacting it with an N-hydroxylamine-based electrophilic group-introducing reagent at a temperature between 0° C. and 70° C. in the presence of a dehydrating-condensing agent selected from the group consisting of 1-ethyl-3-dimethylaminopropylcarbodiimide hydrochloride and 1-cyclohexyl-(2-morphonyl-4-ethyl)-carbodiimide-meso-p-toluenesulfonate, and thereby converting at least part of said carboxy group and/or carboxyalkyl group into active esters bearing an N-hydroxylamine-based electrophilic group.12-04-2008
20090111770Pharmaceutical Composition Free From Dexpanthenol, Calcium Ions, and Phosphate and Use of Calcium Chelating Agent and Ophthalmologically Compatible Viscosity Regulator - The invention relates to a pharmaceutical composition free from dexpanthenol, calcium ions and phosphate, comprising at least one calcium chelating agent and at least one opthalmologically compatible viscosity regulator and optionally one or more pharmaceutical excipients. The invention further relates to the use of a calcium chelating agent and an opthalmologically compatible viscosity regulator for the production of a phosphate-free pharmaceutical composition for the treatment and/or prevention of epithelial defects.04-30-2009
20130072454ANTI-DIABETIC COMPOSTIONS AND METHODS - The present invention is concerned with synergistic compositions effective in the treatment of diabetes. In particular, the present invention is concerned with synergistic compositions comprising inulin, or a suitable source thereof, and Sulphonylureas used in the treatment of type-2 Diabetes Mellitus (T2DM) and hyperglyacemia.03-21-2013
20130072453HEAT STABLE HYALURONIC ACID COMPOSITIONS FOR DERMATOLOGICAL USE - The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.03-21-2013
20130072452PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITING INFLAMMATION - A pharmaceutical composition for inhibiting inflammation is provided. The pharmaceutical composition comprises (a) hyaluronic acid, (b) a vitamin and (c) a pharmaceutically acceptable carrier.03-21-2013
20110015151COMBINATION OF VISCOELASTICS FOR USE DURING SURGERY - An improved viscoelastic composition useful in the performance of ophthalmic surgical procedures and especially cataract procedures is disclosed. The embodiments of the composition comprise combinations of sodium hyaluronate and chondroitin sulfate and exhibit an improved rheological profile.01-20-2011
20130059815NUTRITIONAL COMPOSITIONS CONTAINING HUMAN MILK OLIGOSACCHARIDES AND METHODS FOR USING THE SAME - This disclosure features human milk permeates and compositions containing the same obtained from fractionated whole human milk. The oligosaccharide rich permeate and permeate compositions of the present invention are useful as nutritional supplements for pre-term and full term infants, for establishing or maintaining gut flora and for treating the symptoms of inflammatory bowel disease.03-07-2013
20130059814ANTI-INFLAMMATORY DERMATOLOGICAL COMPOSITION COMPRISING CORTICOSTEROIDS AND HYALURONATE FRAGMENTS, AND USES THEREOF - Anti-inflammatory dermatological composition for topical administration, characterized in that it comprises 0.005% to 0.1%, preferably 0.01% to 0.05% by weight of a corticosteroid and 0.1% to 1%, preferably 0.5% to 1% by weight of hyaluronate fragments with an average molecular weight of between 20 and 500 kDa, preferably between 20 and 375 kDa, more preferentially between 20 and 150 kDa.03-07-2013
20090270345POLYMERIC ARTIFICIAL TEAR SYSTEM - The present invention relates to artificial tear formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a cis-diol such as sorbitol that interferes with the cross-linking of galactomannan and borate. Optionally, the formulations are substantially free of divalent cations.10-29-2009
20090270344Structure and bioactivity of the polysaccharides and oligomers in medicinal plant Dendrobium huoshanense - Compositions and methods are disclosed relating to use of fractions, polysaccharides, and oligosaccharides of 10-29-2009
20090270343Polysaccharide Extract of Lentinus and Pharmaceutical, Cosmetic or Nutraceutical Compositions Comprising Such an Extract - The present invention relates to a polysaccharide extract derived from a mushroom of the 10-29-2009
20120225841Methods of Making and Using a Ruminant Gas Reduction Composition - A method comprising administering an oligosaccharide composition to an organism having a gastrointestinal system to affect the production of GHG produced by the organism allowing for a reduction of the GHG produced by the organism while optimizing the health, feed intake, and protein synthesis of the organism so that management of the organism may realize the synergistic effects of maximizing both typical organism commodity-type concerns (e.g., size and production metrics) and atypical organism commodity-type concerns (e.g., carbon credit trading/monetization). A gas-reducing composition comprising soluble extractable material from a lignocellulosic source. A method of producing a composition, comprising providing a lignocellulosic source; extracting soluble materials from the lignocellulosic source to produce soluble extractable material; and processing the soluble extractable material to yield a gas-reducing composition, wherein the gas-reducing composition comprises hemicellulose and exhibits gas-reducing activity.09-06-2012
20110021457PHARMACEUTICAL COMPOSITIONS COMPRISING MODIFIED FUCANS AND METHODS RELATING THERETO - Compositions and methods relating to fucan agents useful for the treatment, prevention, inhibition, etc., of fibrous adhesions or other diseases.01-27-2011
20090036400Pharmaceutical Preparations for Treating the Consequences of Alcohol Abuse, Hepatitis, Pancreatitis, Alzheimer's Disease, Parkinson's Disease, Diabetes, Toxic Kidney Disease, Reperfusion Damage, Arteriosclerosis, and as an Antidote Against Environmental Toxins and Medicinal Intoxication - A pharmaceutical preparation is disclosed for the prevention, treatment and relief from the consequences of alcohol abuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, Alzheimer's disease, Parkinson's disease, toxic kidney diseases, acute kidney failure, toxic side effects on dosage of chemotherapeutics, diabetes mellitus, Wilson's disease, sideroses and/or ischaemic reperfusion damage, arteriosclerosis and as an antidote against environmental toxins and medicament intoxication. The preparation comprises at least one compound of general formula R-A-X, as active ingredient, where R=straight or branched chain C02-05-2009
20090012040BIOCOMPATIBLE POLYMERS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM - A process for treating fibroses including administering a therapeutically effective amount of a pharmaceutical composition which includes at least one biocompatible polymer of the following general formula (I): A01-08-2009
20100087389Sensory Modifier - Sensory modifiers and compositions comprising sensory modifiers are described. The sensory modifiers comprise polysaccharide carbohydrate having at least about 75% by weight amylopectin and the polysaccharide carbohydrate has been treated and swollen with a substantially anhydrous solvent.04-08-2010
20100087390Universal Sensory Structurant - Universal sensory structurants and compositions comprising the same are described. The universal sensory structurants comprise polysaccharide carbohydrate having at least about 75% by weight amylopectin and the polysaccharide carbohydrate has been treated and swollen with a solvent comprising hydroxylated polymer comprising less than about 100 silane repeat units.04-08-2010
20130165402SURGICAL GEL SYSTEM - A surgical gel system for coating and adhering to a wound area to control bleeding whilst supporting wound healing comprises polyanhydroglucuronic acid or a biocompatible salt in an amount of from 1% to 15% by weight and pectin in an amount of in an amount of from 0.1% to 9% by weight. The gel system may be used for stopping bleeding during or after sinus surgery, for stopping bleeding in ear nose and throat procedures, for stopping bleeding in gynecological procedures, or for stopping bleeding in internal organ procedures.06-27-2013
20090005342Composition Having Blood Pressure Reducing and/or Elevation Suppressing Effect and Food and Drink Containing the Same - The present invention regards the composition having a blood pressure reducing and/or elevation suppressing effect comprising a mannose-based oligosaccharide mass comprising 1 to 10 molecules of monosaccharides linked together, said molecules mainly comprising mannose. It is the object of the present invention to provide an economical and simple food and drink which has an excellent blood pressure reducing and/or elevation suppressing effect without changing ordinary eating habits much, and a composition ingestible with a food and drink which effectively uses waste resources such as coffee extraction residues.01-01-2009
20120238523GLYCOSAMINOGLYCAN MIXTURES - The present invention relates to osteoblast derived glycosaminoglycan mixtures and to their use in one or more of: inhibition of osteoclastogenesis, enhancement of proliferation of osteoblasts, and/or the treatment or prevention of bone fracture or bone deterioration.09-20-2012
20120238522CAROTENOID-CONTAINING COMPOSITIONS AND METHODS - The present invention is directed to carotenoid compositions and methods for inhibiting the growth of pathogenic bacteria or for preventing or treating bacterial infections in subjects by administration of an effective amount of astaxanthin and beta-carotene.09-20-2012
20120238521Compositions and Methods for the Treatment of Musculoskeletal Related Diseases and Disorders Using Metal Ion-Citrate Analog Complexes - The invention is directed to a composition and associated method for the treatment of musculoskeletal related disorders and diseases. In particular, the present invention provides a class of citrate compounds that can be used to for the treatment of diseases/disorders characterized by the degeneration of musculoskeletal tissues including menisci, bone, articular cartilage, and soft tissues. Examples of suitable citrate and citrate analog compounds include citrates having the following base formula (I):09-20-2012
20080293670Edible tremella polysaccharide for prevention and/or improvement of intestinal disorder - It has been found that the polysaccharide isolated from a hot water extract of a Tremella mushroom without adding a chemical reagent has a novel effect of preventing and/or treating of intestinal disorder. The Tremella polysaccharide has excellent stability, water absorbing and holding ability, and swelling capacity, so it can be used to raise fecal water content and increase fecal volume, so as to improve intestinal disorder characterized by constipation and symptom caused by constipation.11-27-2008
20080293669Composition Containing Beta-Glucan, Method of Producing the Same and Foods, Drinks or Skin Moisturizers Containing the Composition - It is intended to utilize β-glucan produced by a bacterium belonging to 11-27-2008
20110028427DIETARY FIBER AND METHOD FOR PREPARING DIETARY FIBER - The invention relates to a soluble antioxidant dietary fiber obtained from pineapple and a method of processing pineapple pulp to provide a soluble antioxidant fiber.02-03-2011
20120270834DEPOLYMERIZED GLYCOSAMINOGLYCAN FROM THELENOTA ANANAS AND PREPERATION METHOD THEREOF - Disclosed is a depolymerized glycosaminoglycan from 10-25-2012
20130165403Process for Manufacturing Partially Cross-Linked Alginate Solution - Described is a microfluidic process for manufacturing partially cross-linked alginate solution, wherein the alginate solution is a homogenous liquid which exhibits an elastic response (G′) which is equal to or greater than its viscous response (G″). In particular, the process may comprise microfluidic mixing of sodium alginate and calcium gluconate solutions to provide an injectable partially cross-linked alginate solution.06-27-2013
20130165404HYBRID COOPERATIVE COMPLEXES OF HYALURONIC ACID - Describes cooperative hybrid complexes of hyaluronic acid, a simple and economical method for production thereof and use thereof in the area of medicine, cosmetics and food.06-27-2013
20100069324NANOPARTICLE OF GLUCIDAMIN FOR TREATING TUMOR AND PREPARATION METHOD THEREOF - A nanoparticle of glucidamin derived from organism for treating tumor and preparation method thereof, wherein the viscosity-average molecular weight of glucidamin is in the range of 1×1003-18-2010
20100062999Composition extracted from shark cartilage marrow - The present invention relates to a composition extracted from shark cartilage marrow. This composition possesses effects of anti-melanoma effect, neutralization of gastric acid, and improvement of blood circulation and comprises Chondroitin Sulfate that is the active component thereof and is 50-60 wt % of the total weight of the composition. Besides, the composition has a molecular weight between 21-100 kilo Daltons and has energy state about 300-350 kilocalories per 100 grams.03-11-2010
20100234319Complex of Polymeric Quaternary Ammonium and Anionic Polymers as a New Antimicrobial Agent for Ophthalmic Compositions - Disclosed herein are ophthalmic solutions and methods of using the solutions which comprise a complex of at least one cationic component and an anionic polymer, wherein the complex can be used as an antimicrobial agent. The solutions described have complexes which can be dissolved in aqueous ophthalmic solutions due to both lower charge load and lower total polymer concentrations than commonly taught. The complexes display different antimicrobial profiles than the non-complexed antimicrobial agents.09-16-2010
20110281817PRODUCTION OF HYALURONIC ACID - Methods for producing hyaluronic acid are described, including altering the activity in 11-17-2011
20100029582Anticoagulant Antithrombotic Dual Inhibitors Comprising a Biotin Label - The present invention relates compounds of the formula: oligosaccharide-spacer-(GpIIb/IIIa antagonist), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising four to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-II mediated) anti-Xa activity per se; the spacer is a bond or an essentially pharmacologically inactive linking residue; the GpIIb/IIIa antagonist is a residue mimicking the RGD and/or K(QA)GD fragment of fibrinogen, comprising a carboxylate moiety and a basic moiety located within the residue at a distance of 10-20 Å from each other; or a pharmaceutically acceptable salt thereof or a prodrug or a solvate thereof; wherein the compound of formula I further comprises at least one covalent bond with a biotin label or an analogue thereof. The compounds of the invention have antithrombotic activity and can be used in treating or preventing thrombotic diseases. The antithrombotic activity of the compound of this invention can be neutralized in case of emergency upon administration of avidin, streptavidin and analogues thereof having high biotin affinity.02-04-2010
20110082103Anoectochilus SPP. polysaccharide extracts for stimulating growth of advantageous bacteria, stimuating release of granulocyte colony-Stimulating factor, modulating T helper cell type I, and/or modulating T helper cell type II and uses of the same04-07-2011
20100267665REMEDY FOR CORNEAL DISEASES - The present invention provides a method for treating a corneal disease by administering to a patient in need of such treatment an effective amount of ozagrel or a salt thereof.10-21-2010
20100267660EFFICIENT PRODUCTION OF OLIGOSACCHARIDES USING METABOLICALLY ENGINEERED MICROORGANISMS - The present invention relates to the enzymatic synthesis of oligosaccharides, particularly, sialylated oligosaccharides comprising the carbohydrate moeities of the gangliosides GM3, GD3, and GT3.10-21-2010
20080300217Combination Therapy with Fumaric Acid Esters for the Treatment of Autoimmune and/or Inflammatory Disorders - The present invention relates to compositions, kits and methods for administration of a first component of fumaric acid ester(s), or a pharmaceutically acceptable salt thereof, and a second component which is a substance that reduces or eliminates flushing.12-04-2008
20080275000COMPOSITIONS FOR REDUCING, AMELIORATING, TREATING, OR PREVENTING CONDITION OF DRY EYE AND METHODS OF MAKING AND USING SAME - Compositions for relief, treatment, or prevention of a condition of dry eye comprise alginate, a polyol, and a combinations of at least two organic acids or salts thereof, wherein the compositions have pH in the range from about 5 to about 7.5, at least one of the organic acids or salts thereof has a pKa in the range from and 6 to about 10. In some embodiments, the second organic acid or a salt thereof has a pKa that is no more than 1.5 units less than the pH.11-06-2008
20110144052NIACIN PRODRUGS AND DEUTERATED VERSIONS THEREOF - The invention relates to prodrugs of niacin and their use in pharmaceutical composition and therapeutic treatment of disease.06-16-2011
20110124594COMPOSITIONS THAT AIM TO PROMOTE THE DEVELOPMENT AND GROWTH OF A BENEFICIAL VAGINAL MICROFLORA - Pharmaceutical compositions and dermatological compositions comprising a prebiotic chosen among gluco-oligosaccharides (GOS), fructo-oligosaccharides (FOS), galacto-oligosaccharides and mixtures thereof; and a plant extract containing isoflavones chosen among soybean (05-26-2011
20100227836PARENTERAL ADMINISTRATION OF A GLUCOSAMINE - Materials and methods for local delivery of a glucosamine are provided to facilitate bone and cartilage growth.09-09-2010
20090170809Pectic Polysaccharides Isolated from Fruit Pods of Okra - The invention relates to a method for producing a high molecular weight pectin-like polysaccharide from fruit pods of okra. The high molecular weight pectin-like polysaccharide, when dissolved in a buffer, exhibit viscoelastic properties, and is very useful in applications such as ophthalmic surgery, dermatology and orthopedics.07-02-2009
20090036403Tunably Crosslinked Polysaccharide Compositions - The present invention generally relates to novel biocompatible crosslinked polysaccharide gel compositions, methods of their manufacture and use, and the novel crosslinkers used to make them. In one aspect of the invention, a novel polyethylene glycol crosslinking agent is described for crosslinking hyaluronic acid. In another aspect of the invention, novel crosslinking agents comprising more than two functional groups are described. These multifunctional crosslinking agents can be used on their own to crosslink hyaluronic acid, or they may be combined with bifunctional crosslinking agents in varying ratios to make hyaluronic acid of tunable mechanical strength and hardness. The present invention also discloses novel hyaluronic acid compositions that have been coated with polyethylene glycol and methods of their use.02-05-2009
20090005340Bioactive Agents Produced By Submerged Cultivation of a Basidiomycete Cell - The invention in one aspect is directed to a method for cultivating a Basidiomycete cell in liquid culture medium, said method comprising the steps of providing a Basidiomycete cell capable of being cultivated in a liquid growth medium, and cultivating the Basidiomycete cell under conditions resulting in the production intracellularly or extracellularly of one or more bioactive agent(s) selected from the group consisting of oligosaccharides, polysaccharides, optionally glycosylated peptides or polypeptides, oligonucleotides, polynucleotides, lipids, fatty acids, fatty acid esters, secondary metabolites such as polyketides, terpenes, steroids, shikimic acids, alkaloids and benzodiazepine, wherein said bioactive agent comprises one or more desirable activities, such as anti-tumour activity, immune stimulating activity, and enhancement of survival of an individual.01-01-2009
20110301117CRYOGENIC SKIN CREAM AND METHOD - A skin cream and skin cream packaging arrangement is disclosed. The arrangement includes, in combination: a skin cream intended to be applied on human skin and found to be most effective when within a determinable temperature range, and a container for containing the skin cream. The container may have a temperature indicator thereon configured to provide a visible indicator when the container is within the determinable temperature range.12-08-2011
20110301119PHARMACEUTICAL COMPOSITIONS CONTAINING FUCOIDAN FOR STIMULATING AND ACTIVATING OSTEOGENESIS - The present invention relates to pharmaceutical compositions containing fucoidan for stimulating and activating osteogenesis. The compositions according to the present invention contain fucoidan as an active ingredient to increase the activities of alkaline phosphatase and the production of osteocalcin, and to increase the production of bone morphogenetic protein (BMP-2).12-08-2011
20110301118Methods of treatment utilising glucan formulations - The present invention relates to methods for the treatment of skin wounds or lesions, and connective tissue damage or injury, comprising administering to a subject an effective amount of a glucan composition. Also provided are methods for the promotion of wound healing and tissue regeneration.12-08-2011
20100152132Use of a Composition Comprising an Antacid, a Mucolytic and a Gelling Agent in the Treatment of Cold - The present invention is concerning a medicine to alleviate and cure colds h} reduced acid content and stimulation of increased mucus production through the fact that active components of the substance consist of acid stanching components like proton p<06-17-2010
20120108538SULFATED POLYSACCHARIDES HAVING ANTIPLASMODIAL ACTIVITY AND METHODS AND PRODUCTS FOR IDENTIFYING ANTIPLASMODIAL ACTIVITY - This invention relates to methods for identifying, producing or rationally designing sulfated polysaccharide molecules that have antiplasmodial activity. Also provided are sulfated polysaccharide molecules having antiplasmodial activity, as well as methods for treating and preventing diseases including malaria with such molecules.05-03-2012
20110166099MIXTURE OF HYALURONIC ACID FOR TREATING AND PREVENTING PEPTIC ULCER AND DUODENAL ULCER - The present invention is related to a hyaluronic acid composition with a binary mixture of hyaluronic acids having mainly different weight-average molecular weight and then different rheological, scaffold and degradation properties in aqueous solution. The resulted compositions have demonstrated an optimal balance between adhesion, tissue scaffold and treating time to the peptic and duodenal ulcer and bleeding. Thus, the present inventive binary mixture exhibits a quick and lasting effect on the treatment and prevention of duodenal or peptic ulcer and bleeding which is very good thing indeed.07-07-2011
20090239822Process for the preparation of esters of diacerein with hyaluronic acid and pharmaceutical compositions containing such esters - A process is described for the preparation of esters of diacerein with hyaluronic acid by means of which stable products are obtained, which are practically free of impurities and characterized by a prolonged anti-inflammatory activity. Also described are pharmaceutical compositions containing said esters having prolonged anti-inflammatory activity and are suitable for intra-articular administration.09-24-2009
20090088405Personal lubricants with built-in or accompanying odorant delivery systems - A personal lubricant paired with an odorant release device.04-02-2009
20110294755BINDING OF GALECTIN-3 BY LOW MOLECULAR WEIGHT PECTIN - Administration of low molecular weight (10,000-20,000 Daltons, or lower) pectins, particularly modified citrus pectins (MCP), like PectaSol-C reduces galectins-3 levels in vivo. Reduction of galectin-3 levels by MCP inhibits inflammation, inhibits fibrosis formation in organs and tissues, and inhibits cancer formation, progression, transformation and metastases. The reduction in circulating, serum and cellular galectin-3, inherently resulting from the administration of MCP, provides benefit over a spectrum of biological conditions, as evidenced by in vivo trials.12-01-2011
20090215720Polysaccharides Compositions Comprising Fucans and Galactans and their Use to Reduce Extravasation and Inflammation - A use of an anti-inflammatory polysaccharides composition comprising fucans and galactans to inhibit the release of one or more of IL-8, PGE2 and VEGF by a cell activated during an inflammatory process and an anti-inflammatory composition comprising a ratio of brown algae fucans/red algae galactans of between about 2.5/1 (w/w) to about 40/1 (w/w), the galactans having a molecular weight higher than about 100 kDa, and the fucans having a molecular weight between about 0.1 kDa and 100 kDa.08-27-2009
20100056473METHOD OF EXTRACTING FUCOIDAN - A method of extracting fucoidan from a biological material is provided. The method comprises (a) combining a biological material containing fucoidan and a medium to form a mixture; (b) applying ultrasonic waves to the mixture while the mixture is at a temperature of less than about 60 C; (c) extracting fucoidan into the medium from the biological material to produce a fucoidan containing solution and insoluble biological matter; and (d) separating the fucoidan containing solution from the insoluble biological matter to obtain a fucoidan containing extract. Methods of using the fucoidan containing extract and pharmaceutical preparations containing the fucoidan containing extract are also provided.03-04-2010
20080318897Composition Containing Swelling Agent Composed of Swellable Water-Soluble Polysaccharide, and Food, Anti-Obesity Agent and Constipation Alleviator Each Containing the Composition - A composition containing a swelling agent is provided, which less burdens the stomach and intestine even after excessive intake. A food, anti-obesity agent and constipation alleviator each containing the composition is also provided.12-25-2008
20100113386N-BENZYL SUBSTITUTED PYRIDYL PORPHYRIN COMPOUNDS AND METHODS OF USE THEREOF - The present invention relates to N-Benzyl-Substituted Pyridyl Porphyrin Compounds, compositions comprising an effective amount of an N-Benzyl-Substituted Pyridyl Porphyrin Compound and methods for treating or preventing injury due to exposure to a reactive species, erectile dysfunction, urinary incontinence, lung disease, hyperoxia, neurodegenerative disease, liver disease, myocardial damage during cardioplegia, an inflammatory condition, a reperfusion injury, an ischemic condition, a cardiovascular disease, diabetes, a diabetic complication, cancer, a side effect of cancer chemotherapy, or a radiation-induced injury, and methods for prolonging the half-life of an oxidation-prone compound, comprising administering to a subject in need thereof an effective amount of an N-Benzyl-Substituted Pyridyl Porphyrin Compound.05-06-2010
20090149420NOVEL COMPOSITIONS AND USE THEREOF FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS - The present invention relates to novel compositions comprising magnolol and/or honokiol and chondroitin as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.06-11-2009
20100267663A COMPOSITION FOR CICATRISATION PROCESSES IN THE TREATMENT OF HYPERTROPHIC SCARS AND FOR IMPROVING THE BIOMECHANICAL PROPERTIES OF THE CUTIS - This invention concerns a composition for pharmaceutical and/or cosmetic and/or in the form of medical device, in particular for the prevention and treatment of hypertrophic scars and/or cheloids, to inhibit any fibrosclerotic process and to improve the biomechanical properties of the skin and to obstruct retraction to cicatrisation of the skin, as it contains, as an active ingredient, at least one of the active principles chosen between fucose (and/or Fucose rich polysaccharides—FROPs), Dimethyl sulfone and acetyl glucosamine.10-21-2010
20100267662AVENANTHRAMIDE-CONTAINING COMPOSITIONS - Methods and compositions for treating or preventing a skin condition, an inflammation, an irritation or an allergy associated with an ectoparasitic infection or infestation on an animal. The methods involve applying to the skin of the animal a pharmaceutical composition that contains a therapeutically effective amount of one or more than one avenanthramide, an optional ecto and/or endo-parasiticidal agent, and a pharmaceutically acceptable diluent or carrier10-21-2010
20100267659EXTRACT OBTAINED FROM ORCHIDACEAE PLANTS, METHOD FOR PRODUCING THE EXTRACT, AND EXTERNAL AGENT FOR SKIN COMPRISING THE EXTRACT - This invention relates to an extract obtained from a plant of the genus 10-21-2010
20090149418Antimicrobial preparations using polysaccharide gel from durian fruit-rind - A water-soluble polysaccharide gel having good gelling property and good antimicrobial activity was extracted from fruit-rind of durian (06-11-2009
20090149419HYDRAZIDO DERIVATIVES OF HYALURONIC ACID - Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.06-11-2009
20120065159COMPOSITION CONTAINING CHAMAECYPARIS OBTUSA POLYSACCHARIDES TO BE EXTERNALLY APPLIED TO THE SKIN - The present invention relates to a composition for skin external application containing a 03-15-2012
20090325899MEDICAL COMPOSITION FOR PROTUBERANCE OF EPITHELIUM - A medical composition for protuberance of epithelium, which comprises a solution comprising a polysaccharide or a medically acceptable salt thereof, wherein the solution has a viscosity of: (1) from 50 to 500 mPa·s at a shear rate of from 7.7 to 10.0 s12-31-2009
20120035128POLYSACCHARIDE DERIVATIVE AND HYDROGEL THEREOF - Disclosed are a polysaccharide derivative obtained by substituting some of the carboxyl groups of a carboxy polysaccharide with —NH—X—CO—Y—Z; and a hydrogel thereof. Here, X is a C02-09-2012
20100267664OPHTHALMIC COMPOSITIONS CONTAINING POLYSACCHARIDE-BORATE GELLING SYSTEM - Topical ophthalmic compositions that form a gel or partial gel upon application to the eye are described. The compositions are particularly useful as artificial tears and ocular lubricants, but may also be utilized for the topical delivery of pharmaceutically active compounds to the eye. The compositions contain a polysaccharide/borate gelling system. The polysaccharides that may be utilized contain cis-diol groups and have a structure that is predominately linear, with a slight degree of branching.10-21-2010
20120122814Composition for Prevention or Treatment of Hypertrophic Scars or Keloids - The present invention relates to a composition for preventing or treating hypertrophic scar or keloid, comprising as an active ingredient a compound represented by the following general formula I:05-17-2012
20110112048Use of beta-glucan on upper respiratory tract infection symptoms and psychological well-being - Studies involving placebo-controlled, double-blinded designs to evaluate the effect of beta-glucan compositions on upper-respiratory tract infections and psychological wellness were carried out. During the course of the reporting periods of these studies, subjects in the treatment groups reported fewer URTI symptoms, better overall health and a more positive psychological assessment based on a POMS survey.05-12-2011
20110195925Sterile Hyaluronic Acid Solutions - A process for sterilizing a solution comprising hyaluronic acid. The process comprises providing an aqueous solution of hyaluronic acid with a weight average molecular weight from 0.6 MDa to 3.6 MDa, and the concentration of the hyaluronic acid is from 0.04% to 0.8% by weight. The aqueous solution also has an ionic strength equivalent to an aqueous concentration of sodium chloride from 3% to 30% by weight. Once the aqueous, high salt, hyaluronic acid solution is prepared the solution is maintained at a temperature from 40° C. to 80° C. for at least 1 hour and not longer than six days. Following the heat treatment step, the aqueous solution is filtered through a sterilization filter medium to provide a sterilized high salt, hyaluronic acid solution.08-11-2011
20120295867METHOD AND PHARMACEUTICAL TO TREAT SPINAL DISCS - Methods for reducing chronic pain caused by a disrupted spinal disc are described. In one method, a solution is injected into the disc. The solution includes chondroitin sulphate, glucosamine HCl, and dextrose. The solution may optionally include dimethyl sulfoxide and/or an anesthetic such as bupivicaine.11-22-2012
20110201571HEAT STERILISED INJECTABLE COMPOSITION OF HYALURONIC ACID OR ONE OF THE SALTS THEREOF, POLYOLS AND LIDOCAINE - An injectable aqueous composition of hyaluronic acid or one of the salts thereof, one or more polyol(s) and lidocaine is used for cosmetic purposes or for therapeutic purposes. It has improved viscoelastic rheological properties and long in vivo persistence. The polyol is chosen, for example, from glycerol, sorbitol, propylene glycol, mannitol, erythritol, xylitol, maltitol and lactitol. The particular properties are obtained by heat sterilising the mixture.08-18-2011
20090258838GEL FORMULATION - The present invention relates to a sterile gel formulation comprising calcium gluconate. It also relates to a sterilisable gel formulation comprising calcium gluconate, which is stable under gamma-radiation sterilisation conditions, and also to the use of these formulations in, for example, treating burns caused by exposure of a human or animal body to hydrofluoric acid, either in liquid or vapour form.10-15-2009
20120295870CROSS-LINKING OF LOW-MOLECULAR WEIGHT AND HIH-MOLECULAR WEIGHT POLYSACCHARIDES, PREPARATION OF INJECTABLE MONPHASE HYDROGELS, POLYSACCHARIDES AND HYDROGELS OBTAINED - A process for the crosslinking of at least one polymer selected from polysaccharides and derivatives thereof, which is carried out in an aqueous solvent by the action of an effective and non-excessive amount of at least one crosslinking agent, characterized in that it is carried out on a mixture containing at least one low-molecular weight polymer and at least one high-molecular weight polymer. A process for the preparation of an injectable monophase hydrogel of at least one crosslinked polymer selected from polysaccharides and derivatives thereof. Crosslinked polymers and injectable monophase hydrogels respectively obtainable by each of said processes.11-22-2012
20120295869Sterile Hyaluronic Acid Solutions - Sterilized aqueous solution comprising 0.04% to 0.8% by weight hyaluronic acid with a weight average molecular weight from 0.6 MDa to 3.6 MDa, and one or more buffer components selected from the group consisting of boric acid, sodium borate and sodium dihydrogen phosphate. The aqueous solution also has an ionic strength equivalent to an aqueous concentration of sodium chloride from 4% to 18% by weight of sodium chloride and a pH from 6.4 to 7.2. The solution is also filtered through a filter medium that has an average pore size of 0.25 μm or less to provide a sterilized high salt, hyaluronic acid solution.11-22-2012
20120295868Medical Uses of Glucans - The invention relates to a glucan having a beta-(1,3)-backbone with one or more beta-(1,3)-side chains linked thereto for use in the treatment of asthma and related diseases of abnormal pulmonary function in an animal. Also described is a method of treating asthma and related diseases of abnormal pulmonary function in an animal comprising administering to said animal an effective amount of a glucan having a beta-(1,3)-backbone with one or more beta-(1,3)-side chains linked thereto.11-22-2012
20090170807Methods and means for producing hyaluronan - The present invention relates to fungal cells and fungi which synthesize hyaluronan and to methods for preparing such fungi, and also to methods for preparing hyaluronan with the aid of these fungal cells or fungi. Furthermore, the present invention relates to the use of fungi for preparing hyaluronan and to food or feed which comprises hyaluronan.07-02-2009
20110172180HEAT STABLE HYALURONIC ACID COMPOSITIONS FOR DERMATOLOGICAL USE - The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.07-14-2011
20110172181Compositions and Methods of Aloe Polysaccharides - The present invention describes a method for preparing a polymannan extract from freeze-dried 07-14-2011
20100249059BONE FILLING COMPLEX AND METHOD FOR FABRICATING THE SAME - Provided is a bone filling complex and a method of preparing the same. The bone filling complex includes a matrix including a hydrogel-type hyaluronic acid derivative; and a bone derivative filling the matrix, and thus adhesion can be prevented and excellent bone generation property can be obtained. For example, the bone filling complex can be used to an injured portion of alveolar bone to derive an regeneration of the alveolar bone.09-30-2010
20090286756PHARMACEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT OF WOUNDS - A pharmaceutical composition that can be used in the treatment of wounds, comprising at least a sulfated polysaccharide and wherein the polysaccharide/s are in the form of solids as powder, flakes or sheets obtained through a lyophylization process. Particularly, this invention relates to the use of one or more sulfated polysaccharides, as solids in the form of sheets obtained by lyophylization, in the healing of wounds in humans and animals.11-19-2009
20110269710PHARMACEUTICAL COMPOSITION OF COMPLEX CARBOHYDRATES AND ESSENTIAL OILS AND METHODS OF USING THE SAME - The invention discloses the discovery that a pharmaceutical composition containing complex carbohydrates with or without natural or synthetic essential oils can work effectively as a topical, oral or mucosal pharmaceutical composition. Such pharmaceutical compositions reduce inflammation, assist in wound healing, protect against bruising, relieve itching, relieve pain and swelling and treat topical bacterial infections such as acne and decubitus ulcers and prevent and treat numerous other conditions and diseases. Such pharmaceutical compositions can be administered to mammals including humans. Also included in this invention are methods to deliver topically applied macromolecules into the tissue of mammals and methods of blocking the adhesion, metastatic and coronary cascades.11-03-2011
20090170808ORAL AGENT FOR IMPROVING AND PROTECTING THE FUNCTION OF JOINT COMPRISING HYALURONIC ACID-PHOSPHOLIPID COMPLEXES - The present invention relates to an oral formulation comprising a hyaluronic acid-phospholipid complex, and to use of a hyaluronic acid-phospholipid complex for the manufacture of a joint function-improving and protecting agent for oral administration which can alleviate the arthritic symptoms in patients with arthritic conditions, increase the concentration of hyaluronic acid in synovial fluid, improve the lubrication of joints, as well as maintain and enhance the normal functions of joints.07-02-2009
20090036404OPHTHALMIC COMPOSITIONS COMPRISING A CARBOXYL-MODIFIED FRUCTAN OR A SALT THEREOF - Ophthalmic composition including a carboxyl-modified fructan or a salt thereof. The ophthalmic composition can be used in an eye care product or a contact lens care product such as a contact lens packaging solution or contact lens disinfecting solution.02-05-2009
20080274999Hyaluronic Acid Fraction with Moisturizing and Anti-Wrinkle Properties - A moisturizing, cosmetic, or anti-wrinkle product comprising hyaluronic acid or a salt thereof, wherein the hyaluronic acid or salt thereof has an average molecular weight in the range of 0.7-0.9 MDa, compositions comprising said product, and uses of said product.11-06-2008
20080280852Composition Containing Fermentable Polysaccharides - The present invention relates to a composition to a nutritional composition comprising 0.1 to 15 gram fermentable e partially hydrolysed gum having a degree of polymerisation between 10 and 300 per 100 gram dry weight of the composition and 0.1 to 15 gram fermentable, indigestible polysaccharide other than a hydrolysed gum having a DP between 10 and 300 per 100 gram dry weight of the composition.11-13-2008
20080287392Wound-Healing Pharmaceutical Compositions in the Form of a Cream Based on Amino Acids and Sodium Hyaluronate - This invention relates to wound-healing pharmaceutical or cosmetic (anti-skin aging) compositions in the form of a cream based on amino acids and sodium hyaluronate.11-20-2008
20100035838Cross-linked polysaccharide gels - The present invention relates to a process for preparing a cross-linked polysaccharide gel comprising contacting a polysaccharide with a cross-linking agent and a masking agent to form a cross-linked polysaccharide gel having resistance to degradation under physiological conditions.02-11-2010
20080306020Skin-Protecting Alkalinity-Controlling Composition and the Use Thereof - A skin-protecting alkalinity-controlling composition comprises one or more carboxylic acid polysaccharides. Said compositions are capable of providing buffering, and thus avoiding a major increase in the pH of an aqueous system and/or are capable of reducing the pH of aqueous systems, in which alkalinity is formed as a result of chemical and/or biological reactions. The compositions may be used in personal care products, such as skin creams and lotions, hygiene products, wound care products, fabric treating products etc.12-11-2008
20080306023Derivatives of Hyaluronic Acid, Their Preparation Process and Their Uses - The present invention relates to the use of a compound having the formula (I) wherein: n represents an integer varying from 720 to 6 200, and i varies from 1 to n, R12-11-2008
20080306021Cosmetic Preparation Comprising Hyaluronic Acid - The present invention relates to cosmetic preparations with an active substance combination of hyaluronic acid and saponins.12-11-2008
20080306022Agent for Applying to Mucosa and Method for the Production Thereof - An agent for applying to mucosa capable of persistently exerting a therapeutic effect on disorders such as inflammation and lesions in the mucosa even by a lower frequency of administration because the agent can stay at a diseased site for a long period of time by exhibiting a high staying property in a mucosal epithelial layer is provided, said agent for application to mucosa containing glycosaminoglycan (GAG) into which a hydrophobic group is introduced via a binding chain, as an active ingredient.12-11-2008
20100279979IMMUNOPOTENTIATING AGENT FOR USE IN ANIMALS - A simplified method for producing an immunopotentiating agent from cell walls of yeast, other fungi or bacteria is provided and its use as an additive to animal feed to increase resistance to various infections and to potentiate the effect of vaccines is described.11-04-2010
20100279980MOENOMYCIN BIOSYNTHESIS-RELATED COMPOSITIONS AND METHODS OF USE THEREOF - The methods and compositions described herein relate to the identification, isolation, and characterization of genes which encode proteins useful for the biosynthesis of transglycosylase inhibitors such as moes. The methods and compositions also relate to the production of such proteins, and their use in the synthesis of moes, the expression of moes, and the production of modified moes.11-04-2010
20080249062Nucleus Pulposus Filler - The present invention provides a nucleus pulposus filler or the like which is to be packed into an area in deformed intervertebral disc wherein normal nucleus should be located and can be stabley maintained for a long time. More preferably, the present invention provides a nucleus pulposus filler comprising a crosslinked chondroitin sulfate as an active ingredient. The photocrosslinked chondroitin sulfate is preferably the following one: a photocrosslinked chondroitin sulfate obtainable by freezing a photoreactive chondroitin sulfate-containing solution comprising: a photoreactive chondroitin sulfate to which a photoreactive group is bound; an aqueous solvent capable of dissolving the photoreactive chondroitin sulfate; and any one substance selected from the group consisting of an alcohol having aqueous solvent miscibility, a surfactant, and a cheleting agent; irradiating the resulting frozen product with light; and then melting the frozen product. The filler can be provided as a kit by packing it into a container from which the filler can be pushed out.10-09-2008
20110207695AGENT FOR APPLYING TO MUCOSA AND METHOD FOR THE PRODUCTION THEREOF - An agent for applying to mucosa capable of persistently exerting a therapeutic effect on disorders such as inflammation and lesions in the mucosa even by a lower frequency of administration because the agent can stay at a diseased site for a long period of time by exhibiting a high staying property in a mucosal epithelial layer is provided, said agent for application to mucosa containing glycosaminoglycan (GAG) into which a hydrophobic group is introduced via a binding chain, as an active ingredient.08-25-2011
20080280853COMPOSITIONS FOR REDUCING, AMELIORATING, TREATING, OR PREVENTING CONDITION OF DRY EYE AND METHODS OF MAKING AND USING SAME - Compositions for relief, treatment, or prevention of a condition of dry eye comprise alginate, at least a polyol, and a pharmaceutically acceptable carrier, wherein the compositions have pH in the range from about 5 to about 7.5. In some embodiment, the compositions can further include a chelating agent, a buffering system or agent, an organic acid, or combinations thereof.11-13-2008
20090156550COMPOSITION CONTAINING OLIGOSACCHARIDES FOR THE TREATMENT/PREVENTION OF INFECTIONS - The present invention relates to the use of oligosaccharide mixtures for the treatment and/or prevention of infections, in particular for reducing the severity of childhood infection or the treatment and/or prevention of childhood infection.06-18-2009
20100137241IMIDATED BIOPOLYMER ADHESIVE AND HYDROGEL - Biologically compatible polymers carry an imide and can be used as an adhesive, a hydrogel or both. A second biologically compatible polymer reactive with the imidated polymer can be used therewith to seal openings.06-03-2010
20120142629PHARMACEUTICAL COMPOSITION FOR RELIEVING PAIN - The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [Ar—CH═CH—COO—(CH06-07-2012
20090181924Compositions Comprising Glycosaminoglycans of Low Viscosity and Use of Said Composition in Therapy of Chronic Cystitis - The present invention concerns new compositions comprising glycosaminoglycans, intended for use in interstitial cystitis therapy, and characterized by a controlled viscosity.07-16-2009
20100298261EDIBLE COMPOSITIONS FOR LOWERING CHOLESTEROL - The present invention is related to improved compositions for reducing serum total and/or LDL cholesterol levels. The compositions are combinations of dietary fibre and plant sterol. The compositions are used as such or more advantageously in food products and comprise one or several fibres, preferably β-glucan, in combination with one or several plant sterols and/or stanols in their free and/or esterified forms.11-25-2010
20100144667METHODS FOR FUCOIDAN PURIFICATION FROM SEA WEED EXTRACTS - Methods for purifying fucoidan in extracts from brown seaweed are disclosed. In particular, methods of purifying fucoidan in the extract to remove heavy metal ions, bacterial and endotoxin contaminants, and other impurities are disclosed. The methods include the use of a chelating agent, selective precipitation, and filtration.06-10-2010
20090181925COMPOSITIONS FOR TREATING AND PREVENTING HYPERLIPIDEMIA - A composition for treatment and prevention of hyperlipidemia consists of phytosterols and phytostanols 30-50%, flavones derived from bamboo leaf 20-40%, procyanidins 10-25% and β-glucan of 5-20% by weight. Said composition demonstrates markedly therapeutic effects on preventing and treating hyperlipidemia, compared with the combinations of two or three components selected from phytosterols or phytostanols, flavones derived from bamboo leaf, procyanidins and β-glucan. When applied in supplementary nutrient foods or medicaments, the present composition can effectively lower the levels of cholesterol and triglyceride in blood, therefore can be useful for treating and preventing hyperlipidemia, cardiovascular diseases, coronary heart disease, atherosclerosis, heart disease and the like.07-16-2009
20090181926SKIN EXTERNAL PREPARATION HAVING EXCELLENT STABILITY - Disclosed is an agent for skin external preparation which is hardly reduced in viscosity even when stored for a long period under extreme high temperature storage conditions and is therefore stable. The preparation is in an emulsion form, and comprises (1) an alginic acid polyol ester having an esterification degree ranging from 75 to 95% (e.g., alginic acid propylene glycol ester) and/or a salt thereof; (2) a polyvalent metal ion (e.g., a calcium ion); and (3) a 4-alkylresolcinol (e.g., 4-n-butylresolcinol) and/or a salt thereof.07-16-2009
20090137525Glycosaminoglycan Composition and Method for Treatment and Prevention of Interstitial Cystitis - The invention provides compositions and methods useful for the treatment and/or prevention of interstitial cystitis and/or a related urinaly tract condition in man or in animals. Specifically, provided are compositions specially formulated for direct instillation into the bladder and/or parenteral use in the treatment and/or prevention of interstitial cystitis. Compositions adapted for direct instillation into the bladder and/or for systemic administration are provided comprised of therapeutic amounts of: chondroitin sulfate in combination with hyaluronan (hyaluronic acid) are provided. Compositions adapted for direct instillation into the bladder and/or for systemic administration are also provided comprised of therapeutic amounts of: chondroitin sulfate, hyaluronan (hyaluronic acid) and N-acetyl D-glucosamine.05-28-2009
20090163439Methods of using beta glucan as a radioprotective agent - The invention relates to methods for treating and preventing radiation and/or chemotherapy related injury and/or afflictions, such as myelosuppression and decreased macrophage activity, by administering a prophylactically or therapeutically effective amount of particulate, bioavailable β(1,3; 1,6) glucan. The invention also relates to methods in which β(1,3; 1,6) glucan is provided in the form of whole glucan particles, microparticulate β-glucan particles or a combination thereof.06-25-2009
20090005341PROCESS FOR THE PREPARATION OF N-ACYL-(EPI)K5-AMINE-O-SULFATE-DERIVATIVES AND PRODUCTS THUS OBTAINED - A new method is described for the oversulfation of (epi)K5-N-sulfates to obtain (epi)K5-amine-O-oversulfates at extremely high degree of sulfation and for the transformation of these intermediates into new N-acyl-(epi)K5-amine-O-oversulfates basically free of activity on the coagulation parameters and useful in the cosmetic or pharmaceutical field. Also described are pharmaceutical compositions containing, as one of their active ingredients, an (epi)K5-amine-O-oversulfate.01-01-2009
20090176733Novel Medicaments for Anti-Herpes Virus Treatments - The invention concerns the use of a sulphated or phosphated polysaccharide for preparing a drug for treating herpes virus mediated diseases, more particularly mediated by alpha-herpes viruses, and in particular by HSV-1 and HSV-2, as well as by strains of those viruses which are resistant to known antiviral agents. The polysaccharide is preferably sulphated laminarin PS3.07-09-2009
20090143329GIP SECRETION INHIBITOR - The present invention provides a postprandial GIP secretion inhibitor comprising potassium alginate as an active ingredient. The postprandial GIP secretion inhibitor of the present invention is useful as a medicine or a food product. The present invention also provides use of potassium alginate for the manufacture of a postprandial GIP secretion inhibitor. The present invention also provides a method for inhibiting postprandial GIP secretion, which comprises administering potassium alginate to a subject in need thereof or causing a subject in need thereof to consume potassium alginate.06-04-2009
20100004197PROCEDURE FOR THE PREPARATION OF GLYOXALATED CATIONIC GUAR - Procedure for the preparation of cationic guar having DS comprised between 0.01 and 3, soluble at basic pH and suitable for the use in the cosmetic field and in household cleaning products comprising the following steps: a) 100 parts by weight of guar flour are reacted with 3-chloro-2-hydroxypropyl trimethylammonium chloride and sodium hydroxide, in from 5 to 500 parts of a water and alcohol mixture containing from 20 to 50% by weight of water; b) the mixture is acidified to a pH between 4 and 6; c) from 2.2 to 3 parts by weight of glyoxal are added, and the reaction is stirred for approximately 30 minutes; d) from 300 to 1200 parts by weight of ambient temperature water are added and mixed for 10 to 90 minutes; e) the mixture is filtered under vacuum and the product dried to obtain glyoxalated purified cationic guar.01-07-2010
20100004196HEPARAN SULFATE PROTEOGLYCAN COMPOSITION AND USE THEREOF - The present invention relates to method for the preparation of glycosaminoglycan compositions, isolated glycosaminoglycan compositions obtainable therefrom, glycosaminoglycan compositions, kits and use thereof. More specifically, the present invention provides a method for isolating glycosaminoglycan compositions of the invention from human follicular fluid. The compositions, related methods and uses according to the present invention are useful in the treatment and/or prevention of thrombotic diseases, cell proliferation disorders, proteolysis and inflammation mediated cell invasion and infertility.01-07-2010
20100004195Decoy Influenza Therapies - The present invention provides umbrella-topology glycan decoys. The present invention provides systems and methods treating influenza infection utilizing inventive umbrella-topology glycan decoys. The present invention provides methods for identifying novel umbrella-topology glycan decoys.01-07-2010
20090118227CAROTENOID-CONTAINING COMPOSITIONS AND METHODS - The present invention is directed to carotenoid compositions and methods for inhibiting the growth of pathogenic bacteria or for preventing or treating bacterial infections in subjects by administration of an effective amount of astaxanthin and beta-carotene.05-07-2009
20090023681METHOD OF USING BETA-GLUCAN FROM SCHIZOPHYLLUM COMMUNE - Disclosed herein is a method for high-yield production of 01-22-2009
20090105191Pharmaceutical and Dermatocosmetic Compositions Comprising Extract of Durio Zibenthinus - The present invention relates to dermatocosmetic and pharmaceutical compositions comprising compounds obtained from 04-23-2009
20110230438VISCOELASTIC GEL FOR DERMATOLOGICAL USE - The invention relates to a polysaccharide gel of natural origin for dermatological use that comprises an aqueous solution of the polysaccharide of 0.1 to 5% by weight/volume, for example hyaluronic acid, and a viscous and strongly hydrophilic biocompatible alcohol at 0.5-5% by weight/volume, for example glycerol, and optionally the adjuvants that are commonly used in dermatology. The gel is prepared by mixing the polysaccharide solution and the strongly hydrophilic viscous alcohol before sterilizing the entire mixture by, for example, moist heat.09-22-2011
20090209485MODULATING ANGIOGENESIS WITH NOD FACTORS SUCH AS GLUCOSAMINE OLIGOSACCHARIDES - This invention relates to the use of Nod factors and derivatives thereof for the modulation of blood vessel growth and development as well as compositions for modulating angiogenesis.08-20-2009
20090163440Ion-Channel Regulator Compositions and Methods of Using Same - A composition and method for the treatment of degenerative joint disease is disclosed. The composition includes a combination of a first ion-channel regulator, at least a second ion-channel regulator, and a pharmaceutically acceptable carrier suitable for intraarticular injection. Methods and kits for treating a degenerative joint disease are also disclosed.06-25-2009
20080261915Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate - This invention relates to wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate.10-23-2008
20090197829Crosslinked polysaccharides and methods of production thereof - A substantially boron-free method for making a cationic guar comprises reacting particles of polysaccharide with a derivatizing agent to produce derivatized polysaccharide particles, washing the derivatized polysaccharide particles, and contacting, prior to or after the washing step, the particles with a glyoxal compound in order to crosslink the derivatized polysaccharide particles. Also disclosed are methods for making crosslinked derivatized polysaccharides, comprising (a) contacting particles of a polysaccharide with a titanium compound in an aqueous medium having an alkaline pH under conditions appropriate to intra-particulately crosslink the particles; (b) reacting, prior to or after the step of contacting the particles of polysaccharide with the titanium compound, the particles of polysaccharide with a derivatizing agent under conditions appropriate to produce derivatized polysaccharide particles; (c) washing the titanium crosslinked and derivatized particles; (d) contacting, concurrently with or after the step of washing the titanium crosslinked and derivatized particles, such particles with an aqueous medium having an acidic pH under conditions appropriate to substantially de-crosslink the particles; and (e) contacting, concurrently with or after step (d), the de-crosslinked particles with a glyoxal compound under conditions appropriate to intra-particulately crosslink the particles. The crosslinked cationic guar of the present invention is especially useful in home and personal care formulations, especially formulations comprising silicone since it improves silicone deposition.08-06-2009
20090253650Teat antiseptic prepared from polysaccharide gel with bactericidal and immuno-stimulating activity isolated from durian fruit-rind - A teat antiseptic having bactericidal activity against bacteria causing bovine mastitis. A post-milking teat dip and teat seal were prepared using polysaccharide gel with bactericidal, immuno-stimulating and wound healing activity isolated from durian fruit rind as active ingredient.10-08-2009
20090239820Compounds and methods for treatment of solid tumors - The present invention relates to pharmaceutical compositions containing targetable bioconjugates of hydralazine, a direct vasodilating agent previously shown to decrease tumor blood flow, oxygenation and interstitial fluid pressure in solid tumors. These bioconjugates are hydralazine prodrugs that contain hydralazine conjugated to biocompatible carrier molecules which specifically bind to sites that are expressed on a diverse variety of tumor cell types. These hydralazine prodrugs are preferably conjugated through an acid-labile hydrazone link that is designed to be stable in plasma and release hydralazine through acid-catalyzed hydrolysis in the acidic environment of the target tumor. Because these prodrugs are stable at physiological pH and in plasma, they are devoid of systemic vasoactive activity; however, they are acid-labile conjugates that can be hydrolyzed upon reaching the more acid environment of the tumor where the vasoactive activity of hydralazine is restored. These prodrugs selectively bind to tumor-specific receptors on tumor cells, and are degraded in the acidic tumor cell environment or the acidic lysosomal compartments after being internalized into the cell.09-24-2009
20090253651DRUG DELIVERY SYSTEM BASED ON REGIOSELECTIVELY AMIDATED HYALURONIC ACID - New drug delivery systems (DDS) are described containing hyaluronic acid and a therapeutic agent, wherein the therapeutic agent is linked, directly or via a linker, to 6-aminohyaluronic acid and where the linkage of the drug or linker with 6-aminohyaluronic acid is realised by an amide bond. Preferred therapeutic agents for use in the present DDS are anti-inflammatory, antibiotic, antitumor drugs. Preferred linkers are: succinic acid, succinic acid linked to aminoacids, succinic acid linked to peptides. The DDS are stable and free of undesired reaction by-products and impurities, and show a high level of pharmacological efficacy.10-08-2009
20090281057Botanically Derived Composition and a Process Thereof - The present invention relates to a novel botanical compound as provided in structural formula I optionally along with excipients for improving body composition and the factors related to the pre-diabetic and diabetic conditions. It also relates to a process of manufacture of the novel botanical compound for improving body composition and factors related to the pre-diabetic and diabetic conditions. The present invention also relates to the use of the novel botanical compound for improving body composition, reducing body fat, increasing muscle mass, enhancing strength and improving impaired glucose metabolism. The present invention also relates to the use of the novel botanical compound for the improvement of factors related to the pre-diabetic and diabetic conditions.11-12-2009
20090062232High-Purity Xylooligosaccharide Compositions - To provide a high-purity xylooligosaccharide composition while preventing the formation of UV-absorbing substances and coloring matters.03-05-2009
20120196829METHOD OF USING BETA-HYDROXY-BETA-METHYLBUTYRATE FOR THE PREVENTION AND TREATMENT OF DISEASE CONDITIONS - The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ω-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.08-02-2012
20090048209COMPOSITIONS COMPRISING DC-SIGN BLOCKERS AND METHODS OF USING DC-SIGN BLOCKERS FOR PREVENTING OR TREATING DISEASES OF A MAMMAL, INCLUDING VIRAL INFECTIONS - The present invention relates to methods and compositions for preventing or treating diseases of a mammal, including viral infections, wherein at least one symptom of the disease is mediated at least in part by the binding of an effector molecule to a DC-SIGN receptor present on cells of the mammal to be treated. The invention also provides methods of identifying compositions, wherein the compositions are useful for treating mammalian diseases, including viral infections, for which at least one symptom of the disease is mediated at least in part by the specific binding of an effector molecule to a DC-SIGN receptor present on the cells that express the DC-SIGN receptor, belonging to the mammal to be treated. The invention further relates to compositions and methods for targeting subject molecules to cells that express the DC-SIGN receptor.02-19-2009
20100261671INULIN PRODUCTS WITH IMPROVED NUTRITIONAL PROPERTIES - The invention relates to novel inulin products and compositions thereof, to their manufacture, to their use for modifying and modulating the bacterial flora and the fermentation pattern of inulin in the large intestine of humans, mammals or other vertebrates, to their use for providing improved inulin-associated nutritional effects/benefits, as well as to their use for the manufacture of consumer products and compositions for providing said effects/benefits in healthy, disfunctioned and diseased humans, mammals and other vertebrates.10-14-2010
20100184721Extract of Lentinus for Its Action on Cellulite and Accumulations of Fat - The present invention relates to the use of an extract of 07-22-2010
20110059918Stable Hyaluronan/Steroid Formulation - A pharmaceutical composition comprising in admixture a hyaluronic acid related component (HARC) and a pharmaceutically effective amount of triamcinolone hexacetonide (TAH). The composition is stable in an accelerated shelf life test in which the composition is heated to 80° C. for 24 hours.03-10-2011
20100216742Soluble Fiber Combinations for Weight Control and Improving Parameters of Cardiovascular Health - A food or pharmaceutical agent is provided for treating or offsetting the risks of a disease or disorder such as a cardiovascular disease, a hypercholesterolemia disorder, a low serum high density lipid (HDL)/low density lipid (LDL) ratio, a hypertriglyceridemia disorder, and diabetes includes a pharmaceutical carrier, and a composition including a purified glucomannan and at least one galactomannan. A method for treating or offsetting the risks of such a disease or disorder includes the step of administering to a human in need thereof an effective amount of the pharmaceutical composition to treat the cardiovascular disease.08-26-2010
20100179102INJECTABLE CROSS-LINKED POLYMERIC PREPARATIONS AND USES THEREOF - A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.07-15-2010
20100216741OPHTHALMIC COMPOSITION - The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) one or more member(s) selected from the group consisting of chondroitin sulfate, alginic acid and salts thereof; and (C) a nonionic surfactant.08-26-2010
20100216740Cereal-based Infant Nutrition with Fibre - Cereal-based semi-liquid and/or semi-solid compositions suitable for supporting the transition period wherein the infant changes from a diet consisting of breast milk or liquid infant formula to solid adult foods, comprising uronic acid carbohydrates with a degree of polymerisation (DP) between 10 and 300 and also uses thereof are disclosed.08-26-2010
20100216739METHOD OF PROMOTING MUSCLE TISSUE REPAIR - A method of treating a muscle tissue which is effected by providing the muscle tissue with an effective amount of a sterile polymer solution being essentially devoid of free multivalent cations and being capable of self-gelling following deposition in or around the muscle tissue.08-26-2010
20100240605NOVEL IMMUNOTHERAPY STRATEGY - The present invention relates to polyacetal-carboxylic acids, more in particular chlorite-oxidized oxyamylose (COAM) for use as a medicine, more in particular for the treatment or prevention of cancer and auto-immune disorders or relates to the use of polyacetal-carboxylic acids for the manufacture of a medicament for the prevention or treatment of cancer or auto-immune disorders. The invention provides also pharmaceutical compositions comprising said polyacetal-carboxylic acids and method of preventing or treating cancer and auto-immune disorders.09-23-2010
20100210585USE OF HYALURONIC ACID FOR THE PREPARATION OF COMPOSITIONS INTENDED FOR IMPROVING IN PARTICULAR THE PROTECTIVE FUNCTION OF THE SKIN, THE EYE AND THE MUCOUS - The present invention relates to the use of hyaluronic acid for the preparation of compositions intended for improving the protective function of the skin, the eye and the mucous membranes, in particular of the upper and lower airways and the intestinal mucosa.08-19-2010
20100210586POMEGRANATE EXTRACTS, NUTRITIONAL PRODUCTS CONTAINING THEM AND THEIR USES - The present invention relates to new pomegranate extracts, combined or not with soluble fiber, compositions free of any kind of organic solvent, soluble in cold water in high concentration, with very low sugar content and specially standardized to punicalagins, and its addition to foods to provide nutritional products and beverages with increased antioxidant capacity to be used as a source of punicalagins for preventing or treating cardiovascular diseases, plaque build-up in the arteries, arterial hypertension, and metabolic syndrome.08-19-2010
20090075935COMPOSITION COMPRISING AT LEAST ONE C-GLYCOSIDE DERIVATIVE AND AT LEAST ONE HYALURONIC ACID AND ITS COSMETIC USE - The present invention relates to a topical cosmetic and/or dermatological composition comprising, in a physiologically acceptable medium, at least one hyaluronic acid or a derivative thereof and at least one C-glycoside derivative.03-19-2009
20090075933CYTOCOMPATIBLE ALGINATE GELS - The present invention relates to a method of making cytocompatible alginate gels and their use in the treatment of cardiomyopathy.03-19-2009
20100168057FUNGAL GROWTH INHIBITOR - A very safe and useful agent for inhibiting fungal growth and the like are provided by the present invention. Specifically, the present invention provides (1) an agent for inhibiting fungal growth comprising hyaluronic acid or a salt thereof excluding a heavy metal salt as the active ingredient, and a method for inhibiting fungal growth, which comprises at least a step of allowing hyaluronic acid or a salt thereof excluding a heavy metal salt to contact with a fungus, (2) an agent for reinforcing activity of inhibiting fungal growth possessed by a cell, which comprises a DNA encoding a hyaluronic acid synthase as the active ingredient, (3) a method for reinforcing activity of inhibiting fungal growth of a cell, which comprises at least a step of transfecting a DNA encoding a hyaluronic acid synthase into the cell, and (4) a method for inhibiting fungal growth, which comprises at least a step of allowing a cell transfected with a DNA encoding a hyaluronic acid synthase to contact with a fungus.07-01-2010
20100210587Swellable Crosslinked Hyaluronan Powder And Method For Producing The Same - The present invention is provides a crosslinked hyaluronan powder excellent in swellability in water and a method for simply producing the same. A method for producing the swellable crosslinked hyaluronan powder is characterized by comprising mixing a crosslinking agent with a hyaluronan powder in a state dispersed in a liquid medium containing a monovalent alcohol having 1 to 4 carbon atoms and a solubility of the hyaluronan powder of less than 0.1 g/L to cause a crosslinking reaction. Also, the swellable crosslinked hyaluronan powder produced by the method has a swelling ratio in water of 500% or more.08-19-2010
20120142630PROCESS FOR PURIFYING GUAR - The present invention relates to processes for purifying guar comprising combining borate and guar in an aqueous solution and treating the aqueous solution with an organic solvent to induce precipitation of purified guar. Another embodiment of the present invention is directed to ophthalmic formulations comprising purified guar produced by the processes described.06-07-2012
20120142628METHODS FOR TREATING CREPITUS - Methods for treating and/or preventing crepitus and other joint problems using hyaluronic acid based formulations are provided.06-07-2012
20100099646W/O/W EMULSION COMPOSITION - A W/O/W emulsion composition having high emulsion stability, which can be prepared extremely easily and for which the production efficiency of the W/O/W emulsion product is favorable, and a method of producing such a W/O/W emulsion composition. The W/O/W emulsion composition of the present invention includes 0.001 to 60% by mass of a component (A) described below and 0.001 to 10% by mass of a component (B) described below; wherein, a mass ratio between the component (A) and the component (B) is within a range from 1:0.01 to 1:1.4. Component (A): a sugar fatty acid ester composition obtained by esterifying a sugar and a fatty acid of 8 to 28 carbon atoms, in which a hydroxyl value of said sugar fatty acid ester composition is within a range from 20 to 220. Component (B): a nonionic surfactant having an HLB value of not less than 7.04-22-2010
20100197631HYALURONIC ACID DERIVATIVES CONTAINING GROUPS ABLE TO RELEASE NO - Disclosed are hyaluronic acid derivatives functionalised with S-nitrosothiol groups of the general formula: wherein HA indicates hyaluronic acid and G indicates a suitable spacer.08-05-2010
20090181923Method of increasing weight gain and reducing diarrhea morbidity, mortality and severity by stimulation of natural immune response, nutritional support of immune function and supplemental nutricines and probiotics - A method for the promotion of growth and weight gain, the abatement of diarrheal disease and the reduction in mortality in a farm animal comprising administering bacterial polysaccharides derived from dried rumen fluid combined with nutritional aids is described. The use of a specialized nutritional composition the first few days of young animals' lives results in decreased diarrhea morbidity, severity and mortality. It also helps supply nutrients for the support of natural immune response and function.07-16-2009
20090318383COMPOSITIONS AND METHODS FOR MODULATION OF VASCULAR STRUCTURE AND/OR FUNCTION - The present invention relates to compositions comprising semi-crystalline β-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a β-1-4 conformation.12-24-2009
20090318382USE OF BACTERIAL POLYSACCHARIDES FOR BIOFILM INHIBITION - A method comprises preventing or inhibiting bacterial adhesion and/or bacterial biofilm development by treating a substrate with a composition of a soluble group II capsular polysaccharide obtained from a bacterial strain.12-24-2009
20090111771INHIBITION OF CATHEPSIN K ACTIVITY AND THE TREATMENT AND PREVENTION OF DISEASE - The present invention provides a candidate compound that is suitable for use in methods of treating animals (preferably mammals) and in the preparation of a medicament, wherein the candidate compound down regulates Cathepsin K activity.04-30-2009
20090111769Antithrombotic Compound - The present invention relates compounds of the formula I: oligosaccharide-spacer-GpIIb/IIIa antagonist I, wherein the oligosaccharide is a negatively charged pentasaccharide residue of the structure (I), the charge being compensated by positively charged counterions; the spacer is an essentially pharmacologically inactive linking residue of a length of 15-50 atoms; the GpIIb/IIIa antagonist is a residue derived from tirofiban or an analogue thereof; or a pharmaceutically acceptable salt thereof or a prodrug or a solvate thereof. The compounds of the invention have antithrombotic activity and can be used in treating or preventing thrombotic diseases.04-30-2009
20130131009Compositions Comprising High Molecular Weight Hyaluronic Acid and Methods For Producing Same - This invention provides cell culture compositions which produce significant quantities of high molecular weight hyaluronic acid. The cell cultures are obtained from cells of mole rats, such as naked mole rats and blind mole rats. The high molecular weight hyaluronic acid can be collected in the conditioned media of these cell cultures. These cell cultures provide a convenient source of large quantities of high molecular weight hyaluronic acid.05-23-2013
20130131010GALACTOSE-PRONGED POLYSACCHARIDES IN A FORMULATION FOR ANTIFIBROTIC THERAPIES - Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-β1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis.05-23-2013
20130131011HYALURONIC ACID-BASED GELS INCLUDING LIDOCAINE - Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.05-23-2013
20100305062USE OF ALGINATE OLIGOMERS IN COMBATING BIOFILMS - The invention provides a method for combating biofilm, said method comprising contacting a biofilm with an alginate oligomer. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use in the treatment or prevention of a biofilm infection in a subject. In another aspect the method can be used to combat biofilms, on abiotic surfaces, e.g., for disinfection and cleaning purposes.12-02-2010
20100323985PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF AND USE OF SAME - The invention relates to a combination of hyaluronic acid and of at least one inhibitor of hyaluronic acid degradation, for use in particular in human dermatology or in reconstructive surgery.12-23-2010
20110112049METHODS OF PREVENTING OR TREATING DISEASES AND CONDITIONS USING COMPLEX CARBOHYDRATES - The invention relates to a method of preventing and treating diseases and conditions associated with allergies, autoimmunity, the adhesion cascade, the metastatic cascade or the coronary cascade comprising administering (i) at least one complex carbohydrate as the sole active ingredient, or (ii) at least one pharmaceutical composition which comprises as an active ingredient a pharmacologically effective amount of at least one low purity or cosmetic grade complex carbohydrate selected from the group consisting of oligosaccharides, sialylated oligosaccharides, polysaccharides and glycosaminoglycans, and an effective amount of at least one transdermal or transmucosal carrier in an amount effective to deliver the complex carbohydrate into the blood stream.05-12-2011
20090036401Particulate-soluble glucan preparation - Particulate β-glucan is solubilized at elevated pressure and temperature to form particulate-soluble β-glucan. The particulate-soluble β-glucan is capable of being dried to a powder form and subsequently re-solubilized.02-05-2009
20100331276TOPICAL COMPOSITIONS AND THE USE THEREOF - The invention relates to a composition for topical application as well as the use of such a composition. The invention is characterised in that it comprises at least one first and one second mono- or oligosaccharide, each of said first and second mono- or oligosaccharides being capable of limiting the adhesion of microorganisms on the skin of warm-blooded animals with coats.12-30-2010
20110009359USE OF NON-DIGESTIBLE CARBOHYDRATES FOR IMPROVING INTESTINAL MICROBIOTA - A composition comprising at least two non-digestible carbohydrates for providing and/or maintaining an optimal intestinal microbiota is provided. The composition is especially suitable for infant nutrition.01-13-2011
20110245200USE OF IDRABIOTAPARINUX FOR DECREASING THE INCIDENCE OF BLEEDINGS DURING AN ANTITHROMBOTIC TREATMENT - The invention relates to the use of idrabiotaparinux for the treatment and secondary prevention of thrombotic pathologies, wherein the use of idrabiotaparinux involves a decrease in the incidence of bleedings, in particular major bleedings, during said treatment.10-06-2011
20110245199Sulfated Depolymerized Derivatives of Expolysaccharides (Eps) from Mesophilic Marine Bacteria, Method for Preparing the Same, and Uses Thereof in Tissue Regeneration - The invention relates to certain low-molecular weight sulphated polysaccharide derivatives of marine native exopolysaccharides (EPSs) excreted by mesophilic marine bacteria from a deep hydrothermal environment, wherein said derivatives can be obtained by means of a method which comprises a step of free radical depolymerisation of said native EPSs followed by a step of sulphating the resulting depolymerised derivatives. The present invention further relates to the use of said low-molecular weight sulphated polysaccharide derivatives as a wound-healing agent, particularly for preparing pharmaceutical compositions suitable for treating or preventing diseases of the connective tissues and particularly skin and gum tissues. The figure demonstrates how polysaccharide derivative GY 785 DRS according to the invention can stimulate fibroblast proliferation in latticed or reconstructed connective tissues at a concentration of 10 μg (m) g/ml.10-06-2011
20110245198ENHANCED TREATMENTS TO KILL OR DEBILITATE PATHOGENIC MICROORGANISMS OF A MAMMALIAN BODY - Present invention relates to a composition of matter and a method that improves treatments to inactivate, kill and debilitate pathogenic microorganisms that infect on or within a mammal body, such as 10-06-2011
20130150322PROCESS FOR OBTAINING AN ACTIVE INGREDIENT WITH AN IMMEDIATE TENSOR EFFECT ON THE SKIN, ACTIVE INGREDIENT AND COMPOSITIONS - The invention relates to a method for obtaining an active ingredient having an immediate anti-wrinkle and skin-tensioning effect, by extracting and purifying high molecular weight polysaccharides from oat bran, fibers and/or grains, and solubilizing and stabilizing the polysaccharides in water. The invention also relates to the product thus obtained, to uses thereof, and to cosmetic compositions containing this active ingredient. The oat bran polysaccharides include alpha-glucans having a molecular weight of between 25 kDa and 300 kDa.06-13-2013
20110034409USE OF PHARMACEUTICAL COMPOUND IN THE TREATMENT OF WOUNDS - A pharmaceutical composition that can be used in the treatment of wounds, comprising at least a sulfated polysaccharide and wherein the polysaccharide/s are in the form of solids as powder, flakes or sheets obtained through a lyophylization process. Particularly, this invention relates to the use of one or more sulfated polysaccharides, as solids in the form of sheets obtained by lyophylization, in the healing of wounds in humans and animals.02-10-2011
20110034407USE OF SPHINGOMYELIN AND NON-DIGESTIBLE CARBOHYDRATES FOR IMPROVING INTESTINAL MICROBIOTA - A composition comprising sphingophospholipid or its degradation product and at least one non-digestible carbohydrate for providing and/or maintaining an optimal intestinal microbiota is provided. The composition is especially suitable for infant nutrition.02-10-2011
20100286086COMPOSITION FOR THE TREATMENT OF OSTEOARTHRITIS - The present invention relates to compositions comprising chondroitin sulphate and mannosamine or a derivative thereof. The mannosamine derivative is preferably N-acetylmannosamine. The compositions may comprise glucosamine. Said compositions are useful in the treatment or prevention of degenerative joint diseases, preferably of osteoarthritis, in the treatment or prevention of tendon or ligament diseases, disorders or injuries and of immune system diseases, preferably of rheumatoid arthritis.11-11-2010
20110086814INHIBITING E.SAKAZAKII GROWTH - The present invention concerns the use of uronic acid saccharide for preventing growth of 04-14-2011
20100216743THERAPY-ENHANCING GLUCAN - This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition.08-26-2010
20100016257METHOD OF TREATMENT FOR OSTEOARTHRITIS BY LOCAL INTRA-ARTICULAR INJECTION OF MICROPARTICLES - A method of treatment of osteoarthritis is described, where a therapeutically effective amount of a composition having biodegradable microparticles in an aqueous vehicle is delivered into the intra-articular space of a joint. In one aspect, the microparticle-containing composition is injected into the synovial fluid-containing portion of an affected joint.01-21-2010
20110251155Methods of Using Diacerein as an Adjunctive Therapy for Diabetes - The present invention provides methods of treating type II diabetes using combinations of diacerein or its derivatives with other antidiabetic agents. The methods may also allow improving glycemic control of type II diabetes patients and/or reducing side effects and/or cardiovascular risks of antidiabetic agents.10-13-2011
20090312283BRANCHED HYALURONIC ACID AND METHOD OF MANUFACTURE - A branched hyaluronic acid, wherein the linear backbone comprises hyaluronic acid in which one or more N-Acetyl-Glucosamine has been deacetylated to Glucosamine, with branching sidechain(s) covalently linked to the primary amine(s) of said deacetylated Glucosamine thus forming a secondary amine(s); a precursor for producing said branched hyaluronic acid; and a method for producing said branching hyaluronic acid12-17-2009
20100063002METHOD OF IMPROVING SKILLS WITH A COMPOSITION COMPRISING NON-DIGESTIBLE SACCHARIDE - The present invention concerns a therapy aimed at language and/or social skills in infants through administration of components stimulating the development of a healthy intestinal flora.03-11-2010
20120245122CAROTENOID-CONTAINING COMPOSITIONS AND METHODS - The present invention is directed to carotenoid-containing compositions and methods for improving bone or respiratory health in a subject comprising administering to the subject a combination of lycopene, beta-carotene, and beta-cryptoxanthin.09-27-2012
20100069325Pharmaceutical composition for treatment of chronic liver diseases and use thereof - A pharmaceutical composition for treatment of chronic liver diseases, the composition including at least cordyceps sinensis polysaccharide, amygdaloside, and gypenoside. The pharmaceutical composition slows down liver fibrosis, stops the development thereof, or reverses the same. A method of using the pharmaceutical composition for treatment of chronic liver diseases.03-18-2010
20090215721DIETARY COMPOSITIONS AND RELATED METHODS OF USE - The present invention provides dietary compositions for mammalian consumption. In particular, the present invention provides compositions comprising pectin, a component comprising electrolytes, thickening agents, a sweetening agent, and water, and methods for making such compositions. In some embodiments, the dietary compositions are used for preventing and/or treating malabsorption dysfunction and associated disorders (e.g., short bowel syndrome, Crohn's disease). In some embodiments, the dietary compositions are used for preventing and/or treating colonic disorders (e.g., ulcerative colitis). The dietary compositions further find use in subjects with diarrhea, regardless of cause, subject suffering from gastric dumping syndrome, and obese patients or patients seeking to lose weight, as the composition delays gastric emptying (e.g., creating feeling of early satiety). In some embodiments, the dietary composition is a prebiotic food supplement.08-27-2009
20090215719LOW MOLECULAR WEIGHT HYALURONIC ACID AND/OR SALT THEREOF, METHOD FOR PRODUCING SAME, AND COSMETIC PREPARATION AND FOOD COMPOSITION CONTAINING SAME - A low-molecular-weight hyaluronic acid and/or its salt is obtained by dispersing hyaluronic acid and/or its salt in an acidic water-containing medium.08-27-2009
20100062997USE OF IDRAPARINUX FOR EXTENDED PROPHYLAXIS OF THROMBOEMBOLISM - The invention relates to the use of idraparinux for the extended prophylaxis of thromboembolism, in particular for the prevention of the recurrence of thromboembolism during 6 months after permanent discontinuation of the treatment with this drug.03-11-2010
20100069322INHIBITION OF CHOLERA TOXINS BY GALATOOLIGOSACCHARIDES (GOS) - The invention relates to nutritional and pharmaceutical compositions comprising non-digestible galactooligosaccharides (GOS) and uses thereof. In particular, it relates to the use of GOS species in preventing or treating disease caused by bacterial toxins. Provided is the use of GOS having a polymerization degree of 5 or higher, preferably 6 or higher, for the manufacture of a nutritional or pharmaceutical composition for the treatment or prevention of an acute or chronic disease associated with or caused by the adhesion and/or uptake of a cholera toxin family member. Also provided is a method for providing a GOS fraction capable of inhibiting cholera toxin (Ctx) binding to GM1 and fractions obtainable thereby.03-18-2010
20100069323COMPOSITION FOR APPLICATION TO SKIN OR MUCOSA - Disclosed is a composition for application to skin or mucosa comprising alginic acid and/or salts thereof, which has reduced cytotoxicity against a skin cell or mucosa cell and higher safety, the composition for application to skin or mucosa comprises an alginic acid and/or salts thereof that contains substantially no low-molecular-weight fraction having a molecular weight of 3,500 or less.03-18-2010
20100069320SYNERGISM OF GOS AND POLYFRUCTOSE - The present invention relates to the filed of prebiotics. Provided are uses for compositions comprising synergistically effective amounts of polyfructose and galactooligosaccharides (GOS).03-18-2010
20100249060Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes - A new topical formulation is provided, with a high chemical stability, of for example a low dose clobetasol propionate, suitable for the topical treatment of skin and mucous membrane conditions associated with disorders including psoriasis, eczema, and other forms of dermatitis and also topical use associated with the mouth, such as lichen planus. The formulation includes an aqueous vehicle of based on propylene glycol as a solvent and moisture-retaining agent, and macrogol-glycerol hydroxystearate as a non-ionic emulsifier, being capable of holding surprisingly low concentrations of clobetasol. The vehicle holds concentrations about 0.005% to about 0.05% by weight of 17-clobetasol propionate, more preferably about 0.02 to 0.025%, even more preferably 0.025% by weight of 17-clobetasol propionate. The formulation has a good chemical stability, resulting in a long durability.09-30-2010
20110098245AGENT FOR PREVENTING OR AMELIORATING OBESITY - The present invention provides a method for preventing or ameliorating obesity, for inhibiting accumulation of visceral fat, for inhibiting accumulation of liver lipid, for preventing or ameliorating fatty liver, including using a material for a pharmaceutical product or food, which has inhibitory actions on body weight increase, accumulation of visceral fat and accumulation of liver lipid. The present invention is also directed to a method for preventing or ameliorating obesity, a method for inhibiting accumulation of visceral fat, a method for inhibiting accumulation of liver lipid, and a method for preventing or ameliorating fatty liver, which methods include administering potassium alginate to a subject in need thereof or having the subject take potassium alginate.04-28-2011
20110098246METHOD FOR PREVENTING CORTICOSTEROID USAGE - The present invention relates to the use of nutritional compositions comprising non-digestible oligosaccharides for preventing corticoid administration, particularly to infants.04-28-2011
20110251156VEHICLE FOR DELIVERING A COMPOUND TO A MUCOUS MEMBRANE AND RELATED COMPOSITIONS, METHODS AND SYSTEMS - PSA is delivered to the host by outer membrane vesicles (OMVs), secretion structures that target bacterial molecules to host cells. Purified OMVs direct the in vitro differentiation of functional Tregs with potent suppressive activity in a PSA dependent manner. Treatment of animals with OMVs containing PSA prevents experimental colitis and suppresses pro-inflammatory cytokine responses in the gut, and indicate that compositions, medicaments, and methods useful for the treatment of inflammation, and more particularly, inflammatory bowel diseases.10-13-2011
20110251154SULFATED POLYSACCHARIDE COMPOUND AND THE PREPARATION AND USE THEREOF - The present invention relates to a sulfated polysaccharide compound and the preparation and use thereof, and in particular to a narrow distribution low molecular weight, highly sulfated pentosan (in this instance a xylan) referred to as glucuronoxylan sulfate (GXS). The invention has been developed primarily for use in the treatment of various clinical conditions. However, it will be appreciated that the invention is not restricted this particular field of use.10-13-2011
20110077216COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OTHER RELATED DISEASES - The present invention provides compositions and methods for the treatment of atherosclerosis and other related diseases. In some embodiments, a method comprises providing a composition and forming a coating of the composition on at least a portion of the interior and/or exterior surface of a tissue lumen or other body surface. The composition may remain associated with the tissue lumen or other body surface even in the presence of a strong flow of a fluid (e.g., blood flow in a blood vessel). The composition may associate with the tissue lumen via a plurality of covalent bonds. In some cases, the compositions may comprise at least one additive, for example, a therapeutically active agent or an imaging agent.03-31-2011
20110077218WOUND-HEALING PHARMACEUTICAL COMPOSITIONS IN THE FORM OF A STERILE POWDER BASED ON AMINO ACIDS AND SODIUM HYALURONATE - This invention relates to wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate.03-31-2011
20110046084EXOPOLYSACCHARIDE - An isolated polysaccharide has the structure [-β(1,3)-D-GalpNAc-β(1,4)-D-Glcp-]02-24-2011
20110077217SELECTIVELY DEPOLYMERIZED GALACTOMANNAN POLYSACCHARIDE - Disclosed herein are compositions and methods for treating diseases such as cancer. The compositions comprise one or more polysaccharides in an admixture with one or more therapeutic agents. This admixture can be administered to a subject in need thereof using any known method of administration. The therapeutic agent, if administered alone, can cause undesirable side-effects in the subject. The polysaccharide component minimizes or eliminates these side effects. The compositions described herein effectuate an enhanced therapeutic effect along with reduced toxicity.03-31-2011
20110071106GLYCOSAMINOGLYCAN ORAL USE AND COMPOSITIONS - The present invention concerns the use of a glycosaminoglycan association of hyaluronic acid and chondroitin sulfate for the preparation of oral compositions for the prevention or for the treatment of upper gastro-intestinal tract disorders and for the preparation of upper gastro-intestinal epithelial damage, as well as the oral compositions comprising said glycosaminoglycan association.03-24-2011
20110071104Methods for Treating Osteoarthritis - A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more osteoarthritis treatment agent(s) is also disclosed.03-24-2011
20120202769FGF RECEPTOR-ACTIVATING N-SULFATE OLIGOSACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - The invention relates to FGF receptor-activating N-sulfate oligosaccharides having Formula (I), wherein R08-09-2012
20110257124Esterified Polysaccharide Osmotics - The present invention relates to esterified polysaccharide osmotics, use of same, processes for synthesis of same as well as compositions containing same.10-20-2011
20080249063Composition for promoting the maintenance and function of muscle-specific progenitor cells - The biological function of skeletal muscle precursor cells in the repair and growth of skeletal muscle in response to exercise is promoted by providing a supplemental composition comprising at least creatine and fucoidin to reinforce biochemical pathways involved in the maintenance of skeletal muscle satellite cells and other myogenic precursors. The composition and method of the present invention induce muscle hypertrophy via satellite cells fusion to muscle fibres and induce a substantially simultaneous replenishment of myogenic precursor cells in response to exercise in a mammal.10-09-2008
20100113383BIFIDOBACTERIAL GENE SEQUENCES AND THEIR USE - This invention provides nucleic acids and proteins involved in oligosaccharide modification in the species 05-06-2010
20100063000FOOD CONTAINING GLYCOGEN AND USE THEREOF - The object is to improve a blood glucose level, a visceral fat level, a blood cholesterol level, a neutral fat level and the like. Disclosed is a food containing glycogen as a carbohydrate. The food can be ingested to improve a blood glucose level, a visceral fat level, a blood cholesterol level, a neutral fat level and the like comprehensively.03-11-2010
20120202768MICROALGAL POLYSACCHARIDE COMPOSITIONS - Provided herein are microalgal polysaccharide compositions and. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel microalgal compositions useful for improving the health and appearance of skin. The invention also includes insoluble polysaccharide particles for application to human skin.08-09-2012
20120202770ANIMAL FEEDS AND VETERINARY COMPOSITIONS - The present invention relates to an animal feed composition comprising protein from the family Fabaceae and protein from the family Asteraceae and to such formulations which also comprise glucan and/or mannan; such feeds finding utility in stabilising or increasing weight in a target animal, particularly fish, as well as in treating ectoparasitic infections, diarrhoea and bowel disease.08-09-2012
20120202771THERAPEUTIC AGENT FOR INFLUENZA VIRUS INFECTION DISEASES - Provided is a therapeutic agent for an influenza virus infectious disease, which utilizes an active ingredient derived from a natural product and has an excellent effect. The therapeutic agent for an influenza virus infectious disease includes, as an active ingredient, a β-glucan-containing composition obtained from a culture of a microorganism belonging to 08-09-2012
20090029941METHODS FOR CELL MOBILIZATION USING IN VIVO TREATMENT WITH HYALURONAN (HA) - The use of forms of hyaluronic acid having a molecular weight less than about 750,000 daltons selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof is provided for the same purposes known for using recombinant GM-CSF or G-CSF.01-29-2009
20090029940Plymorphic form of inulin and uses thereof - The present invention relates to a new polymorphic form of inulin, designated delta inulin (dIN), to methods for the preparation of dIN, compositions comprising dIN and uses thereof. The present invention also relates to the use of dIN and compositions comprising dIN in the preparation of gamma inulin (gIN), compositions comprising gIN and uses thereof.01-29-2009
20090170810METHODS OF TREATMENT OF CARDIOVASCULAR AND CEREBROVASCULAR DISEASES WITH LOW MOLECULAR WEIGHT FUCOIDAN - A method for treating an ischemic cardiovascular or cerebrovascular disease comprising administrating to a patient in the need of such treatment a pharmaceutical composition comprising low molecular weight fucoidan.07-02-2009
20090118230FUCOSE CONTAINING PROTEOGLYCAN OR ACIDIC GLYCAN AND THEIR PHARMACEUTICAL USE - A class of proteoglycans containing fucosylated acidic glycans, e.g., as produced by marine sponges and sea urchin embryos, have been found to stimulate selective proliferation of mammalian natural killer (NK) cells and γδT cells. These compounds are useful as pharmaceuticals, particularly as immunostimulants, e.g., in the treatment of cancer and viral infections.05-07-2009
20090118228CAROTENOID-CONTAINING COMPOSITIONS AND METHODS - The present invention is directed to methods for improving optical or skin health in a subject comprising administering to the subject a combination of lutein, zeaxanthin, lycopene, and beta-carotene.05-07-2009
20100056471SEMI-FLUID FOOD PRODUCT COMPRISING BETA-GLUCAN FIBRES - The present invention relates to a semi-fluid thermised aqueous solution comprising β-glucan fibres and a sufficient amount of at least one viscosity depressant chosen from the group composed of maltodextrins having a maximum DE of 18, at least partially hydrolysed guar gum, inulin and fructooligosaccharides. Another subject of the invention is a process for preparing such a thermised aqueous solution comprising a step of slowly cooling a thermised dispersion comprising water, at least one viscosity depressant and β-glucan fibres, under shear. The invention lastly relates to the use of such a thermised aqueous solution in a food product.03-04-2010
20090082307METHOD FOR PRODUCING OLIGOPOLYSACCHARIDES - The invention concerns the production by microbiological process of oligopolysaccharides of biological interest. More particularly, the invention concerns a method for synthesizing in vivo the oligopolysaccharides by internalization of an exogenous precursor in growing bacterial cells expressing adequate modifying and glycosylating genes.03-26-2009
20080312182OPHTHALMIC COMPOSITION WITH HYALURONIC ACID AND POLYMERIC BIGUANIDE - An ophthalmic composition comprising 0.5 ppm to 3 ppm of poly(hexamethylene biguanide), and 0.002 wt. % to 0.03 wt. % of hyaluronic acid. The weight ratio of hyaluronic acid to poly(hexamethylene biguanide) in the composition is from 45:1 to 120:1. The invention is also directed to a method of cleaning, disinfecting or packaging contact lenses with the composition, or to a method of rewetting contact lenses with the composition.12-18-2008
20090186850PERITONEAL DIALYSIS METHOD - A peritoneal dialysate containing adenosine triphosphate or a salt thereof, and a peritoneal dialysis method using the dialysate.07-23-2009
20110021456Sweetening compositions and processes for preparing them - The invention relates to sweetening compositions containing from about 16% to about 75% mogroside V and from about 30% to about 95% total terpene glycosides on a dry weight basis, and wherein a filtered (0.2 μm) solution of the composition in water having a solids content of 1% w/v has an absorbance at 420 nm of about 0.55 or below. The invention also relates to methods of preparing such compositions.01-27-2011
20110053887SOCS3 EXPRESSION PROMOTER, DRUG AND FOOD CONTAINING THE SAME AND METHOD OF PROMOTING THE EXPRESSION OF SOCS3 - A SOCS3 expression promoter includes hyaluronic acid having an average molecular weight of 500,000 or more and/or a salt thereof as an active ingredient.03-03-2011
20110053886Delayed Self-Gelling Alginate Systems and Uses Thereof - Dispersions that comprise insoluble alginate/gelling ion particles in an alginate solution, wherein the dispersion exhibits less than 10% of final gel storage modulus after one minute in the absence of addition of non-gelling cations are disclosed. Kits and compositions for making such dispersions are disclosed and methods for making and using the dispersions, and the components used in the dispersions are also disclosed.03-03-2011
20110053885PHARMACEUTICAL AGENT HAVING LONG-LASTING EFFECT OF TREATING ARTHRITIC DISORDERS - The present invention relates to an injection solution for intra-articular administration for treating arthritic disorders comprising a cross-linked hyaluronic acid derivative wherein part of functional groups of a hyaluronic acid are cross-linked with a cross-linking group to the extent of 0.6 to 15% of cross-linking extent as an active ingredient in an amount having a long-lasting analgesic effect and a pharmaceutically acceptable carrier, and an analgesic composition for suppressing a cartilage degeneration caused by arthritic disorders or a composition for suppressing a cartilage degeneration or an inflammation of synovium caused by arthritic disorders each comprising the cross-linked hyaluronic acid derivative and a pharmaceutically acceptable carrier.03-03-2011
20110028428HIRSUTELLA SINENSIS MYCELIA COMPOSITIONS AND METHODS FOR TREATING SEPSIS AND RELATED INFLAMMATORY RESPONSES - Compositions comprising 02-03-2011
20110028426DEWATERING BIOMASS MATERIAL COMPRISING POLYSACCHARIDE, METHOD FOR EXTRACTING POLYSACCHARIDE FROM BIOMASS MATERIAL, AND DEWATERED BIOMASS MATERIAL - A process for dewatering biomass material comprising polysaccharide and water. The process comprises wetting the biomass material with a wetting composition comprising an alcohol to form a biomass slurry comprising wetted biomass material and a liquid component, mechanically separating a portion of the liquid component from the biomass slurry, and mechanically separating at least a portion of the water from the wetted biomass material. A process for extracting polysaccharide from the biomass material and a dewatered biomass material are also disclosed.02-03-2011
20100286085NOVEL CHONDROITIN SULFATE HAVING DECREASED MOLECULAR WEIGHT AND USE THEREOF - An object of the present invention is to provide a chondroitin sulfate having a decreased molecular weight which has utilization as an inhibitor of peritoneal disorder caused by long-term use of a peritoneal dialysis fluid containing glucose or a polysaccharide thereof as an osmotic agent, utilization as an osmotic agent in a peritoneal dialysis fluid, and the like. The chondroitin sulfate having a decreased molecular weight of the present invention as a means for achieving the object is characterized by having a weight average molecular weight of from 1000 to 20000 and containing a constituent disaccharide unit represented by the following structural formula in an amount of from 65 o to 100% (molar ratio) of the total.11-11-2010
20110118206HYALURONIC ACID BASED FORMULATIONS - Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on low molecular weight hyaluronic acids and pharmaceutically acceptable salts thereof, and methods of manufacturing same.05-19-2011
20110257123ARYL/ALKYL VINYL SULFONE HYALURONIC ACID DERIVATIVES - A hyaluronic acid derivative, and methods of producing and using said derivative, the derivative comprising n repeating units and having the general structural formula (I), wherein, in at least one repeating unit, one or more of R1, R2, R3, R4 comprises an etherbound aryl/alkyl sulfone having the general structural fomula (II), wherein R comprises an alkyl- or aryl-group, and otherwise R1, R2, R3, R4 are hydroxyl groups, OH.10-20-2011
20100298260NON-ANTICOAGULANT POLYSACCHARIDE COMPOSITIONS - Preparations of polysaccharides lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.11-25-2010
20100298262PROCESS FOR THE ULTRAPURIFICATION OF ALGINATES - A process for the ultrapurification of alginates is provided. In particular, the process may be used for microencapsulation in human cell transplants.11-25-2010
20110136758CARBOHYDRATE COMPOSITIONS FROM BASIDIOMYCETE FUNGI AS BIOCIDAL AGENTS ACTIVE AGAINST PATHOGENS - The invention provides biologically active compositions comprising oligosaccharides, and which are produced by growing a fungal culture, and are at least partially purified for use. The compositions of the invention have antibacterial, antifungal and nematicidal activity, and are thus useful to reduce the impact of such pathogens on growing plants, to reduce the occurrence of such pathogens on surfaces and in substances, and to treat infections caused by such pathogens in animals and humans. The invention also provides methods for producing such compositions from certain fungal cultures.06-09-2011
20110257125Mucomimetic compositions and uses therefore - The present invention relates to mucomimetic and ophthalmic solutions comprising a cationic multimeric antimicrobial agent such as polyaminopropyl biguanide and a magnesium, calcium or magnesium/calcium complex of an anionic polymer such as hyaluronate, alginate, carboxymethyl cellulose, chondroitin sulfate or mixtures thereof. In specific embodiments, the solutions include additional components such as a surfactant, a viscosity-modifying agent, a tonicity agent and a buffer. The solutions are biocompatible with and are highly comfortable when administered to mucous membranes, including those of the eye, as well as are effective disinfectants.10-20-2011
20120302522SYNERGISTIC ANTIVIRAL COMPOSITION AND USE THEREOF - The present invention relates to iota- and/or kappa-carrageenan in combination with a neuraminidase inhibitor for use as a medicament in the prophylactic or therapeutic treatment of a symptom, condition or disease caused by or associated with an infection by an influenza virus.11-29-2012
20120302521INHIBITION OF PANCREATIC LIPASE - The present invention provides the use of an alginate Io inhibit pancreatic lipase. The use may be directed to the control of weight in animals including human beings. Preferably the fraction of guluronate dimers in the alginate is at least 0.5.11-29-2012
20100168059HYALURONIC ACID NUTRITIONAL SUPPLEMENTS AND METHODS OF USING THE SAME - Hyaluronic acid nutritional supplements and methods of using the same. In at least one embodiment of a nutritional supplement of the present disclosure, the nutritional supplement comprises a quantity of a hyaluronic acid, or a salt or digest thereof, and a food acceptable carrier.07-01-2010
20100168056DIETARY FIBER FORMULATION AND METHOD OF ADMINISTRATION - The invention provides dietary fiber formulation and related methods for its administration. In one embodiment, the invention provides a dietary fiber formulation comprising: partially-hydrolyzed guar gum (PHGG); and fructooligosaccharides (FOS), wherein the dietary fiber formulation exhibits a prebiotic potential greater than a prebiotic potential of PHGG and FOS individually.07-01-2010
20100168058NOVEL ANTAGONISTS OF THE TOLL-LIKE RECEPTOR 4 - The present invention relates to a novel antagonist of the Toll-like receptor 4 (TLR-4). More specifically, the present invention relates to a lipopolysaccharide (LPS) isolated from the bacterium 07-01-2010
20100062998Prevention and/or Treatment of Neurodegenerative Disorders - A pharmaceutical composition for use in the prevention and/or treatment of a neurodegenerative disorder comprising a compound comprised of one or more disaccharide units, the or each disaccharide unit comprising a uronate moiety linked to a glucosamine moiety, wherein the 2-O atom of the uronate moiety is substituted with a hydrogen atom, the 6-O atom of the glucosamine moiety is substituted with a sulphate group and the 2-N atom of the glucosamine moiety is substituted with an atom or group other than a sulphate group. The composition is particularly preferred for use in the prevention and/or treatment of Alzheimer's disease.03-11-2010
20100210588Hyaluronic Acid Linked with a Polymer of an Alpha Hydroxy Acid - The invention concerns a product comprising hyaluronic acid or a salt thereof, wherein the hyaluronic acid has been partially or fully linked or crosslinked with a polymer of an alpha hydroxy acid. The invention also concerns manufacture of the product, uses of the product of the invention in the field of biodegradable plastic materials for the preparation of sanitary and surgical articles, in the pharmaceutical and cosmetic fields; including the various articles made with the same in such fields.08-19-2010
20120309711MODIFIED PECTINS, COMPOSITIONS AND METHODS RELATED THERETO - The present invention provides compositions of modified pectin and methods for preparing and using them.12-06-2012
20120309710Compound sea cucumber preparation and manufacturing method thereof - A sea cucumber preparation and manufacturing method thereof, comprising steps as follows: put the cut and well-cleaned fresh sea cucumber or soaked sea cucumber into an airtight container; at 70˜130° C., gelatinate for 1 min˜20 h, freeze-dry till the water content is less than 10 wt %, then sequentially carry out coarse, ultra-micro and nanometer crushing till the fineness reaches 10˜1000 nm. Add water into the sea cucumber nanometer powder to carry out proteinase enzymolysis, after the enzymolysis is finished, inactivate the proteinase, separate and take the supernatant and dry to get nanometer sea cucumber extract. Evenly mix the extract with panax pseudo-ginseng saponins extract at the proportion of 99˜70%:1˜30%. The content of the sea cucumber polysaccharide in the mixture is 2.5˜8.0 wt %, the content of panax pseudo-ginseng saponins is 0.3˜21.0 wt %. The compound preparation has complementary and synergistic effects on pharmacological effect. The side effects of single preparation can be eliminated through the compound preparation, the pharmacological functions of the sea cucumber or panax pseudo-ginseng single preparation are greatly enhanced, and can be used for anti-coagulation, diabetes and other various medicinal purposes.12-06-2012
20120309709Ion-Channel Regulator Compositions and Methods of Using Same - A composition and method for the treatment of degenerative joint disease is disclosed. The composition includes a combination of a first ion-channel regulator, at least a second ion-channel regulator, and a pharmaceutically acceptable carrier suitable for intraarticular injection. Methods and kits for treating a degenerative joint disease are also disclosed.12-06-2012
20090176734Method For Simulating The Functional Attributes Of Human Milk Oligosaccharides In Formula-Fed Infants - The present invention is directed to a novel method for increasing the production of acetate, decreasing the production of butyrate, increasing the population and species of beneficial bacteria and slowing the rate of fermentation of prebiotics within the gut of a formula-fed infant. The method comprises administration of a therapeutically effective amount of PDX to the infant.07-09-2009
20100190742COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISING HYALURONIC ACID AND ADMINISTRATION THEREOF FOR REDUCING SIGNS OF AGING - Cosmetic/pharmaceutical compositions contain, formulated into a physiologically acceptable medium, at least (i) hyaluronic acid and/or one of its derivatives and (ii) a C-glycoside compound, at least one of the constituents (i) and (ii) advantageously being in a form suitable for administration by injection, and administration thereof for filling depressions on the surface of the skin and for reducing signs of aging or for re-establishing the volume of the body or face.07-29-2010
20100190741INJECTABLE CROSS-LINKED POLYMERIC PREPARATIONS AND USES THEREOF - A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.07-29-2010
20110201570NUCLEUS PULPOSUS FILLER - The present invention provides a nucleus pulposus filler or the like which is to be packed into an area in deformed intervertebral disc wherein normal nucleus should be located and can be stabley maintained for a long time More preferably, the present invention provides a nucleus pulposus filler comprising a crosslinked chondroitin sulfate as an active ingredient. The photocrosslinked chondroitin sulfate is preferably the following one: a photocrosslinked chondroitin sulfate obtainable by freezing a photoreactive chondroitin sulfate-containing solution comprising: a photoreactive chondroitin sulfate to which a photoreactive group is bound; an aqueous solvent capable of dissolving the photoreactive chondroitin sulfate; and any one substance selected from the group consisting of an alcohol having aqueous solvent miscibility, a surfactant, and a cheleting agent; irradiating the resulting frozen product with light; and then melting the frozen product. The filler can be provided as a kit by packing it into a container from which the filler can be pushed out.08-18-2011
20100022470METHOD FOR TREATING ALLERGIC DISEASES - The present invention relates to use of polysaccharides obtained from 01-28-2010
20100022472LIQUID, EYE-INSTILLABLE PREPARATIONS COMPRISING SODIUM HYALURONATE - A liquid, eye-instillable preparation comprises a viscosity-enhancing agent comprised of one or both of sodium hyaluronate and chondroitin sulphate, a preservative comprised of polyhexanide, and one or more carriers in which the agent and the preservative are dispersed.01-28-2010
20100022471Oral Moisturizer for Alleviating Dry Mouth - An oral moisturizer is disclosed to provide relief from dry mouth. The moisturizer may be provided in different flavors that are palatable, with clinical benefits such as anti-nausea, appetite stimulant, etc., in addition to relief from the deteriorating dental effects of dry mouth. One disclosed oral moisturizer includes glycerin, xylitol, sodium hyaluronate, cetylpyridinium chloride, polysorbate surfactants and a palatable flavor.01-28-2010
20090099128Composition and method for treating autoimmune disease and mucosal disorder - The present invention provides the composition and the method for treating autoimmune diseases and a mucosal disorder via oral-tolerance induction and innate immunity promotion. The composition for treating the autoimmune disease and mucosal disorder includes the polysaccharide prepared from a plant, wherein the plant belongs to Genus 04-16-2009
20110218172COMPOSITION FOR DOWN-REGULATING PRO-INFLAMMATORY MARKERS - The present invention provides a composition for down-regulating pro-inflammatory markers. The composition comprises boswellic acid fraction and polysaccharide faction obtained from 09-08-2011
20090099129INULIN OF VERY HIGH CHAIN LENGTH - The invention relates to a long-chain inulin and its preparation from artichoke roots, to its use in foodstuffs and cosmetic preparations and to foodstuffs and cosmetic preparations which comprise the long-chain inulin.04-16-2009
20100113384BACTERIAL ENDOTOXIN FOR THE PREVENTION OF METABOLIC DISORDERS AND BACTERIAL INFECTIONS - The invention provides compositions and methods for preventing a metabolic disorder or bacterial infection in a subject, the composition comprising a bacterial endotoxin.05-06-2010
20110046085Oral Immunostimulation of Fish from (1-4) Linked Beta-D-Mannuronic Acid - An oral, immunostimulating material for mammals, birds, fish, and reptiles comprising an immunostimulating amount of an alginate having a M content of at least 40% and an acceptable carriers.02-24-2011
20100279981OPHTHALMIC COMPOSITIONS BASED ON TAMARIND SEED POLYSACCHARIDE AND HYALURONIC ACID - The invention concerns ophthalmic solutions indicated for use as tear substitutes, containing a combination of hyaluronic acid and a polysaccharide known as TSP (11-04-2010
20090247485BARRIER FILM-FORMING COMPOSITIONS AND METHODS OF USE - Long-lasting persistent, uniform, film-forming skin protecting compositions provide long-lasting persistent barrier films when applied to skin. The compositions have particular utility as barrier teat dips for protecting cows against mastitis and as wound care agents. A barrier film-forming agent is selected from pullulan, pullulan derivatives and combinations thereof. The barrier film-forming agent is stably solubilized in a solvent that dries to form the long-lasting, persistent, uniform film over the animal skin. The compositions may contain additives, such as antimicrobial agents that kill microorganisms.10-01-2009
20110009360Nutraceutical Composition and Methods for Preventing or Treating Multiple Sclerosis - The present invention embraces nutraceutical compositions containing isolated 01-13-2011
20100184720USE OF A NATURAL POLYSACCHARIDE GEL FOR THE PREPARATION OF AN INJECTABLE FORMULATION FOR TREATMENT OF ARTICULAR DEGENERATION - A sterile injectable aqueous formulation in the form of a gel is made up of hyaluronic acid (or one of the salts thereof) with or without other natural polysaccharide(s) and one or more polyols. The formulation is of intra-articular application in the treatment of joint degeneration, in some cases having a rheology similar to that of synovial liquid and always with an elevated resistance to degradation due to a synergistic action between the hyaluronic acid and the polyols.07-22-2010
20090312282Novel Low Molecular Weight Hyaluronic Acid and/or Salt Thereof, and Cosmetic Preparation, Pharmaceutical Composition, and Food Composition Each Using Same - A low-molecular-weight hyaluronic acid and/or its salt has an average molecular weight of 5000 to 20,000, and has a molecular weight distribution in which the proportion of components having a molecular weight of 10,000 or less is 40 wt % or more and the proportion of components having a molecular weight of 50,000 or more is 5 wt % or less.12-17-2009
20100160253SULPHATED XYLANS FOR TREATMENT OR PROPHYLAXIS OF RESPIRATORY DISEASES - The present invention relates generally to agents and medicinal protocols useful in the prophylaxis and/or treatment of respiratory diseases or conditions such as asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD). More particularly, the present invention relates to the use of a sulfated xylan or a derivative or homolog thereof in the treatment of respiratory diseases or conditions.06-24-2010
20090042832NOVEL SALTS OF BOSWELLIC ACIDS AND SELECTIVELY ENRICHED BOSWELLIC ACIDS AND PROCESSES FOR THE SAME - New salts or ion pair complexes obtained by a reaction between boswellic acids or selectively enriched 3-O-acetyl-11-keto-β-boswellic acid (AKBA) or 11-keto-β-boswellic acid (KBA) compounds obtained through a new improved process, and an organic amine, more particularly with glucosamine. These salts or ion pair complexes are useful in nutraceuticals and in food supplements for anti-inflammatory and analgesic treatment of joints and cancer prevention or cancer therapeutic agents. These salts or ion pair complexes could also be used in cosmetic or pharmaceutical composition for external treatment of body parts or organs to treat inflammatory diseases or cancer.02-12-2009
20110034408HIGH OIL CONTENT O/W EMULSIONS STABILIZED WITH A HYDROPHOBICALLY MODIFIED INULIN AND A HYDROPHILIC ACRYLIC POLYMER - The invention relates to a composition in the form of an oil-in-water emulsion comprising, in a physiologically acceptable medium: i) at least 0.005% by weight, preferably at least 0.01% by weight, relative to the total weight of the composition, of at least one inulin modified with hydrophobic chains, and ii) at least 0.01% by weight, preferably at least 0.05% by weight, of active substance relative to the total weight of the composition, of at least one hydrophilic acrylic polymer selected from the at least partially neutralized, crosslinked acrylic homopolymers or copolymers, the polyacrylamidomethyl-propanesulphonic acid (AMPS) homopolymers and mixtures thereof. It also relates to a cosmetic method employing said composition.02-10-2011
20130012471MEANS AND METHODS FOR PRODUCING ARTIFICIAL CAPSULAR POLYSACCHARIDES OF NEISSERIA MENINGITIDIS - The invention provides for an in vitro method for producing capsular polysaccharides of 01-10-2013
20130012470ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE - Novel compositions comprising viral fusion inhibition compounds and viral replication inhibition compounds as well as methods of their use are disclosed. The novel compositions are useful, inter alia, in the prevention, inhibition and/or treatment of Dengue Fever (DF) or Dengue Hemorrhagic Fever (DHF).01-10-2013
20130012472COMPOSITION AND METHODS OF INHIBITING GASTROINTESTINAL PATHOGEN INFECTION - Compositions comprising a milk-derived oligosaccharide such as trifucosyl(1,2-1,2-1,3)-lacto-N-octoase (TFiLNO) and uses thereof for inhibiting invasion of gastrointestinal pathogen into intestinal epithelial cells or for treating an infectious disease (e.g., a disease caused by a gastrointestinal pathogen such as an ETEC) or an inflammatory diseases such as inflammatory bowel disease.01-10-2013
20100160252OPHTHALMIC COMPOSITIONS CONTAINING MUCOADHESIVE POLYSACCHARIDES ABLE TO PROMOTE CORNEAL RE-EPITHELIZATION - Ophthalmic solutions containing arabinogalactans with a protective activity on the corneal epithelium, particularly suitable for use as artificial tears stimulating the recovery of corneal lesions and also particularly useful for contact lens users, containing from 1% to 10% by weight of arabinogalactan in an aqueous solution and possible other excipients, among which tonicity-adjusting agents, pH correctors, buffers and preservatives, except for benzalkonium chloride.06-24-2010
20110059919ANTIVIRAL COMPOSITION COMPRISING A SULFATED POLYSACCHARIDE - The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus. The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus.03-10-2011
20090105190Method for Producing Fucoidan, Fucoidan, and Fucoidan-Containing Composition - The present invention provides a method for producing high molecular-weight fucoidan, which is expected to be promising as a cosmetic composition or an agent in the field of dermatology, and a high molecular-weight fucoidan-containing composition.04-23-2009
20090075934USE OF SULFATED OLIGOSACCHARIDES AS SLIMMING COSMETIC INGREDIENTS - This invention relates to the use of a preparation comprising sulfated oligosaccharides which trap spermine or spermidine or both, as an active slimming ingredient in a cosmetic, pharmaceutical and/or nutraceutical composition.03-19-2009
20100197632ANTI-INFLAMMATORY DERMATOLOGICAL COMPOSITION COMPRISING CORTICOSTEROIDS AND HYALURONATE FRAGMENTS, AND USES THEREOF - Anti-inflammatory dermatological composition for topical administration, characterized in that it comprises 0.005% to 0.1%, preferably 0.01% to 0.05% by weight of a corticosteroid and 0.1% to 1%, preferably 0.5% to 1% by weight of hyaluronate fragments with an average molecular weight of between 20 and 500 kDa, preferably between 20 and 375 kDa, more preferentially between 20 and 150 kDa.08-05-2010
20120040926Process For Obtaining Polysaccharides From Jatoba (Hymenea Courbaril L) Seeds, Cosmetic Composition Comprising Said Polysaccharides And Uses Thereof - The present invention relates to a process for obtaining polysaccharides from jatoba seeds, comprising the steps of: a) seed processing (dry process); b) aqueous extraction at 1% to 5% of powder mass per volume, preferably 2% of powder mass per volume; c) precipitation with ethanol 969GL using 1 to 3 times the aqueous extract volume; d) press filtration of the precipitate obtained in (c); e) solublization of the polysaccharides obtained in step (d) with water; and f) drying the polysaccharides obtained in step (e). In another embodiment, the present invention relates to a cosmetic composition containing polysaccharides obtained according to the process defined above and to the use of said polysaccharides.02-16-2012
20110077219OPHTHALMIC PHARMACEUTICAL COMPOSITIONS BASED ON AMINO ACIDS AND SODIUM HYALURONATE - This invention relates to opthalmic wound-healing pharmaceutical compositions based on amino acids and sodium hyaluronate.03-31-2011
20100063001MICROBIAL-DERIVED CHONDROITIN SULFATE - Described is chondroitin sulfate obtained from microbial sources, and related compositions and methods.03-11-2010
20110071105WOUND-HEALING PHARMACEUTICAL COMPOSITIONS IN THE FORM OF A CREAM BASED ON AMINO ACIDS AND SODIUM HYALURONATE - This invention relates to wound-healing pharmaceutical or cosmetic (anti-skin aging) compositions in the form of a cream based on amino acids and sodium hyaluronate.03-24-2011
20090048208METHOD FOR PRODUCING THE LOW MOLECULAR WEIGHT BETA-GLUCAN BY IRRADIATION AND LOW MOLECULAR WEIGHT BETA-GLUCAN PRODUCED BY THE METHOD - Disclosed herein is a method for the preparation of low-molecular weight beta-glucan by irradiation. The low-molecular weight beta-glucan prepared by irradiation shows a random distribution of all beta-glucan structures, low viscosity and high water solubility, and acts as an excellent antioxidant and to activate immune cells, finding useful application in many fields including the food, medical and cosmetics industries.02-19-2009
20110319357Hyaluronic Acid Derivatives - The present invention relates to the modification of hyaluronic acid (HA) with aryl/alkyl succinic anhydrides (ASA) to produce aryl/alkyl succinic anhydride HA derivatives, to the derivatives as such, and to their applications and uses, particularly in the cosmetic and biomedical industries. The ASA-HA derivatives are expected to have interesting properties that can be used for advanced formulation (bind stronger to the skin compared to non-modified HA), possibly also in delivery systems for actives or drugs by encapsulation (nano/micro capsules) or formation of nano/micro spheres. Further, the low MW ASA-HA derivatives are expected to penetrate the skin more efficiently than non-modified HA of the same MW.12-29-2011
20090036402Use of compounds from centella asiatica - Use of compounds extracted from 02-05-2009
20120004194ALDEHYDE-FUNCTIONALIZED POLYSACCHARIDES - Novel aldehyde-functionalized polysaccharide compositions are described that are more stable in aqueous solution than oxidized polysaccharides or other types of polysaccharides containing pendant aldehyde groups. The aldehyde-functionalized polysaccharides may be reacted with various amine-containing polymers to form hydrogel tissue adhesives and sealants that may be useful for medical applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, preventing leakage of fluids such as blood, bile, gastrointestinal fluid and cerebrospinal fluid, ophthalmic procedures, drug delivery, and preventing post-surgical adhesions.01-05-2012
20100173867INJECTABLE CROSS-LINKED POLYMERIC PREPARATIONS AND USES THEREOF - A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.07-08-2010
20120010166Stable iron oligosaccharide compound - The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.01-12-2012
20080234224External Preparation For Skin - The present invention provides an external preparation for skin, which comprises a multi-branched polysaccharide derivative with multi-branched polysaccharide skeleton consisting of saccharides as constituent units, wherein at least one of hydroxyl (OH) groups in the multi-branched polysaccharide skeleton is substituted by OR (wherein R represents a hydrogen atom, a hydrocarbon having 1 to 30 carbon groups or a hydrocarbon having 1 to 30 carbon groups which has hetero atom), which can give moisture and turgor to the skin, and cosmetics containing the external preparation.09-25-2008
20080207560Composition For External Use - An object of the present invention is to provide a composition for external use in which the percutaneous absorbability of vitamin A, vitamin A derivative(s), vitamin C, specific vitamin C derivative(s), xanthine derivative(s), ubiquinone(s) and/or hyaluronic acid is improved.08-28-2008
20110166100MIXTURE OF HYALURONIC ACID FOR TREATING AND PREVENTING INFLAMMATORY BOWEL DISEASE - The present invention is related to a hyaluronic acid formulation including a mixture of hyaluronic acids having different weight-average molecular weight and different rheological, tissue scaffold, insulation and degradation properties in aqueous solution. The resulting formulation demonstrated an optimal balance between adhesion, tissue scaffold, insulation and treating time on the treatment and prevention of IBD (inflammatory bowel disease) such as ulcerative colitis and Crohn's disease. Thus, the formulation of the present invention exhibits a quick and lasting effect on the treatment and prevention of duodenal or peptic ulcer and bleeding which is very good thing indeed.07-07-2011
20110166098MIXTURE OF HYALURONIC ACID FOR TREATING AND PREVENTING INFLAMMATORY BOWEL DISEASE - The present invention is related to a hyaluronic acid formulation including a mixture of hyluronic acids having different weight-average molecular weight and different rheological, tissue scaffold and degradation properties in aqueous solution. The resulting formulation demonstrated an optimal balance between adhesion, tissue scaffold and treating time on the treatment and prevention of IBD (inflammatory bowel disease) such as ulcerative colitis and Cohn's disease. Thus, the formulation of the present invention exhibits a quick and lasting effect on the treatment and prevention of duodenal or peptic ulcer and bleeding which is very good thing indeed.07-07-2011
20120015902ARABINOXYLO-OLIGOSACCHARIDES USEFUL AGAINST GASTROINTESTINAL INFECTIONS - The present invention relates to the use of oligosaccharides derived from arabinoxylan for use in the prevention and treatment of gastrointestinal infection. More particularly the invention provides a method for preventing or reducing the gastrointestinal infection of a animal or human being with bacteria associated with gastroenteritis through the supplementation of their diets with the said oligosaccharides.01-19-2012
20120015903PHARMACEUTICAL COMPOSITION FOR INHIBITING INCREASE OF IgA - The present invention discloses a pharmaceutical composition for inhibiting increase of immunoglobulin A (IgA) comprising β-glucan and a pharmaceutical acceptable carrier. The β-glucan is extracted from 01-19-2012
20120022017COMPOSITION AND A METHOD THEREOF - The present invention describes a palatable and orally administrable form of composition comprising proteins, galactomannans and base matrix optionally along with acceptable additives.01-26-2012
20120022018ANTI-VIRAL PROPERTIES OF ALOE VERA AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) TREATMENT - A pharmaceutical composition comprising a combination of formulations derived from Aloe vera for the treatment of Acquired Immune Deficiency Syndrome (AIDS) or HIV infection is described herein. The composition comprises: (i) an injectable sterile polymannan extract, (ii) Raidox (aloe anthraquinones and their diacetyl derivatives), and (iii) a freeze dried aloe vera powder, aloe vera juice, aloe gel or a combination. In addition one or more nutritional supplements comprising fatty acids, proteins, minerals and metals, vitamins, salts, amino acids, and other pharmaceutically acceptable excipients may also be include to counteract the chronic diarrhea, digestive upsets, and weight loss seen in some patients before and during the treatment course. A method for treating the AIDS or HIV infection using the composition of the present invention is also disclosed.01-26-2012
20080306024METHOD FOR MICRO-INCISION CATARACT SURGERY, A METHOD OF EVALUATION OF A VISCOELASTIC MATERIAL , A COMPOSITION FOR EVALUATION OF A VISCOELASTIC MATERIAL AND A METHOD FOR EVALUATION USING THE COMPOSITION - A method for micro-incision cataract surgery, wherein a solution containing hyaluronic acid having a weight average molecular weight of from 600,000 to 1,200,000 or a salt thereof is injected into the anterior chamber, and flow rate of a perfusion liquid in the anterior chamber is set to about be 35 to 40 mL/min or less, a method for evaluating retentivity of a viscoelastic material, which uses a device consisting of a micro-flare ultrasonic chip arranged in water, a sleeve which covers said chip and a hollow cylinder into which said chip is inserted, and a composition for evaluation of retentivity of a viscoelastic material, which comprises at least said viscoelastic material and a fluorescent granule, are provided.12-11-2008
20120058969Cystitis treatment with high dose chondroitin sulfate - Interstitial cystitis and related GAG-deficient conditions of the bladder and urinary tract are treated by instillation of high dose chondroitin sulfate, such as 400 mg/20 mL. The higher dose of chondroitin is effective for the rapid reduction of symptoms, particularly in patients with severe and otherwise recalcitrant cystitis.03-08-2012
20120058968COMPOSITION CONTAINING FERMANTABLE POLYSACCHARIDES - The present invention relates to a composition to a nutritional composition comprising 0.1 to 15 gram fermentable partially hydrolysed gum having a degree of polymerisation between 10 and 300 per 100 gram dry weight of the composition and 0.1 to 15 gram fermentable, indigestible polysaccharide other than a hydrolysed gum having a DP between 10 and 300 per 100 gram dry weight of the composition.03-08-2012
20120058967VASCULAR PROTECTING AGENT HAVING SALT-ABSORPTION INHIBITORY ACTIVITY - This invention provides a vascular protecting agent having salt-absorption inhibitory activity with the use of alginate oligosaccharide salt absorbed by the body via degradation to an oligosaccharide, so that a patient can easily and safely ingest such agent on a routine basis. A vascular protecting agent having salt-absorption inhibitory activity comprises, as an active ingredient, alginate oligosaccharide obtained by treating sodium alginate with a 03-08-2012
20100305061MIXED BUTYRIC-FORMIC ESTERS OF ACID POLYSACCHARIDES, AND THEIR PREPARATION AND USE AS SKIN COSMETICS - Disclosed are acid polysaccharides characterised by the concomitant presence of alcohol groups esterified with butyric and formic acids.12-02-2010
20120157408MIXTURE OF HYALURONIC ACID FOR TREATING AND PREVENTING PEPTIC ULCER AND DUODENAL ULCER - The present invention is related to a method of treating and preventing peptic ulcer and duodenal ulcer by administering hyaluronic acid composition with a binary mixture of hyaluronic acids having mainly different weight-average molecular weight and then different rheological, scaffold and degradation properties in aqueous solution. The resulted compositions have demonstrated an optimal balance between adhesion, tissue scaffold and treating time to the peptic and duodenal ulcer and bleeding. Thus, the present inventive binary mixture exhibits a quick and lasting effect on the treatment and prevention of duodenal or peptic ulcer and bleeding.06-21-2012
20120065158FUCOIDAN HAVING ANTITUMOR ACTIVITY - Disclosed is a medium-molecular weight fucoidan which can be used in treating and/or preventing proliferative diseases, in particular, cancer. Specifically disclosed are a medium-molecular weight fucoidan, a method for producing the same, a medicinal composition containing the same, and use of the medium-molecular weight fucoidan in producing a drug for treating and/or preventing preventing proliferative diseases, in particular, cancer. The aforesaid medium-molecular weight fucoidan has an average molecular weight of about 6,000 to about 2,000,000, preferably an average molecular weight of about 40,000 to about 330,000, more preferably an average molecular weight of about 40,000 to about 244,000, and still more preferably an average molecular weight of about 80,000 to about 200,000.03-15-2012
20120065157PARTICULATE-SOLUBLE GLUCAN PREPARATION - Particulate β-glucan is solubilized at elevated pressure and temperature to form particulate-soluble β-glucan. The particulate-soluble β-glucan is capable of being dried to a powder form and subsequently re-solubilized.03-15-2012
20090105192GLYCOSAMINOGLYCANS DERIVED FROM K5 POLYSACCHARIDE HAVING HIGH ANTICOAGULANT AND ANTITHROMBOTIC ACTIVITIES AND PROCESS FOR THEIR PREPARATION - Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation/N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in which said epimerization is performed with the use of the enzyme glucoronosyl C5 epimerase in solution or in immobilized form in the presence of divalent cations. New, particularly interesting antithrombin compounds are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final N-sulfation step to depolymerization.04-23-2009
20120108537PROCESS FOR PREPARING A CROSSLINKED GEL - A process for preparing a crosslinked gel of at least one polymer or one of its salts, including a) providing an aqueous medium containing at least one polymer, b) forming a homogenous gel from the medium from step a), c) bringing the gel obtained in step b) into contact with an effective amount of at least one crosslinking agent; d) crossliking the mixture formed in step c); and e) recovering the crosslinked hydrogel, wherein at least steps a) to d) are carried out within a hermetic cavity delimited at least partially by a deformable wall, the mixture present in the cavity being exposed, in step d), to conditions conducive to crosslinking.05-03-2012
20120108536PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITING INFLAMMATION - A pharmaceutical composition for inhibiting inflammation, comprising (a) hyaluronic acid, (b) a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, and (c) a pharmaceutically acceptable carrier, is provided. Also provided is a method for inhibiting inflammation in a mammal, comprising administrating to the mammal an effective amount of a composition comprising (a) hyaluronic acid and (b) an HMG-CoA reductase inhibitor.05-03-2012
20120115808PHARMACOLOGICAL PREPARATION FOR TOPICAL USE CONTAINING N-PALMITOYL-VANILLAMIDE - The present invention relates to topical preparations containing N-palmitoyl-vanillamide having hyperalgesic activity. In particular, the invention relates to N-palmitoyl-vanillamide for use in the treatment of pathologies selected from: post-herpetic neuralgia, neuralgia of trigeminus, occipital neuralgia, dental neuralgia, glottopharyngeal neuralgia, uremic neuralgia, diabetic neuralgia, headache of different origin, neuropathic itch, neurogenic itch, uremic itch, vulvodinia, vulvar vestibulitis, ano-rectal pain and itch, balano-preputial pain and itch, painful urogenital disorders of dogs and cats, psoriasis-associated pruritus and pain, itching skin diseases (e.g. atopic dermatitis) in the human and veterinary field, muscular pain, pain of the tendon, osteoarthritis associated pain in humans, dogs and cats; painful eye diseases in the human and veterinary field, inflammatory pathologies of the oral cavity in the human and veterinary field.05-10-2012
20120071442LIPID CONJUGATES IN THE TREATMENT OF CHRONIC RHINOSINUSITIS - This invention provides a method of treating, suppressing, inhibiting, or preventing chronic rhinosinusitis in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. This invention also provides a method of treating, suppressing, inhibiting, or preventing nasal polyps in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.03-22-2012
20120071440Pharmaceutical Composition For Enhancing Adiponectin Production And Food Useful Therefor - A pharmaceutical product having excellent adiponectin production ability, and food useful for the pharmaceutical product is provided. The pharmaceutical product contains, as active ingredients, a sugar having a polymerization degree of 2-10, wherein mannose units account for not less than 50% based on the number, and a chlorogenic acid.03-22-2012
20120071439CARTILAGE PRODUCTION PROMOTER AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH CARTILAGE DAMAGE - Disclosed is a therapy which is for preventing or treating cartilage damage and diseases associated with cartilage damage, such as arthritides and osteoarthritis, and utilizes a more effective and more safe medicinal agent. Specifically disclosed are a cartilage production promoter, a glucosaminoglycan and/or proteoglycan production promoter, and a prophylactic or therapeutic agent for diseases associated with cartilage damage, each of which comprises fucoidan as an active ingredient.03-22-2012
20120071437TUNABLE CROSSLINKED POLYSACCHARIDE COMPOSITIONS - The present specification generally relates to injectable dermal fillers including multifunctional polyethylene glycol-based crosslinking agents, hydrogel compositions comprising a matrix polymer crosslinked with such crosslinking agents, and methods of treating a soft tissue condition using such hydrogel compositions.03-22-2012
20120071443NANOPARTICLES - Materials and methods for studying and modulating the interaction of carbohydrate-containing moieties with other species are described, in particular, small particles, e.g. clusters of metal or semiconductor atoms, which can be employed as a substrate for immobilising a plurality of ligands comprising carbohydrate groups. These “nanoparticles” can then be used to study carbohydrate mediated interactions, e.g. with other carbohydrates or proteins, and as therapeutics and diagnostic reagents.03-22-2012
20120157407GALACTOSE-PRONGED POLYSACCHARIDES IN A FORMULATION FOR ANTIFIBROTIC THERAPIES - Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-β1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis.06-21-2012
201200714416'-SIALYLLACTOSE SALTS AND PROCESS FOR THEIR SYNTHESIS AND FOR THE SYNTHESIS OF OTHER ALPHA-SIALYLOLIGOSACCHARIDES - The present invention relates to a process of synthesis of α-sialyl oligosaccharides and in particular of 6′-sialyllactose and its salts comprising a step of coupling by Koenigs-Knorr reaction under conditions that allow its use on an industrial scale.03-22-2012
20120071438ANTIMICROBIAL COMPOSITIONS CONTAINING CATIONIC ACTIVE INGREDIENTS AND QUATERNARY SUGAR DERIVED SURFACTANTS - The antimicrobial composition of the present invention comprises a cationic active ingredient, a quaternized sugar-derived surfactant, and an optional foam boosting surfactant. These formulations have a high cidal activity in a short amount of time and provide stable copious foam. The formulations of the present invention also exhibit enhanced tissue (e.g. skin) compatibility as defined by an in vitro whole toxicology assessment method.03-22-2012
20110082104ALKYLATED SEMI SYNTHETIC GLYCOSAMINOGLYCOSAN ETHERS, AND METHODS FOR MAKING AND USING THEREOF - Described herein is the synthesis of alkylated and semi-synthetic glycosaminoglycosan ethers, referred to herein as “SAGEs.” The synthesis of sulfated alkylated SAGEs is also described. The compounds described herein are useful in a number of applications including wound healing, drug delivery, and the treatment of a number of inflammatory diseases and skin disorders.04-07-2011
20110065666METHOD OF PRODUCING A BRAN PRODUCT - The present invention relates to a method of manufacturing a cereal bran product containing beta-glucan. According to the method, a plastic mass is formed from cereal bran by means of a thermo-mechanical treatment, and the mass is brought into contact with an enzyme that breaks up beta-glucan, with or without an enzyme that breaks up starch. After inactivating the enzyme, the bran is dried and, when so needed, ground. The cereal bran product manufactured according to the method has an essentially inextensible structure in a water environment. The product is suitable to be added to aqueous foodstuffs or to foodstuffs, the manufacture of which employs water.03-17-2011
20100093658Therapeutic Agent For Metabolic Syndrome and Food Containing the Therapeutic Agent - It is an object of the invention to provide a novel therapeutic agent that can reduce visceral fat accumulation to prevent or treat metabolic syndrome. In order to achieve this object, the invention provides a therapeutic agent for metabolic syndrome that comprises, as an active ingredient, dietary fiber aggregation in which water-soluble β-glucan has the highest content. Particularly effective as the water-soluble β-glucan is water-soluble β-glucan having a β-1,3 glycoside bond and β-1,4 glycoside bond in the same molecule.04-15-2010
20120316129LIQUID DRESSING CONTAINING CHITOSAN DERIVATIVE AND PREPARATION METHOD THEREOF - The invention relates to a liquid dressing containing a chitosan derivative, comprising the following components in percentage by weight: 1-5% of CMCS (carboxymethyl chitosan), 0.1-0.5% of collagen albumen powder, 10-15% of humectant, 0.2-2% of antibacterial agent, 2-10% of penetration enhancers and the balance of deionized water. The liquid dressing is obtained by mixing the components in sequence, stirring evenly and bulking. The liquid dressing has the advantage of good biocompatibility, good antimicrobial, antiphlogistic and hemostatic effects and high biological safety, and is convenient to use.12-13-2012
20120316130COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-DEPENDENT DISEASES AND CONDITIONS - A pharmaceutical composition for the treatment of an estrogen-dependent disease or condition comprises: (1) at least one polysaccharide selected from the group consisting of an alginate and a fucoidan in a quantity effective to treat an estrogen-dependent disease or condition; and (2) a pharmaceutically acceptable carrier. The composition can include both an alginate and a fucoidan. The composition can include other ingredients such as at least one compound selected from the group consisting of diindolylmethane and indole-3-carbinol in a quantity sufficient to inhibit the activity of estrogen. Methods for use of the composition for the treatment of an estrogen-dependent disease or condition, especially endometriosis, are described.12-13-2012
20120316131Stable Hyaluronan/Steroid Formulation - A pharmaceutical composition comprising in admixture a hyaluronic acid related component (HARC) and a pharmaceutically effective amount of triamcinolone hexacetonide (TAH). The composition is stable in an accelerated shelf life test in which the composition is heated to 80° C. for 24 hours.12-13-2012
20120122813COMPOSITION CONTAINING OLIGOSACCHARIDES FOR THE TREATMENT/PREVENTION OF INFECTIONS - The present invention relates to oligosaccharide mixtures and their use in the treatment and/or prevention of infections, and in particular, for reducing the severity of childhood infection or in the treatment and/or prevention of childhood infection.05-17-2012
20120122812ANTI-AGING AGENT - The invention relates to chemical and pharmaceutical industry, in particular, to the medicinal products and medications in the form of intra-articular and intradermal solutions and gels, and can be applied in Orthopedics, Traumatology, Arthrology, Reumatology and Vertebrology as an agent for protection of the cartilages and restoration of fluid balance in the synovial cavity and also in Dermatology, Medical Cosmetology and Plastic Surgery to delay skin ageing.05-17-2012
20090131364BIOACTIVE FRACTION FROM ZINGIER OFFICINALE AND A PROCESS FOR THE PREPARATION THEREOF - Ulcer is a serious oxidative stress induced disease with complex pathologic events including upregulation of H05-21-2009
20120165289TREATMENT - The invention provides composition comprising a therapeutically effective amount of a soluble fibre derivable from fruit of the 06-28-2012
20110183936REGIMENS FOR INTRA-ARTICULAR VISCOSUPPLEMENTATION - The invention provides viscosupplementation methods for treating osteoarthritis and joint injury with HA-based viscosupplements, particularly viscosupplements with an intra-articular residence half-life shorter than 3 weeks. Viscosupplements for use in the methods of the invention may be further characterized in that they contain less than 20 mg/ml HA, at least 5% (w/w) of which is in a gel form, such as, e.g., hylan B. In an illustrative embodiment, hylan G-F 20 (Synvisc®) is administered in a single intra-articular knee injection of 6±2 ml.07-28-2011
20110183935HEARTWATER - There is provided a water product for general consumer comprising water suitable for human consumption and a food additive in the amount effective to alter a level of serum marker that indicates a likelihood of cardiovascular disease, thereby the water product is intended to lower the risk of cardiovascular disease of said general consumer. The preferred additive is Barliv™ betafiber.07-28-2011
20110183934METHODS AND COMPOSITIONS TO IMPROVE GERM CELL AND EMBRYO SURVIVAL AND FUNCTION - Sperm, oocyte, and embryo survival and function is improved in vivo or in vitro by the use of a polysaccharide containing arabinose, galactose and/or hexuronic acid. In particular, a nonspermicidal lubricant containing such a polysaccharide (e.g., gum arabic, pectin, or galacturonic acid) increases the fertilization potential of the sperm during coitus, artificial insemination or sperm collection. Similarly, a freezing medium containing a polysaccharide containing arabinose, galactose and/or hexuronic acid enhances sperm, oocyte, or embryo viability.07-28-2011
20120165290GLUCOOLIGOSACCHARIDES COMPRISING (ALPHA 1->4) AND (ALPHA 1->6) GLYCOSIDIC BONDS, USE THEREOF, AND METHODS FOR PROVIDING THEM - The invention relates to the field of poly- and oligosaccharides and their nutritional effects. In particular, it relates to the application of α-glucanotransferases in methods for preparing dietary fibers, including prebiotic oligosaccharides, and to novel oligosaccharides obtainable thereby. Provided is a method for producing a mixture of gluco-oligosaccharides having one or more consecutive (α1→6) glucosidic linkages and one or more consecutive (α1→4) glucosidic linkages, comprising contacting a poly- and/or oligosaccharide substrate comprising at least two (α1→4) linked D-glucose units with an ?-glucanotransferase capable of cleaving (α1→4) glucosidic linkages and making new (α1→4) and (α1→6) glucosidic linkages. Also provided are (isolated) gluco-oligosaccharides obtainable thereby, and their application in nutritional and cosmetic compositions.06-28-2012
20100210584LIQUID OR PASTE COMPOSITIONS INTENDED TO PROVIDE ELEMENTS ESSENTIAL FOR THE SYNTHESIS AND FORMATION OF PROTEOGLYCANS, IN PARTICULAR, FOR THE TREATMENT OF CARTILAGE DEGRADATION - The invention relates to the field of pharmaceuticals, dietary supplements and food and, more specifically, to the field of dietary supplements intended for the treatment of degradation of cartilage of any origin. The invention relates to liquid or paste compositions based on glucosamin and chondroitin sulphate, intended to provide elements essential for the synthesis and formation of proteoglycans, in which the chondroitin sulphate/glucosamin combination is stabilised with the addition of carboxylic acids such that the pH of the medium is between 2 and 5 and the chemical degradation rate of the active substances is less than 10% when stored at 25° C. and 60% relative humidity for 10 months for doses of between 300 and 2400 mg chondroitin sulphate and between 500 and 3000 mg glucosamin. The invention is suitable for the treatment of cartilage degradation and, more specifically, arthrosis.08-19-2010
20120135957COMPOSITIONS CONTAINING MIXTURES OF FERMENTABLE FIBERS - The present invention relates to synergistic compositions comprising mixtures of fermentable fibers. The present invention specifically relates to composition comprising inulin and arabinoxylan for use in reducing, preventing and/or treating inflammation, wherein said arabinoxylan is partially hydrolyzed arabinoxylan and wherein the ratio of said inulin to said arabinoxylan and/or partially hydrolyzed arabinoxylan is between 65%/35% by weight and 90%/10% by weight.05-31-2012
20120135956COMPOSITIONS FOR PREVENTING AND TREATING AN IMMUNE SYSTEM DISORDER - The present invention relates to methods of treating, preventing, or decreasing the occurrence of a condition characterized by Th2 overactivation or impaired Th1, or mitigating symptoms associated with a condition characterized by Th2 overactivation or impaired Th1, comprising orally administering to a subject in need thereof an effective amount of a composition comprising a plant stanol and/or plant stanol ester. The present invention also relates to methods of improving the health status of a subject suffering from asthma and increasing the levels of IL-10 in a subject in need thereof.05-31-2012
20100173865Anti-Cancer Agent-Hyaluronic Acid Conjugate Compositions and Methods - Methods of making conjugates comprising an anti-cancer agent and hyaluronic acid, together with mixtures of reaction products comprising such conjugates and methods of using such conjugates in therapeutic and research applications are disclosed.07-08-2010
20120172329PHYTOCHEMICAL COMPOSITIONS INCLUDING XANTHONES FOR ANTI-INFLAMMATORY, ANTI-CYTOKINE STORM, AND OTHER USES - A composition (e.g., a phytochemical composition) including a predetermined concentration of xanthones, and in certain embodiments predetermined concentrations of both xanthones and sesamin. The composition facilitates at least one of decreasing pro-inflammatory cytokines, increasing anti-inflammatory cytokines, enhancing a connective tissue anti- degeneration effect, and inhibiting viral neuraminidase (e.g. neuraminidase of an influenza A virus). The composition can further decrease at least one of gene expression and release of pro-inflammatory cytokines. The phytochemical composition can increase at least one of gene expression and release of anti-inflammatory cytokines. The phytochemical composition provides at least one of an anti-inflammatory, an anti-viral (e.g., anti-influenza), and a connective tissue anti-degradation effect in a living organism. A use of xanthones for manufacturing phytochemical compositions that include predetermined concentrations of xanthones is also provided. A use of xanthones in combination with sesamin for manufacturing phytochemical compositions that include predetermined concentrations of both xanthones and sesamin is additionally provided.07-05-2012
20120172328HYALURONIC ACID-BASED GELS INCLUDING LIDOCAINE - Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.07-05-2012
20120172327NUTRITIONAL FORMULATIONS INCLUDING HUMAN MILK OLIGOSACCHARIDES AND ANTIOXIDANTS AND USES THEREOF - Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.07-05-2012
20120172326Moisturizing Mixture, Cosmetic And/Or Pharmaceutical Compositions Containing The Moisturizing Mixture, Use Of The Moisturizing Mixture, And Cosmetic Method - The present invention refers to a moisturizing mixture for sensitive skins, atopic dermatitis and/or 07-05-2012
20100120710Branched alpha-glucan, alpha-glucosyltransferase which forms the glucan, their preparation and uses - The present invention has objects to provide a glucan useful as water-soluble dietary fiber, its preparation and uses. The present invention solves the above objects by providing a branched α-glucan, which is constructed by glucose molecules and characterized by methylation analysis as follows: 05-13-2010
20100048505Composition Having Effect of Treating, Preventing, or Improving Diabetes or Diabetic Complication and Drink Comprising the Same - A safe, economical, and convenient food drink having the effect of treating, preventing, or improving diabetes or diabetic complications without involving significantly changed dietary life habits is provided. A food or drink is provided for treating, preventing, or improving diabetes or diabetic complications, comprising oligosaccharides at a concentration of 0.15 to 10% by weight wherein the oligosaccarides include mannose molecules linked together with degree of polymerization of 2 to 10 (inclusive).02-25-2010
20100048506Composition for treating arthritic disorder - The present invention provides compositions and methods for treating a joint disease containing as an active ingredient thereof a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is possible to provide a composition for treating a joint disease which has the effects of protecting cartilage from mechanical irritation, inhibiting degenerative changes in cartilage caused by wear and inflammation, repairing cartilage injuries, suppressing inflammation and pain of joint tissue, inhibiting degeneration of synovial tissue, and inhibiting osteochondral destruction.02-25-2010
20100273736COSMETIC COMPOSITION COMPRISING GLYCOGEN FOR SKIN APPLICATION WITH VELVET EFFECT - This invention relates to a cosmetic composition for skin application having a velvet effect on the skin comprising, as the cosmetic active ingredient, a glycogen having less than 1,000 ppm of nitrogen and less than 1% by weight of reducing sugars, in at least one cosmetically-acceptable vehicle.10-28-2010
20100273734Derivatives of Hyaluronic Acids - The present invention relates to methods for preparing a derivative of a hyaluronic acid, comprising: (a) mixing a liquid solution comprising the hyaluronic acid and a diamine, a polyamine, or a combination thereof, at a pH suitable to form an imine; (b) reducing the imine to an amine with a reductant at a pH suitable to produce the derivative of the hyaluronic acid; and (c) recovering the derivative of the hyaluronic acid. The present invention also relates to isolated derivatives of a hyaluronic acid, comprising the hyaluronic acid and a diamine, a polyamine, or a combination thereof.10-28-2010
20100273735SOLUBLE, HIGHLY BRANCHED GLUCOSE POLYMERS FOR ENTERAL AND PARENTERAL NUTRITION AND FOR PERITONEAL DIALYSIS - The invention relates to soluble, highly branched glucose polymers which are obtained by enzymatic treatment of starch, having a reducing sugars content of less than 3.5%, exhibiting a proportion of α-1,6-glucosidic linkages of between 20% and 30%, a Mw, determined by light scattering, of between 20·1010-28-2010
20100009932Liquid Satiety Enhancing Composition - The present invention relates to shelf-stable satiety enhancing and/or satiating liquid compositions that can be used as satiety enhancing and/or satiating composition in a method of treating or preventing any of a variety of diseases and/or disorders associated with overeating and/or excessive caloric intake of a subject. It was found that liquid compositions comprising specific combinations of pectins and alginates, can be used to reduce the tendency of a subject to overeat and/or to reduce caloric intake of a subject. These compositions have acceptable taste and texture characteristics, are convenient and/or economical to manufacture and, in particular, are stable during manufacture and storage, and, upon ingestion, gelate in the strongly acidic environment that prevails in the stomach.01-14-2010
20100009931ASSOCIATION OF A TENSOR AGENT OR DEVICE AND A SACCHARIDE COMPOUND - The invention concerns a composition for topical application on the skin comprising, in a physiological acceptable medium, at least one saccharide compound which augments the expression of mechanoreceptors in skin cells and at least one tensor agent. The invention also concerns a skin care health kit comprising (a) a composition comprising at least one tensor agent and (b) a composition comprising at least one saccharide compound which increases the expression of mechanoreceptors in skin cells. The invention also concerns a kit comprising (a) a composition comprising at least one saccharide compound which augments the expression of mechanoreceptors in skin cells and (b) a tensor device designed to apply and/or maintain in a controlled manner mechanical constraints on the skin. The invention also concerns a process for cosmetic treatment of the skin comprising the simultaneous or sequential application of said compositions and/or tensor devices.01-14-2010
20100292182Cystitis treatment with high dose chondroitin sulfate - Interstitial cystitis and related GAG-deficient conditions of the bladder and urinary tract are treated by instillation of high dose chondroitin sulfate, such as 400 mg/20 mL. The higher dose of chondroitin is effective for the rapid reduction of symptoms, particularly in patients with severe and otherwise recalcitrant cystitis.11-18-2010
20120220547FOOD FORMULATION COMPRISING GLYCOGEN - The present invention relates to a food formulation for the controlled release of glucose comprising glycogen and at least one other edible component, as well the use of glycogen for its preparation.08-30-2012
20120225842HYALURONIC ACID COMPOSITIONS FOR DERMATOLOGICAL USE - The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations hyaluronic acid and at least one additional constituent selected from the group consisting of vitamin B, C and vitamin E, wherein the formulation exhibits greater stability than an HA gel formulation without the additional constituent. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.09-06-2012
20120258931Regimens for Intra-Articular Viscosupplementation - The invention provides viscosupplementation methods for treating osteoarthritis and joint injury with HA-based viscosupplements, particularly viscosupplements with an intra-articular residence half-life shorter than 3 weeks. Viscosupplements for use in the methods of the invention may be further characterized in that they contain less than 20 mg/ml HA, at least 5% (w/w) of which is in a gel form, such as, e.g., hylan B. In an illustrative embodiment, hylan G-F 20 (Synvisc®) is administered in a single intra-articular knee injection of 6±2 ml.10-11-2012
20120190644VISCOELASTIC GELS AS NOVEL FILLERS - Biomaterials obtainable by mixing 07-26-2012
20090018102Phamaceutical/cosmetic compositions comprising hyaluronic acid and treatment of dermatological conditions therewith - Pharmaceutical/cosmetic compositions containing a dermatologically effective amount of hyaluronic acid, at least one retinoid and/or salt and/or derivative thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, formulated into a physiologically acceptable medium therefor, are useful for the treatment of wrinkles, fine lines, fibroblast depletions and scars.01-15-2009
20110124595METHOD FOR PREPARING POLYSACCHARIDE OF GREEN TEA AND COSMETIC COMPOSITION FOR SKIN WHITENING, MOISTURIZATION AND ANTI-WRINKLE EFFECTS COMPRISING THE POLYSACCHARIDE - Disclosed is a method for preparing polysaccharides of green tea, and more particularly to a method for preparing polysaccharides of green tea comprising the steps of: a) removing chlorophyll and a low molecular weight polyphenol from green tea powder using a solvent; b) hot-water extracting a water-soluble active ingredient from the green tea residue of step a); and c) separating the polysaccharides of green tea from the hot-water extract of step b) by ultrafiltration and ethanol precipitation. Also, the present invention relates to a cosmetic composition for skin whitening, moisturization and anti-wrinkle effects comprising the polysaccharides of green tea as an effective ingredient.05-26-2011
20120232031INJECTABLE FORMULATIONS FOR INTRA-ARTICULAR OR PERI-ARTICULAR ADMINISTRATION - Described herein are injectable formulations for intra-articular or peri-articular administration, wherein the formulation is administered to treat joint pain. An injectable formulation for intra-articular or peri-articular administration disclosed herein comprises a therapeutically-effective amount of a leukotriene synthesis inhibitor compound formulated for intra-articular or peri-articular administration.09-13-2012
20120232030HEAT STABLE HYALURONIC ACID COMPOSITIONS FOR DERMATOLOGICAL USE - The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.09-13-2012
20100323986COMPOSITIONS AND METHODS FOR MODULATION OF VASCULAR STRUCTURE AND/OR FUNCTION - The present invention relates to compositions comprising semi-crystalline β-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a β-1-4 conformation.12-23-2010
20100204176ADVANCED GLYCATION END PRODUCTS AS ACTIVE INGREDIENTS - Cosmetic composition comprising at least one compound from advanced glycation end products (‘AGEs’) and/or precursors thereof as an agent for skin treatment, especially for protection and/or care of the skin. The present invention further provides a cosmetic composition comprising at least one compound from the group of the AGEs and/or precursors thereof, wherein the AGEs are prepared by reacting sugars with the amino acids lysine and/or arginine.08-12-2010
20100204175USE OF CONJUGATES OF HYALURONIC ACID IN THE LOCAL TREATMENT OF HYPERPROLIFERATIVE SKIN DISEASES - The use is described of a conjugate between hyaluronic acid or a derivative thereof and antitumoral drugs for the preparation of pharmaceutical compositions for the topical treatment of hyperproliferative skin diseases.08-12-2010
20110003768PREBIOTIC COMPOSITIONS - The present invention concerns nutritional compositions comprising oligosaccharides for controlling inflammatory bowel disease and related disorders, such as diarrhoea and constipation.01-06-2011
20120264712CARIES RISK TEST FOR PREDICTING AND ASSESSING THE RISK OF DISEASE - Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole (unfractionated) saliva sample from a subject; contacting an aliquot of the saliva with two or more lectins under conditions that allow the two or more lectins to bind to a lectin-binding component of the saliva; detecting the amount of bound lectin; and comparing the amount of bound lectin to the amount known to bind a saliva sample from a control patient, to predict the risk of a disease in the subject. Also provided are methods for reducing the risk of a disease and a method for assessing the risk of the disease at a defined level.10-18-2012
20120322756METABOLIC IMPRINTING EFFECTS OF STRUCTURED LIPIDS - The invention relates to the use of triglycerides which an enhanced portion of the palmitic acid residues in the sn-2 position for an early in life diet for improving the development of a healthy body composition, in particular prevention of obesity, later in life.12-20-2012
20110046086Composition Comprising Polysaccharide Extracted from Panax Ginseng Preventing and Treating Liver Diseases - The present disclosure relates to a 02-24-2011
20090239821DESTRUCTION OF MICROBIAL PRODUCTS BY ENZYMATIC DIGESTION - Methods of treating a dialysis component by providing a dialysis component and contacting the dialysis component with an enzyme are provided. The enzyme breaks down microbial contaminants in the dialysis component. The enzyme may be separated from the dialysis component to provide a purified dialysis component. The purified dialysis component may be substantially free of microbial contaminants that cause a cytokine response in humans.09-24-2009
20120270833IMMUNE ACTIVATION OF GREEN TEA HYDROLYSATE AND METHOD FOR PREPARING FOOD COMPOSITION CONTAINING THE SAME - Disclosed are an immune-boosting food composition containing a green tea hydrolysate as an active component, and a method for preparing the same.10-25-2012
20120094951COMPOSITIONS - The specification relates to compositions comprising honey and chondroitin and/or glucos amine wherein the ingredients form a stably homogeneous composition. The subject compositions are contemplated for oral use as nutraceuticals or functional food to provide health benefits to subjects in need.04-19-2012
20110212914STABILIZED PENTOSAN POLYSULFATE (PPS) FORMULATIONS AND METHODS OF ANALYZING THEM - Various pentosan polysulfate (PPS) formulations useful for treatment of osteoarthritis, interstitial cystitis, and other conditions of mammals are provided. These formulations showed improved resistance to degradation and discoloration and improved stability at physiological pH, even after sterilization. Capillary electrophoresis analysis of these formulations indicates that various formulations remain stable under conditions that caused degradation of PPS in prior art PPS formulations.09-01-2011
20120322757Methods for Aloe Processing - A composition and process for generating an anthraquinone rich aloe product from aloe leaves comprising the steps of: removing one or more rind parts from the aloe leaves comprising a top rind, a bottom rind, or both by filleting the aloe leaves on a filleting table into a mucilage layer below the rind parts of the aloe leaves to remove the top rind, the bottom rind, or both from an internal fillet or a gel layer; and separating the internal fillet or the gel layer from the rind parts; removing a mucilage layer attached to the one or more rind parts by scraping, heat-treating the rind parts and the extracted mucilage; and adding one or more preservatives to the heat-treated mucilage after cooling, wherein the extracted and heat-treated mucilage comprises the anthaquinone rich aloe product.12-20-2012
20100234320EMULSIFYING COMPOSITIONS BASED ON ALKYL POLYGLYCOSIDES AND ESTERS - Emulsifying composition containing 1 to 98% of a mixture of alkyl glycosides, a mixture of alcohol esters, a mixture of alcohol esters, 1 to 90% of an alcohol and 0 to 97% of a mixture of alkyl glycoside esters.09-16-2010
20100234318OPHTHALMIC COMPOSITION CONTAINING ALGINIC ACID OR SALT THEREOF - An ophthalmic composition that, despite containing alginic acid and/or a salt thereof, has improved tackiness during use and provides a satisfactory use feeling. The composition has an improved ability to remain on the eye mucosa. The ophthalmic composition contains (A) alginic acid and/or a salt thereof in combination with (B) hyaluronic acid and/or a salt thereof.09-16-2010
20120277182ANOECTOCHILUS SPP. POLYSACCHARIDE EXTRACTS FOR STIMULATING GROWTH OF ADVANTAGEOUS BACTERIA, STIMULATING RELEASE OF GRANULOCYTE COLONY-STIMULATING FACTOR, MODULATING T HELPER CELL TYPE I, AND/OR MODULATING T HELPER CELL TYPE II AND USES OF THE SAME11-01-2012
20120329752ALLERGY INHIBITOR - The present invention provides an allergy inhibitor using the efficacy of amorphous paramylon which is a substance obtained by changing the crystalline structure of paramylon.12-27-2012
20120329751METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS - Described herein are methods of disrupting (e.g., reducing the viscosity of, or dissolving) a preformed biofilm in a subject, the method comprising: administering to the subject an effective amount of a composition comprising a soluble chitosan or derivatized chitosan wherein the soluble chitosan or derivatized chitosan when administered contacts the preformed biofilm, thereby disrupting (e.g., reducing the viscosity of, or dissolving) the preformed biofilm.12-27-2012
20110281819LOW-MOLECULAR POLYSULFATED HYALURONIC ACID DERIVATIVE AND MEDICINE CONTAINING SAME - A low-molecular-weight polysulfated hyaluronic acid derivative useful for prevention and/or treatment of an allergic disease. An agent for prevention and/or treatment of an allergic disease selected from pollinosis, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, and asthma, represented by the following general formula (IA) or (IB);11-17-2011
20110281818HIGH FRUCTAN CEREAL PLANTS - The invention provides cereal plants having a high level of fructan useful for the production of a range of food, beverage, nutraceutical and pharmaceutical products. The invention provides methods of producing high-fructan products from plants modified to comprise a reduced level of an endogenous polypeptide with starch synthase activity, and products so produced. In some embodiments, plants are modified by introduction of an agent such as a nucleic acid molecule which down regulates endogenous starch synthase II gene expression.11-17-2011
20120101060SKIN PROTECTANT, PARTICULARLY AGAINST HYDROPHOBIC (LIPOPHILIC) AND AGAINST HYDROPHILIC (LIPOPHOBIC) HARMFUL SUBSTANCES - The invention relates to a skin protectant, particularly against hydrophobic (lipophilic) and hydrophilic (lipophobic) harmful substances, obtainable by means of an amount of at least one barrier-forming component, particularly against hydrophobic (lipophilic) harmful substances, wherein the nephelometric turbidity unit of the barrier-forming component is determined by means of turbidimetry and at least one barrier-forming component, a 1% solution in water thereof having a nephelometric turbidity unit of greater than 40 (NTU), is used to produce the protectant and a method for producing skin protectants, particularly against hydrophobic (lipophilic) and hydrophilic (lipophobic) harmful substances, where in the barrier-forming component is selected for production of the protectant such that the nephelometric turbidity unit of the barrier-forming component of the skin protectant is determined by means of turbidimetry and at least one barrier-forming component, a 1% solution in water thereof having a nephelometric turbidity unit of greater than 40 (NTU), is used to produce the skin protectant.04-26-2012
20120101059Sulphated hyaluronic acids as regulator agents of the cytokine activity - The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered its exclusive capacity in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, HIV, Cytomegalovirus and the virus of vesicular stomatitis.04-26-2012
20120101058Pharmaceutical Composition For Prevention Or Treatment Of Lifestyle-Related Disease, And Food Useful For Prevention Or Treatment Of Lifestyle-Related Disease - A pharmaceutical composition for preventing or treating lifestyle-related disease is provided. Also provided is a food useful for the prevention or treatment of lifestyle-related disease. The pharmaceutical composition contains, as an active ingredient, a sugar in which a mannose unit makes up 66% or more in terms of the number of mannose units and which has a polymerization degree of 3 to 10.04-26-2012
20120289477BIOTECHNOLOGICAL SULPHATED CHONDROITIN SULPHATE AT POSITION 4 OR 6 ON THE SAME POLYSACCHARIDE CHAIN, AND PROCESS FOR THE PREPARATION THEREOF - A process for the preparation of a chondroitin sulphate salt with an average molecular weight (Mw) of 10-30 kDa via chemical sulphation of an unsulphated chondroitin backbone is provided. The unsulphated chondroitin can be obtained by acid hydrolysis of a capsular polysaccharide K4 made directly from 11-15-2012
20120289478HYALURONIC ACID ESTERS, THEIR PREPARATION AND USE IN DERMATOLOGY - New ester derivatives of hyaluronic acid with hydroxy-cinnamic acid, their rheological and anti-radical properties are used as protective agents in dermatology.11-15-2012
20120149658MODIFIED PECTINS, COMPOSITIONS AND METHODS RELATED THERETO - The present invention provides compositions of modified pectin and methods for preparing and using them.06-14-2012
20100173866APPARATUS AND METHOD FOR OCULAR TREATMENT - The invention provides tools, materials and related methods to surgically access the suprachoroidal space of an eye for the purpose of performing minimally invasive surgery or to deliver drugs to the eye. The invention provides a flexible microcannula or microcatheter device (07-08-2010
20130018015Nutritional Composition and Methods of Making and Using Same - A Nutritional Composition comprising soluble extractable material from a lignocellulosic source. A method of producing a composition, comprising providing a lignocellulosic source, extracting soluble materials from the lignocellulosic source to produce soluble extractable material, and processing the soluble extractable material to yield a Nutritional Composition, wherein the Nutritional Composition comprises hemicellulose and exhibits pathogen blocking, anti-adhesion activity.01-17-2013
20130023492PHARMACEUTICAL COMPOSITIONS COMPRISING PLANT-BASED POLYSACCHARIDES AND USES THEREOF - A composition for providing relief to a discomfort of an eye comprises a pharmaceutically acceptable carrier and a polysaccharide extracted from a plant source. In certain embodiments, such a polysaccharide can be extracted from mushrooms, such as from the 01-24-2013
20130023493ANDROGRAPHIS PANICULATA EXTRACT - An extract of 01-24-2013
20090281056Cationized Hyaluronic Acid - The present invention provides a cationic polymer which is much closer to the component of a human body, and capable of forming a polyion complex together with an anionic material such as hyaluronic acid. The cationized hyaluronic acid of the present invention is a hyaluronic acid wherein at least one part of hydroxylic hydrogen atoms of hyaluronic acid is replaced with a group having a quaternary ammonium cation group. The cationized hyaluronic acid can be synthesized by reacting hyaluronic acid with a cationizing agent such as glycidyltrialkyleammonium halide. The cationized hyaluronic acid of the present invention can form a polyion complex gel with hyaluronic acid or the like in the presence of water.11-12-2009
20080249065Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate - This invention relates to ophthalmic wound-healing pharmaceutical compositions based on amino acids and sodium hyaluronate.10-09-2008
20080242635Method for Lengthening the Seasonal Mobility Period of Fish - This invention is in the field of animal feed, more in particular in the field of fish feed. Surprisingly, it has been found that the seasonal mobility period of fish may be lengthened by interfering with the diet of the fish. We found that it is possible to increase the seasonal mobility period of fish to such an extent that it is even active at temperatures as low as 2 degrees Celsius. Such may be accomplished by adding naturally occurring substances to the feed of the fish. Examples of these naturally occurring substances are immune enhancing ingredients like beta-glucans and/or small amounts of phytohormones like auxin or gibberellic acid. Also, combinations of these substances, in particular the combination of beta-glucans and phytohormones, were shown to have a synergistic effect in that they lengthened the seasonal mobility period of the fish more than the individual components on their own.10-02-2008
20080227751METHOD AND AGENT FOR THE PREVENTION, INHIBITION AND TREATMENT OF SEPSIS - The invention relates to the use of Asialo-G09-18-2008
20080227750COMPOSITIONS AND METHODS FOR REGULATING RECEPTOR CLUSTERING - The invention relates to isolated complexes comprising one or more galectin associated with a Mgat5 modified glycan or polylactosamine modified glycan, and isolated lectin-Mgt5 modified glycan lattice comprising an array of mulitvalent interactions among lectins, Mgat5 modified glycans, polylactosamine modified glycans, and/or glycoproteins. Methods for evaluating a test compound for its ability to regulate receptor clustering through glycans on cell surfaces; and methods for regulating receptor clustering on cell surfaces comprising altering glycans on the cell surface associated with receptor clustering are also disclosed.09-18-2008
20080227749CARRAGEENAN-BASED FORMULATIONS AND ASSOCIATED METHODS OF USE - A method is provided for treating a female individual who suffers from or is prone to dyspareunia. The method involves vaginal and/or vulvar administration of a formulation comprising a therapeutically effective amount of a carrageenan and a pharmaceutically acceptable aqueous carrier. In addition, a carrageenan-based formulation is provided as a new composition of matter. Packaged kits for an individual to use in the administration of a carrageenan-based formulation as provided as well.09-18-2008
20080227748Medicament Made From Laminarine or Oligolaminarines For Treatment of Septicemia and Septic Shock - The invention relates Lo the use of laminarine, preferably in the soluble form thereof or an oligolaminarine, for the production of a medicament for treatment of septicemia and septic shock.09-18-2008
20080227747COMPOSITION AND METHODS FOR TREATING OR PREVENTING DEGENERATIVE JOINT AND CARDIOVASCULAR CONDITIONS - A therapeutic composition and methods for the treatment and prevention of a degenerative joint disorder and/or a cardiovascular disease comprising polycosanols, glucosamine and chondroitin are disclosed.09-18-2008
20130172288Process for the simultaneous substitution and crosslinking of a polysaccharide via its hydroxyl functional groups - A process for the simultaneous substitution and crosslinking of a polysaccharide via its hydroxyl functional groups, in an aqueous phase, which includes the following steps: 07-04-2013
20130172289METHOD FOR THE PREPARATION OF SODIUM CHONDROITIN SULPHATE - The present invention concerns a method for obtaining sodium chondroitin sulphate from cartilage, notably of avian origin, as well as a sodium chondroitin sulphate preparation.07-04-2013
20110263527Sulfated Galactans With Antithrombotic Activity, Pharmaceutical Composition, Method for Treating or Prophylaxis of Arterial or Venous Thrombosis, Method of Extraction and Use Thereof - The present invention relates to low molecular weight sulfated galactans, obtained from algae, particularly genus 10-27-2011
20080249064Activities of an active principle obtained from powdered alfalfa seeds (Medicago sativa), active principle used and process of obtaining the same - The object of the invention is an active principle derived from a powder of alfalfa seeds (10-09-2008
20080221064Medicinal composition for ophthal use containing acetylated hyaluronic acid - The present invention provides an ophthalmic pharmaceutical composition containing acetylated hyaluronic acid and a pharmacologically acceptable carrier. Preferably, the average molecular weight of the acetylated hyaluronic acid is 10,000 to 1,000,000, and the acetyl group substitution number is from 2.0 to 4.0. In a preferred embodiment, this ophthalmic pharmaceutical composition is used in the treatment or prevention of dry eye, and in an even more preferred embodiment it is a dry-eye instillation.09-11-2008
20080221063Heterocyclic Sulfonamide Derivatives As Inhibitors Of Factor Xa - The invention relates to heterocyclic derivatives of formula (I), Chemical formula should be inserted here. Please see paper copy wherein R09-11-2008
20080221062Hyaluronic Acid Derivative and Drug Containing the Same - A hyaluronic acid derivative in which an anti-inflammatory drug is bound to hyaluronic acid through a covalent bond via a spacer having a biodegradable region, and a production process thereof.09-11-2008
20130143838COMPLEX OBTAINED FROM HYALURONIC ACID OR A SALT THEREOF AND CHONDROITIN SULPHATE MIXTURES - The present invention relates to a novel complex, obtainable by mixing hyaluronic acid or a salt thereof and chondroitin sulphate or a salt thereof, and forming an aqueous solution of said mixture, which is further subjected to a drying process. The invention also relates to various compositions and formulations comprising the complex of the invention, process for obtaining said complex and uses thereof.06-06-2013
20130143839CYSTITIS TREATMENT WITH HIGH DOSE CHONDROITIN SULFATE - Interstitial cystitis and related GAG-deficient conditions of the bladder and urinary tract are treated by instillation of high dose chondroitin sulfate, such as 400 mg/20 mL. The higher dose of chondroitin is effective for the rapid reduction of symptoms, particularly in patients with severe and otherwise recalcitrant cystitis.06-06-2013
20130178442GENE EXPRESSION PROFILES AND PRODUCTS FOR THE DIAGNOSIS AND PROGNOSIS OF POSTINJURY SYNOVITIS AND OSTEOARTHRITIS - Associations between inflammation and pain/function scores were tested by univariate and multivariate analyses. Gene expression was analyzed by microarray and real-time PCR comparing patients with and without synovial inflammation. Synovitis was present in 43% of patients presenting for arthroscopic menisectomy. Inflammation was associated with pre-operative Lysholm scores, independent of age, gender, and BMI. Synovial RNA microarray analysis revealed 260 genes differently expressed ≧2-fold between patients with and without synovitis. A chemokine signature identified in the “inflammatory” biopsies was confirmed by real-time PCR. In conclusion, in patients presenting for arthroscopic menisectomy, synovitis is associated with symptoms. Comparison of expression patterns revealed enrichment of chemokines associated with cellular recruitment and activation in patients with synovitis. These chemokines may represent targets for therapeutic intervention to reduce inflammatory symptoms in patients with meniscal injury.07-11-2013
20130096081DERMAL FILLER COMPOSITIONS - The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions made with a di-amine or multiamine crosslinker in the presence of a carbodiimide coupling agent.04-18-2013
20130102563DERMAL FILLER WITH LIDOCAINE - Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.04-25-2013
20130102561Stabalized Glycosaminoglycan Preparations and Related Methods - Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.)04-25-2013
20130102562INHIBITION OF CATHEPSIN K ACTIVITY AND THE TREATMENT AND PREVENTION OF DISEASE - The present invention provides a candidate compound that is suitable for use in methods of treating animals (preferably mammals) and in the preparation of a medicament, wherein the candidate compound down regulates Cathepsin K activity.04-25-2013
20130102560NUTRITIONAL COMPOSITION COMPRISING IMMUNOGLOBULINS AND OLIGOSACCHARIDES - The present invention provides a method and composition for the treatment and/or prevention of infection, said method comprising orally administering a composition to a mammal, said composition comprising a galactose containing indigestible oligosaccharide and immunoglobulin from the milk or colostrum of hyperimmunized cows.04-25-2013
20130143837INHIBITION OF TNF-ALPHA INDUCED ACTIVATION OF NFKB BY PENTOSAN POLYSULFATE - Oral pentosan polysulfate (PPS) compositions treat diseases such as diabetes, inflammation, atherosclerosis. The compositions are also effective in reducing matrix metalloproteinases (MMPs).06-06-2013
20080200429Purified Beta Glucan Composition - The invention provides methods of using beta glucans to treat conditions associated with bone loss or low bone density as well as methods for promoting bone growth in situations where enhanced bone growth is desirable. In the invention methods beta glucans are administered so as to enhance the development of osteoblasts and the inhibition of the development and recruitment of osteoclasts. The inhibition of the recruitment and development of osteoclasts, coupled with the enhancement of osteoblast maturation by beta glucans leads to decreased bone resorption and increased bone formation, making beta glucans ideal agents for the treatment of osteoporosis and other bone resorption diseases.08-21-2008
20080200427Topical Compositions and the Use Thereof - The invention relates to a composition for topical application as well as the use of such a composition. The invention is characterised in that it comprises at least one first and one second mono- or oligosaccharide, each of said first and second mono- or oligosaccharides being capable of limiting the adhesion of microorganisms on the skin of warm-blooded animals with coats.08-21-2008
20080200426Use of Chondroitin Sulphate E (Cs-E) for the Treatment of Diseases or Conditions Related to Collagen Fibril Formation - The present invention comprises the use of chondroitin sulphate (CS-E) or an active fragment thereof for the treatment of diseases or conditions related to collagen fibril formation. Said compounds can be administrated either by oral, topical, injectable or by any other suitable route.08-21-2008
20110224165FORMULATIONS AND METHODS FOR REDUCING WAIST CIRCUMFERENCE - Methods for reducing abdominal fat and waist circumference in a human subject are disclosed. The method includes a composition containing 09-15-2011
20110224164FLUID COMPOSITIONS FOR IMPROVING SKIN CONDITIONS - The present specification discloses fluid compositions comprising a matrix polymer and stabilizing component, methods of making such fluid compositions, and methods of treating skin conditions in an individual using such fluid compositions.09-15-2011
20110275593STABILIZED OPHTHALMIC GALACTOMANNAN FORMULATIONS - The present invention relates to viscosity stabilized ophthalmic formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a diol alcohol such as sorbitol and, optionally, a pharmaceutically acceptable divalent cation salt such as magnesium chloride.11-10-2011
20130137656PHARMACEUTICAL/ COSMETIC COMPOSITION COMPRISING HYALURONIC ACID AND TREATMENT OF DERMATOLOGICAL CONDITIONS THEREWITH - Pharmaceutical/cosmetic compositions containing a dermatologically effective amount of hyaluronic acid, at least one retinoid and/or salt and/or derivative thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, formulated into a physiologically acceptable medium therefor, are useful for the treatment of wrinkles, fine lines, fibroblast depletions and scars.05-30-2013
20130150320METHOD OF INHIBITING INCREASE OF IMMUNOGLOBULIN A - The present invention discloses a method of inhibiting increase of immunoglobulin A, comprising a step of administering an effective amount of a pharmaceutical composition comprising β-glucan and at least one pharmaceutically acceptable carrier to a subject in need.06-13-2013
20130150321Acetaminophen/Ibuprofen Combinations And Method For Their Use - A pharmaceutical dosage form is provided comprising a non-steroidal anti-inflammatory agent and acetaminophen, and methods for their use. In one embodiment, the dosage form is comprised of ibuprofen and acetaminophen as the sole pharmaceutically effective agents, wherein the ibuprofen and acetaminophen are in a weight ratio of about 12 parts:about 88 parts.06-13-2013
20130123212ANTI-FATIGUE COMPOSITION, FORMULATION AND USE THEREOF - An anti-fatigue composition consisting of 20(S)-protopanoxadiol and 05-16-2013
20120258930The Improvement of Gastrointestinal Health, Immunity and Performance by Dietary Intervention - This invention relates to the improvement of gastrointestinal health, immunity and performance by direct dietary intervention with a composition comprising a glucan and/or a fucan, and relates in particular to the transfer of associated health benefits to offspring via glucan and/or a fucan supplementation of the maternal diet. Accordingly the present invention provides a composition comprising at least one glucan, at least one fucan, or at least one glucan and at least one fucan for use in improving or maintaining the gastrointestinal health or function of a progeny of a maternal animal by administration to the maternal animal, and a method for improving or maintaining the gastrointestinal health or function of a progeny of a maternal animal, the method comprising administering a composition comprising at least one glucan, at least one fucan, or at least one glucan and at least one fucan to the maternal animal.10-11-2012
20100317616ALKYLATED SEMI-SYNTHETIC GLYCOSAMINOGLYCAN ETHERS, AND METHODS OF MAKING AND USING THEREOF - Described herein is the synthesis of alkylated and semi-synthetic glycosaminoglycosan ethers, referred to herein as “SAGEs.” The synthesis of sulfated alkylated SAGEs is also described. The compounds described herein are useful in a number of applications including wound healing, drug delivery, and the treatment of a number of inflammatory diseases and skin disorders.12-16-2010
20100317615Method of enhancing ocular penetration of a drug in an eyedrop - A method of enhancing ocular penetration of a drug in an eyedrop by administering to an eye, an eyedrop containing, particulate agar having a weight-average molecular weight of from 5,000 to 1,200,000, the particulate agar being obtained by dissolving agar into an aqueous solution by heating and then cooling the resultant mixture to avoid gelling, while applying a stress by vibration, shearing, stirring, compression or pulverizing, wherein the particulate agar is in an amount of 0.1 to 10 wt %.12-16-2010
20100317614COMPOSITIONS AND METHODS FOR PEST CONTROL - Provided herein are compositions and kits comprising carbohydrate-based inhibitors that bind GNBP and/or inhibit β(1,3)-glucanase activity. Also provided are methods of using such inhibitors to protect against or treat pest infestation, as are compositions and kits comprising subparts of the carbohydrate-based inhibitors.12-16-2010
20100317613ACTIVITY ENHANCER FOR DETOXIFYING ENZYME - It is intended to provide a drug, a food or a feed which has an effect of enhancing the activity of a second-phase detoxifying enzyme and an effect of increasing intracellular glutathione content.12-16-2010
20130157974Preparation Comprising Iron(III) Complex Compounds And Redox-Active Substance(s) - A preparation is disclosed that comprises one or more iron(III) complex compounds which have a redox potential at pH 7 of from −324 mV to −750 mV relative to a normal hydrogen electrode (NHE), and one or more redox-active substances, wherein the carbohydrates are selected from the group consisting of dextrans and hydrogenated dextrans, dextrins, oxidised or hydrogenated dextrins, as well as pullulan, oligomers thereof and/or hydrogenated pullulans, and wherein the redox-active substance(s) is/are selected from the group consisting of ascorbic acid; vitamin E; cysteine; physiologically acceptable phenols/polyphenols selected from the group consisting of quercetin, rutin, flavones, flavonoids, hydroquinones; and glutathione, and in particular is ascorbic acid.06-20-2013
20120283213Aryl/Alkyl Succinic Anhydride Hyaluronan Derivatives - The present invention relates to the modification of hyaluronic acid (HA) with aryl/alkyl succinic anhydrides (ASA) to produce aryl/alkyl succinic anhydride HA derivatives, to the derivatives as such, and to their applications and uses, particularly in the cosmetic and biomedical industries. The ASA-HA derivatives are expected to have interesting properties that can be used for advanced formulation (bind stronger to the skin compared to non-modified HA), possibly also in delivery systems for actives or drugs by encapsulation (nano/micro capsules) or formation of nano/micro spheres. Further, the low MW ASA-HA derivatives are expected to penetrate the skin more efficiently than non-modified HA of the same MW.11-08-2012
20120283212USE OF POLYSACCHARIDES FOR TREATING STRESS AND ANXIETY - The present invention relates to a composition including a mix of a polysaccharides having: 15% to 50% of glucoside linkages 1-6; a reducing sugar content of less than 20%; a polymolecularity index of less than 5; an average molecular weight with number Mn of less than 4500 g/mole and at least one active agent for treating stress, anxiety and depressive behaviour, sleep disorders, obsessive-compulsive disorder, bulimia and epilepsy in humans or animals. The present invention also relates to the use of the polysaccharide for treating stress, anxiety or depressive behaviour, sleep disorders, obsessive-compulsive disorder, bulimia and epilepsy in humans or animals.11-08-2012
20130184234BIOMATERIALS CONSISTING OF SULPHATED HYALURONIC ACID AND GELLAN TO BE USED IN THE PREVENTION OF SPINAL ADHESIONS - New biomaterials consisting of a combination of sulphated hyaluronic acid and gellan (as well as gellan that has not been associated with other polymers), to be used as a highly effective barrier to prevent post-surgical adhesions in abdominal, pelvic and, above all, spine surgery.07-18-2013
20130184235HYALURONIC ACID DERIVATIVES CONTAINING GROUPS ABLE TO RELEASE NO - Disclosed are hyaluronic acid derivatives functionalised with S-nitrosothiol groups of the general formula: wherein HA indicates hyaluronic acid and G indicates a suitable spacer.07-18-2013
20100069321Biological Materials and Uses Thereof - The invention relates to the modification of proteins to improve their, biochemical, immunological or biophysical properties, in turn leading to such proteins having increased diagnostic, biotechnological or therapeutic benefit. In particular the invention relates to polysialylation of proteins or conjugates of proteins. There is also provided, nucleotide sequences and expression vectors encoding, host cells expressing, compositions comprising and uses of the polysialylated molecules of the invention.03-18-2010
20130123211PECTIC ENZYME TREATED PECTIN, METHOD OF PRODUCING THE SAME AND APPLICATION THEREOF - A pectic enzyme treated pectin (PET-pectin) and a method of producing the same are disclosed. Citrus pectin solution is subjected to an enzymatic hydrolysis by using a mixed pectinase solution under an acidic condition, so as to obtain PET-pectin that is completely hydrolyzed. The PET-pectin has several biological functions, including stability of emulsification, anti-oxidation and inhibition of cancer cell growth, thereby being applied on food emulsion stabilizers, food antioxidants and compositions for inhibiting cancer cell growth and so on.05-16-2013
20130096080STERILE ALGINATE-BASED AQUEOUS COMPOSITION FOR MEDICAL USE AND PROCESS FOR THE PREPARATION THEREOF - The present invention relates to ready-to-use sterile, alginate-based, aqueous compositions for medical use. More particularly, the invention relates to an aqueous composition for medical use that has been sterilized by heat sterilization and having a viscosity at 25° C. of at least 300 cP) (Helipath® T F spindle, 100 rpm at 25° C.), said composition having a pH in the range of 6.5-7.5; containing 0.5-10 wt. % of an alginate salt; and further containing 10-500 mM of one or more dissolved C04-18-2013
20110312913METHOD AND PHARMACEUTICAL TO TREAT SPINAL DISCS - Methods for reducing chronic pain caused by a disrupted spinal disc are described. In one method, a solution is injected into the disc. The solution includes chondroitin sulphate, glucosamine HCl, and dextrose. The solution may optionally include dimethyl sulfoxide and/or an anesthetic such as bupivicaine.12-22-2011
20110312912TREATMENT OF ARTHRITIS AND OTHER MUSCULOSKELETAL DISORDERS WITH CROSSLINKED HYALURONIC ACID - A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.12-22-2011
20110312911GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE - Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.12-22-2011
20130190268BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY - The invention relates to novel polysaccharides with an antithrombotic activity, having at least one covalent bond with biotin or a biotin derivative, wherein said covalent bond is resistant to metabolic cleavage and comprises a linkage X selected from the group consisting of —O—, —N(R)—, —N(R)—CO— and —N(R′)—CO—N(R″)—, wherein R is an alkyl group and R′ and R″, which may be identical or different, are, independently of one another, a hydrogen atom or alkyl group.07-25-2013
20130190269POLYSACCHARIDES COMPOSITIONS COMPRISING FUCANS AND GALACTANS AND THEIR USE TO REDUCE EXTRAVASATION AND INFLAMMATION - A method for inhibiting the release of one or more of IL-8, PGE2 and VEGF by a cell activated during an inflammatory process, said method comprising administering to said cell an anti-inflammatory polysaccharide composition comprising fucans and galactans to a cell, wherein the ratio of fucans to galactans in said composition enables a reduction in the cytotoxicity of said galactans and an anti-inflammatory composition comprising a ratio of brown algae fucans/red algae galactans of ranging from about 2.5/1 (w/w) to about 40/1 (w/w), the galactans having a molecular weight higher than about 100 kDa, and the fucans having a molecular weight ranging from about 0.1 kDa and 100 kDa.07-25-2013
20130190267POLYSACCHARIDE-BASED POLYMER TISSUE ADHESIVE FOR MEDICAL USE - Tissue adhesives formed by reacting an oxidized polysaccharide with a water-dispersible multi-arm polyether amine, wherein at least three of the arms are terminated by primary amine groups, are disclosed. The use of the tissue adhesives for medical and veterinary applications such as topical wound closure; and surgical procedures, such as intestinal anastomosis, vascular anastomosis, tissue repair, and ophthalmic procedures; drug delivery; anti-adhesive applications; and as a bulking agent to treat urinary incontinence are described.07-25-2013
20090325898SKIN MATERIAL FOR EXTERNAL USE AND ANTIPRUTIRIC AGENT FOR EXTERNAL USE AND WRINKLE-INSTRUMENT USING THE SAME - A skin composition for external use containing an acidic composition (A) which contains an alginate(s), at least one of weak acid selected from among phosphoric acid-type weak acids and ethylenediaminetetraacetic acid-type weak acids, and water; and a solidifying/gelling agent (B) containing a calcium salt(s) which is to be supplied to the acidic composition (A) sticking to the skin surface. In some cases, the skin composition for external use further includes an absorbent to be impregnated with the acidic composition (A).12-31-2009
20130196943NOVEL CHONDROITIN SULFATE HAVING DECREASED MOLECULAR WEIGHT AND USE THEREOF - A chondroitin sulfate having a decreased molecular weight which has utilization as an inhibitor of peritoneal disorder caused by long-term use of a peritoneal dialysis fluid containing glucose or a polysaccharide thereof as an osmotic agent, utilization as an osmotic agent in a peritoneal dialysis fluid, and the like. The chondroitin sulfate having a decreased molecular weight of the present invention as a means for achieving the object is characterized by having a weight average molecular weight of from 1000 to 20000 and containing a constituent disaccharide unit represented by the following structural formula in an amount of from 65% to 100% (molar ratio) of the total:08-01-2013
20130196944FILLER COMPOSITION COMPRISING BETA-GLUCANS - The present invention pertains to a filler composition comprising β-glucan moieties and optionally a cosmetically and/or pharmaceutically acceptable carrier. It further relates to a filler composition, wherein the β-glucan moieties are cross-linked. in one embodiment of the instant invention the filler composition is a dermal filler. In one further embodiment of the present invention the filler composition is for the treatment of wrinkles and/or folds. In another embodiment of the instant invention the filler composition is for use in the treatment of a medical condition. The filler composition provided in the present invention may further comprise one or more active pharmaceutical ingredients. Further, the present invention pertains to a process for preparing the filler composition as claimed herein.08-01-2013
20080200428Antiproliferative Drug - Object of the present invention are esterified conjugates of hyaluronic acid having anti-proliferative activity.08-21-2008
20120035127PROCESS FOR THE PRODUCTION OF A COMPOSITION, THE COMPOSITION AND THE USE THEREOF AS FOOD ADDITIVE - The present invention relates to a process for the production of a functional food additive, such as a prebiotic composition, comprising the steps of. (a) providing a plant based material wherein the plant is selected from the group consisting of cereals, legumes, tubers and mixtures thereof, wherein said plant based material comprises dietary fiber optionally starchy material and optionally glucose, or wherein said plant based material comprises starchy material, and optionally glucose; (b): (b1) hydrolyzing or tranglucosylating at least part of the dietary fiber into glucose and into at least one non-digestible oligosaccharide and optionally into at least one non-digestible polysaccharide, and optionally hydrolyzing and transglucosylating at least part of the starchy material to glucose and into at least one non-digestible oligosaccharide, or, (b2) hydrolyzing and transglucosylating at least part of the starchy material to glucose and into at least one non-digestible oligosaccharide, and optionally hydrolyzing at least part of the maltooligosaccharides produced in step (b2) into glucose; (c) oxidizing at least part of the total glucose, consisting of at least part of said gluconic acid and/or a salt thereof obtained in step (c); thereby obtaining a composition comprising dietary fiber and gluconic acid or a salt thereof, wherein said dietary fiber comprises at least one non-digestible oligosaccharide and optionally at least one non-digestible polysaccharide as defined in claim 02-09-2012
20090105193CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF - Described herein are crosslinked compounds useful in numerous treatments. Described herein are methods of making crosslinked compounds via (1) the oxidative coupling of two or more thiol compounds or (2) by the reaction between at least one thiol compound with at least one thiol-reactive compound.04-23-2009
20090209486Compositions of carbohydrates as dietary supplements - In accordance with the present invention, there is to provide a dietary supplement that provides humans and animals with the essential carbohydrates needed to maintain proper health and functionality, to fend off illness, act as viral inhibitors, lessen the aging process of cells and to provide pets with another level of medications equal to that for humans.08-20-2009
20130203696DERMAL FILLER COMPOSITIONS FOR FINE LINE TREATMENT - The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions which are particularly advantageous for correction of fine lines in the face.08-08-2013
20130203697CROSSLINKED HYALURONIC ACID COMPOSITION AND SELF-CROSSLINKING HYALURONIC ACID PARTICLES - The present invention provides a crosslinked hyaluronic acid composition including self-crosslinking hyaluronic acid particles having an equilibrium swelling capacity of 3-fold to 10-fold, and an aqueous solvent, wherein a dry weight of the self-crosslinking hyaluronic acid particles based on the total volume of the crosslinked hyaluronic acid composition is 3 w/v % to 8 w/v %.08-08-2013
20130203698AQUEOUS IRON CARBOHYDRATE COMPLEXES, THEIR PRODUCTION AND MEDICAMENTS CONTAINING THEM - Water soluble Iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and medicament for the treatment and prophylaxis of iron deficiency conditions.08-08-2013
20120088735One-Step Processing of Hydrogels for Mechanically Robust and Chemically Desired Features - The application of a highly controlled, micron-sized, branched, porous architecture to enhance the handling properties and degradation rate of hydrogels is described in the instant invention. A previously described pattern created through one-step nucleated crystallization in a hydrogel film creates tunable mechanical properties and/or chemical stability for use in tissue engineering applications. The bulk mechanical properties and the degradation rate of the material can be tuned easily by the addition or subtraction of crystalline structure or by the addition and subtraction of backfill material, making this useful for a variety of applications. Relevant mechanical properties that can be tuned through the application of this unique porosity are moduli, elasticity, tensile strength, and compression strength. The method of the present invention can be applied to biopolymers and natural materials as well as synthetic materials.04-12-2012
20120094952Polysialic Acid Derivatives, Methods of Production, and Uses in Enhancing Cancer Antigen Production and Targeting - The present invention relates to compositions and methods of their production and use, including use in increasing de-N-acetyl sialic acid antigen of a mammalian cell and methods that exploit the increase in deNAc sialic acid antigen on such cells.04-19-2012
20120094950Nutraceutical Composition and Methods for Preventing or Treating Multiple Sclerosis - The present invention embraces nutraceutical compositions containing isolated 04-19-2012
20130210764CARBOHYDRATE COMPOSITIONS - The invention provides a low-viscosity reduced-sugar syrup, methods of making such a low-viscosity reduced-sugar syrup, and uses of such syrup.08-15-2013
20130210762SOLID PHARMACEUTICAL COMPOSITION FOR NEUTRALIZING STOMACH ACID - A pharmaceutical composition including an alkaline metal alginate, an alkaline salt, and less than 10% by weight based on the weight of the alkaline metal alginate of a calcium salt. The pharmaceutical composition is intended for the treatment or prophylaxis of dyspepsia in a mammal.08-15-2013
20130210763SYNERGISM OF GOS AND POLYFRUCTOSE - The present invention relates to the field of prebiotics. Provided are uses for compositions comprising synergistically effective amounts of polyfructose and galactooligosaccharides (GOS).08-15-2013
20130210760DERMAL FILLER COMPOSITIONS INCLUDING ANTIOXIDANTS - Provided are injectable, hyaluronic acid-based dermal filler compositions including conjugated vitamin C derivatives. The compositions provide for extended release of active vitamin C into tissue, promoting collagenesis and other benefits to skin.08-15-2013
20130210761METHODS AND COMPOSITIONS FOR TREATING WOUNDS UTILIZING CHITOSAN COMPOUNDS - Described herein are methods of treating wounds, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan wherein the soluble or derivatized chitosan when administered contacts the wound, thereby treating the wound.08-15-2013

Patent applications in class Polysaccharide

Patent applications in all subclasses Polysaccharide